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Preface
Several decades ago, the international community made a solemn commitment with the Single 
Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol1 and the Convention on 
Psychotropic Substances of 1971:2 to make adequate provision to ensure, and not to unduly restrict, 
the availability of drugs that were considered indispensable for medical and scientific purposes. In 
recent decades, that promise has not been completely fulfilled. Too many people still suffer or die 
in pain or do not have access to the medications they need. Unnecessary suffering resulting from 
a lack of appropriate medication due to inaction and excessive administrative requirements is a 
 situation that shames us all. 
Around 5.5 billion people still have limited or no access to medicines containing narcotic drugs, 
such as codeine or morphine, leaving 75 per cent of the world population without access to proper 
pain relief treatment. Around 92 per cent of morphine used worldwide is consumed in countries 
in which only 17 per cent of the world population lives: primarily the United States of America, 
Canada, Western Europe, Australia and New Zealand. Inadequate access contradicts the notion of 
article 25 of the Universal Declaration of Human Rights,3 including the right to medical care, which 
also encompasses palliative care.
The imbalance in the availability of opioid analgesics is particularly worrying, as the latest data 
show that many of the conditions that require pain management, particularly cancer, are prevalent 
and increasing in low- and middle-income countries.4 At the same time, in recent years there has 
been an increase in the abuse of prescription drugs and related overdose deaths in countries with 
high per capita levels of consumption of opioid analgesics. 
Apart from the needs related to cancer, pain treatment is required for many other health condi-
tions. In several regions of the world, pain relief drugs are not commonly prescribed. Other inter-
nationally controlled drugs such as methadone and buprenorphine are used in the management of 
drug dependence, but their use is also limited in some countries despite a considerable prevalence 
of heroin abuse. 
In addition to narcotic drugs, the present report also discusses the availability of psychotropic sub-
stances controlled under the 1971 Convention. There are significant concerns regarding the con-
sumption and accessibility of these substances, which are necessary in the treatment of a range of 
serious health conditions. According to the World Health Organization (WHO), mental disorders 
afflict hundreds of millions of people and their families, but the resources available in most coun-
tries to treat such conditions are insufficient. The vast majority of countries allocate less than 2 per 
cent of their health budgets to mental health, leaving more than 75 per cent of the population in 
many low- and middle-income countries with no access to such treatment. Insufficient attention 
has been devoted to this problem. Levels of consumption of psychotropic substances, which are 
used for the treatment of mental and neurological disorders, such as anxiety, insomnia and epi-
lepsy, continue to vary widely among countries and regions. This reflects on the one hand a diver-
sity in medical practice and related variations in prescription patterns, and on the other hand a 
lack of accurate data, both quantitative and qualitative, on the consumption of such substances. 
Addressing the discrepancy in the availability of narcotic drugs and psychotropic substances for 
medical and scientific purposes is one of the obligations of Governments in complying with the 
international drug control conventions. In 1961, the international community committed to 
 1 United Nations, Treaty Series, vol. 976, No. 14152.
 2 Ibid., vol. 1019, No. 14956.
 3 General Assembly resolution 217 A (III).
 4 World Health Organization and Worldwide Palliative Care Alliance, Global Atlas of Palliative Care at the End of Life 
(Worldwide Palliative Care Alliance, 2014).
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making adequate provision to ensure the availability of narcotic drugs for the relief of pain and 
suffering. At the same time, parties to that Convention recognized the problem of addiction to nar-
cotic drugs. Both of those principles were set forth in the preamble to the Single Convention. This 
dual responsibility is at the centre of the discussion that Member States are currently having on the 
achievements and future prospects of the international drug control system. 
Equally, the parties to the 1971 Convention, while expressing a determination to prevent and com-
bat abuse of and trafficking in psychotropic substances, recognized that the use of such substances 
for medical and scientific purposes was indispensable and that their availability for such purposes 
should not be unduly restricted. 
The Board has raised the issue of availability on various occasions in its history. It devoted special 
reports to that topic in 1989, 1995 and 2010. The 2010 report5 contained a number of recommen-
dations based on the information provided by Member States. These recommendations focused on 
the availability of narcotic drugs and psychotropic substances, appropriate use, national control sys-
tems and the prevention of diversion and abuse.
The inequitable use of opioid analgesics does not seem to be attributable to a lack of raw materi-
als. Global production of opiate raw materials has exceeded global demand for many years. As a 
result, stocks have been increasing, albeit with some fluctuation. Over the past 20 years, global 
 consumption of opioids has more than tripled. Available data indicate that the amount of opiate 
raw material that is available for the manufacture of narcotic drugs for pain relief is more than 
 sufficient to satisfy the current level of demand as estimated by Governments. For psychotropic 
substances, the issue of supply is more complex. That topic is addressed in detail in the chapter 
devoted to those substances.
Impediments and barriers that can adversely affect availability include regulatory, attitudinal, 
 knowledge-related, economic and procurement-related factors. In 2010, the impediments most often 
cited by countries were concerns about addiction, reluctance to prescribe or stock, and insufficient 
training for health professionals. Unduly restrictive laws and burdensome regulations were also 
commonly perceived as playing a significant role in limiting the availability of opioids. A smaller 
number of Governments reported that difficulties involving distribution, supply and the cost of 
 opioids were major obstacles to making opioids adequately available. 
To assist Governments, INCB decided to prepare the present report on availability five years after 
the one published in 2010. It has been prepared with inputs from various stakeholders. Member 
States received a questionnaire in 2014, and more than 100 countries responded, providing valua-
ble information on policies and practices at the national level. Intergovernmental organizations such 
as WHO, the Joint United Nations Programme on HIV/AIDS (UNAIDS) and the United Nations 
Office on Drugs and Crime (UNODC) have been consulted and have offered relevant data and 
information to  complement those available to INCB. Various civil society organizations  representing 
patients, families, health professionals and other stakeholders have also contributed data and 
 information, and offered their views. In addition, a number of researchers have provided relevant 
analyses and insights.
The analysis of the latest data on consumption of narcotic drugs shows that, despite the persistence 
of serious inequalities, there has been significant progress with regard to the availability of opioid 
analgesics for medical purposes. The data show measurable increases in the average amount of 
 opioid analgesics consumed during the 2011-2013 period compared with the 2000-2003 period. In 
addition, in comparing the responses provided by Member States in the surveys that were carried 
out in 1995, 2010 and 2014, it emerges that concerns about the risk of addiction and legislative 
 5 Report of the International Narcotics Control Board on the Availability of Internationally Controlled Drugs: Ensuring 
 Adequate Access for Medical and Scientific Purposes (E/INCB/2010/1/Supp. 1).
vimpediments are becoming less relevant and that countries believe that it is necessary to address 
other key impediments such as lack of training and education, streamlining of supply, costs and 
limited financial resources.
These data confirm that it is possible, within the framework of the international conventions, to 
improve the availability of internationally controlled drugs. To achieve this, it is important to have 
sensible and rational national legislation that both ensures that medicines are available to patients 
and also protects their health, with health professionals trained in responsible and rational prescrib-
ing and aware of the risk of overprescription and abuse.
The data related to psychotropic substances show disparities among countries and regions in the 
levels of consumption of such substances. Inadequate availability and poor access to necessary 
 medical treatment, as well as excessive availability and medically unsound use of psychotropic 
 substances, all pose challenges to their control and use.
The Board is presenting this special report to Member States in the hope that the analysis and 
 recommendations presented therein may assist them in the development of national policies and 
control systems that are capable of achieving the goals of the international drug control  conventions 
in relation to ensuring availability of narcotic drugs and psychotropic substances. Member States 
have already underlined the importance of this issue in a number of resolutions and political dec-
larations adopted by the Commission on Narcotic Drugs. They also referred to it in the Political 
Declaration of the High-Level Meeting of the General Assembly on the Prevention and Control of 
Non-communicable Diseases6 and in resolution WHA67.19 of the World Health Assembly, on 
strengthening of palliative care as a component of comprehensive care throughout the life course.7 
Furthermore, the present report is being offered to the international community ahead of the spe-
cial session of the General Assembly on the world drug problem to be held in 2016, and the Board 
hopes that this contribution will help Member States in their deliberations. At a time when coun-
tries are discussing the achievements of the international drug control system, the Board would 
like to offer a reminder that the overall goal of the international drug control conventions is a well-
functioning national and international system for managing the availability of narcotic drugs and 
psychotropic substances by ensuring the safe and rational delivery of the best affordable drugs to 
those patients who need them and, at the same time, preventing the diversion of such drugs for 
the purpose of abuse. 
 Werner Sipp
 President
 International Narcotics Control Board
 6 General Assembly resolution 66/2.
 7 Available from http://apps.who.int/gb/e/e_wha67.html.
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Executive summary 
Indispensable and adequately available for medical and scientific purposes: those two fundamental 
principles were set forth in the Single Convention on Narcotic Drugs of 1961 as amended by the 
1972 Protocol. Later, psychotropic substances were also recognized as being indispensable for medi-
cal and scientific purposes. In the Convention on Psychotropic Substances of 1971, Parties  further 
recognized that the availability of such substances should not be unduly restricted.
The present supplement to the annual report of the International Narcotics Control Board (INCB) 
for 2015 analyses global access to narcotic drugs and psychotropic substances. It also reviews pat-
terns and trends relating to consumption, as well as information provided by Member States on 
the policies and practices at the country level for ensuring the availability of these controlled sub-
stances, and the impediments thereto. 
The 1961 and 1971 Conventions indicate the primary interest of the international community in 
protecting the health and welfare of humankind by making these indispensable substances availa-
ble for medical and scientific purposes while ensuring that there is no diversion or abuse. The con-
ventions established a control regime to serve this dual purpose. After several decades since their 
entry into force, this essential element of the conventions is far from being achieved globally. The 
importance of making these substances available for those who need them is also highlighted in 
international human rights instruments and in a series of resolutions of the Commission on Narcotic 
Drugs, the World Health Assembly and regional intergovernmental organizations. 
Over the years, INCB has pointed out to Member States the importance of this significant aspect of 
the international drug control system. In 2010, INCB launched a report entitled Availability of 
Internationally Controlled Drugs: Ensuring Adequate Access for Medical and Scientific Purposes, which 
analysed the global situation with regard to the consumption of internationally controlled substances. 
Similar reports had been produced in 1989 and 1995. In 2010, the scope of the report was  broadened 
to include psychotropic substances. Five years on, the Board is reviewing the situation and providing 
Member States and the international community with an update and a series of recommendations to 
address the problem of availability of narcotic drugs and psychotropic substances.
Narcotic drugs
Opioid analgesics like morphine are indispensable for the treatment of pain caused by cancer, HIV/
AIDS, cardiovascular disease, chronic respiratory disease, diabetes, childbirth, surgery, injuries and 
other conditions or situations. INCB estimates that 92 per cent of morphine is consumed in coun-
tries in which only 17 per cent of the world population lives (United States, Canada, countries in 
Western Europe, Australia and New Zealand). At the same time, 75 per cent of the world popula-
tion, predominantly in lower-income countries, is left with limited or no access to proper pain 
relief. The increase in global consumption of opioid analgesics since 1991 seems to have been driven 
mainly by North America, Europe, Australia and New Zealand, where there has been growing con-
cern about prescription drug abuse.
Low levels of consumption of opioid analgesics in some countries and regions does not seem to be 
to the result of a lack of supply of opiate raw materials and opioids. Data available to INCB indi-
cate that global demand is fully met—and, based on submitted estimates, is expected to continue 
to be met—by the global production of opiate raw materials, the increasing manufacture of  narcotic 
drugs, and growing stocks.
Despite some progress, levels of opioid consumption continue to be low in Africa, Asia, Central 
America and the Caribbean, and parts of South America, Eastern and South-Eastern Europe and 
some small island States in Oceania. Looking at the prevalence of health conditions requiring 
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palliative care, it becomes apparent that these widespread conditions are often not matched by an 
adequate opioid treatment and palliative care infrastructure. Measuring the levels of consumption 
of opioid analgesics against cancer rates reveals insufficient consumption in parts of Africa, Asia, 
Central America and the Caribbean, Eastern and South-Eastern Europe and some small island 
States in Oceania. Inadequate opioid availability to treat pain related to AIDS seems to be pro-
nounced in sub-Saharan African and Asian countries. In addition, even in the presence of high 
levels of national consumption, access for some sectors of the population (rural and poor commu-
nities) may be impaired by the limited provision of palliative care services.
The impediments to availability that were most frequently identified by Member States included a 
lack of training/awareness among medical professionals, fear of addiction, limited financial resources, 
problems in sourcing, cultural attitudes and fear of diversion. A comparison with data from previ-
ous INCB surveys reveals that mentions of fear of addiction and onerous regulations as barriers 
had declined considerably since 1995.
Inadequate awareness and training of health-care professionals with regard to pain and pain relief, 
rational prescribing and the safe use of opioid analgesics can lead to such substances being insuf-
ficiently prescribed and administered. Fear of addiction seems to be related to a lack of awareness 
and training, and cultural attitudes. Access is determined not only by physical availability and prac-
tical accessibility, but also by affordability. Limited resources can impair the capacity of Governments 
to provide or subsidize drugs and of patients to afford them. Also, drug prices might be high due 
to costs arising from regulation, licensing, taxation, import, poor distribution systems, lack of pub-
lic reimbursement and insufficient availability of inexpensive formulations. Manufacturers and 
importers/exporters may not produce or trade affordable formulations of internationally controlled 
drugs when they perceive such formulations to be insufficiently profitable. Finally, inadequate esti-
mates, lengthy and burdensome regulatory requirements, and delays in the supply chain can also 
cause shortages.
Access to internationally controlled substances might also be unduly restricted out of fear of their 
diversion into illicit channels, as well as fear of prosecution or sanction. The latter might be exacer-
bated in the context of unclear, stigmatizing legislation, insufficient legal knowledge among health 
professionals, or harsh penalties for unintentional violations. Among regulations that are well 
beyond the provisions of the drug control treaties and that might discourage the prescription, 
 dispensing and use of narcotic drugs are the following: short prescription validities, special 
 multiple-copy prescription forms, onerous record-keeping requirements, and overly restricted access 
to prescription forms, prescribing/dispensing agents and narcotic drugs (which are often especially 
limited in rural areas). In addition, most countries or territories do not permit nurses to prescribe 
narcotic drugs and do not allow drug refills without a new prescription. Such regulations may 
impede access in areas with an insufficient health-care infrastructure.
Psychotropic substances
Insufficient or inadequate access to psychotropic substances seems to be particularly pronounced 
in low- and middle-income countries, where it is estimated that about four out of five people who 
need mental, neurological or substance abuse treatment do not receive such treatment. Regarding 
the supply and consumption of substances controlled under the 1971 Convention that the World 
Health Organization lists as essential drugs (buprenorphine, diazepam, lorazepam, midazolam and 
phenobarbital), diverse patterns emerge. The reported global manufacture and calculated levels of 
consumption of buprenorphine used for pain relief and opioid dependence treatment have increased 
significantly in the past decade. While some countries (especially in Europe) show very high  levels 
of consumption, the calculated level of consumption of the majority of countries and regions still 
remains below 0.1 S-DDD8 per 1,000 population per day, indicating insufficient access to this 
medicine.
 8 Defined daily doses for statistical purposes.
xBetween 2004 and 2013, reported manufacture of benzodiazepines fluctuated for the sedative- 
hypnotic midazolam and the anxiolytic diazepam, while it remained relatively stable for the  anxiolytic 
lorazepam. During that period, the global average rate of consumption of diazepam, lorazepam and 
midazolam decreased by 20, 13.4, and 0.4 per cent, respectively, with levels below the global  average 
in Africa and Asia, and Oceania in the case of lorazepam and midazolam. The reported  manufacture 
of the anti-epileptic phenobarbital fluctuated between 2004 and 2013, falling sharply near the end 
of the period. Global consumption of phenobarbital declined by 12 per cent, with Europe and the 
Americas remaining the regions with highest average consumption and Asia, Africa and Oceania 
showing levels that were below the global average.
As was the case for narcotic drugs, Member States identified a lack of awareness and training as 
the major impediment to the availability of psychotropic substances. Problems in sourcing, fear of 
diversion and fear of prosecution or sanction were mentioned as barriers relatively more often with 
regard to psychotropic substances than they were for narcotic drugs. Among policymakers, men-
tal health care may not be given the priority it deserves, especially in the context of limited resources 
and stigma associated with mental health conditions and the related use of psychotropic substances. 
In addition, some countries have identified financial issues as impediments to the availability of 
psychotropic substances. Furthermore, overly stringent regulations can unduly restrict the availa-
bility of such substances. 
Availability of internationally controlled drugs for the treatment of 
opioid dependence 
An analysis of levels of consumption of methadone and buprenorphine, as well as opiate  substitution 
treatment services, indicates that access to these services is either not available, or not sufficiently 
available, in all countries where there is a significant prevalence of people who inject drugs. This 
can be due to the non-recognition of the effectiveness of such services, cultural resistance, eco-
nomic or structural incapacity and/or political inaction. 
Ensuring adequate availability of internationally controlled drugs in 
emergency situations
Most narcotic drugs and a large number of psychotropic substances controlled under the interna-
tional treaties are indispensable in medical practice. Simplified control measures are in place for 
the provision of internationally controlled medicines for emergency medical care. Competent 
national authorities may allow the export of internationally controlled substances to affected coun-
tries even in the absence of import authorizations or estimated requirements. 
Recommendations
Inadequate and insufficient access to internationally controlled substances seems to be the result of 
limited training and awareness of health-care professionals, policymakers and the general public 
(reflected in underuse, fear and overregulation), problems in sourcing, limited resources and inad-
equate infrastructure. Ensuring access does not mean an increase in abuse and diversion, but it is 
necessary to maintain a balance between control on the one hand, and availability and  accessibility 
on the other hand.
To this end, international cooperation and assistance, the involvement of the entire community, 
and the commitment of Governments and organizations are required. INCB recommends  reviewing 
legislation and regulatory systems with the aim of removing unduly restrictive provisions while pre-
venting diversion and facilitating access by, for example, allowing a larger base of health-care 
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professionals to prescribe medications containing substances under international control, where 
required. An adequate and well-resourced infrastructure needs to ensure the provision and distri-
bution of narcotic drugs and psychotropic substances, including in rural areas. Public funding and 
reimbursement schemes, in addition to the supply of affordable formulations by pharmaceutical 
companies, can help overcome financial barriers. Improved training of health-care professionals and 
heightened awareness can reduce fear, misconceptions, stigma and prejudices that hinder access to 
and use of internationally controlled substances, while curbing diversion and abuse. Finally, the 
capacity of competent national authorities to adequately estimate and assess the need for these sub-
stances has to be further developed and strengthened.
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1Chapter I.
Introduction
1. “Pharmakon” is the ancient Greek word for drug. It 
has been commonly translated as “remedy” or “poison”,9 
even though it has other meanings that do not corre-
spond exactly with the two main ones.
2. This double meaning represents well the problem that 
many cultures and societies have faced in the course of 
 history in relation to drugs. Several substances that are 
available in nature, or that more recently have been syn-
thesized from natural substances or artificially produced, 
have the capacity to treat or alleviate certain health 
 conditions. For this reason, they are widely used. If taken 
beyond certain limits, however, they can have negative 
effects and can damage the health of the persons using 
them. In addition, there may also be negative consequences 
for the families of such persons and the broader 
community.
3. Dealing with the difficult balance between “remedy” 
and “poison” has been a longstanding problem in many 
 societies. It was at the heart of the development of the inter-
national drug control system as outlined in the Single 
Convention on Narcotic Drugs of 1961 as amended by the 
1972 Protocol10 and the Convention on Psychotropic 
Substances of 1971.11 In the preambles to those conventions, 
Parties indicated the primary interest of the international 
community in protecting the health and welfare of human-
kind by making such indispensable substances available for 
medical and scientific purposes while ensuring that there 
was no diversion or abuse. The conventions established a 
control regime to serve this dual purpose.
 9 Michael Rinella, Pharmakon: Plato, Drug Culture, and Identity in 
Ancient Athens (Lexington Books, 2010).
 10 United Nations, Treaty Series, vol. 976, No. 14152.
 11 Ibid., vol. 1019, No. 14956.
A. Role of the international drug 
control conventions
4. In particular, parties to the 1961 Convention, while 
recognizing that addiction to narcotic drugs constituted 
a serious evil for the individual and was fraught with 
social and economic danger to humankind, also recog-
nized “that the medical use of narcotic drugs continues 
to be indispensable for the relief of pain and suffering 
and that adequate provision must be made to ensure the 
availability of narcotic drugs for such purposes”.
5. Similarly, parties to the 1971 Convention, while 
 noting with concern the public health and social  problems 
resulting from the abuse of certain psychotropic  substances 
and expressing their determination to prevent and com-
bat abuse of and trafficking in psychotropic substances, 
recognized “that the use of psychotropic substances for 
medical and scientific purposes is indispensable and that 
their availability for such purposes should not be unduly 
restricted”.
6. Since the entry into force of the three international 
drug control conventions,12 these principles have been reit-
erated in a number of resolutions adopted by the 
Commission on Narcotic Drugs and then by the Economic 
and Social Council. More recently, the Commission 
adopted resolutions 53/4 and 54/6,13 with a view to pro-
moting adequate availability of internationally controlled 
 12 Including the United Nations Convention against Illicit Traffic in 
Narcotic Drugs and Psychotropic Substances of 1988 (United Nations, 
Treaty Series, vol. 1582, No. 27627), which focuses more on measures 
related to illicit trafficking.
 13 See E/2010/28-E/CN.7/2018, chap. I, sect. C; and E/2011/28-E/
CN.7/2011/15, chap. I, sect. C, respectively.
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substances for medical and scientific purposes while 
 preventing their diversion and abuse. In its resolution 53/4, 
the Commission decided, among other things, to establish 
a specific agenda item to examine impediments to  adequate 
availability and efforts to prevent the  diversion and abuse 
of narcotic drugs and psychotropic substances. 
7. The importance of making internationally controlled 
drugs available for medical and scientific purposes is also 
mentioned in the 2009 Political Declaration and Plan of 
Action on International Cooperation towards an 
Integrated and Balanced Strategy to Counter the World 
Drug Problem14 and in the Joint Ministerial Statement of 
the 2014 High-Level Review by the Commission on 
Narcotic Drugs of the Implementation by Member States 
of the Political Declaration and Plan of Action on 
International Cooperation towards an Integrated and 
Balanced Strategy to Counter the World Drug Problem.15 
B. Availability of and access to 
internationally controlled drugs as 
a health and human right
8. The need to have access to essential drugs is also 
prominent in other international legal instruments16 
under the concept of the right to health set out in arti-
cle 25 of the Universal Declaration of Human Rights:17
  Everyone has the right to a standard of living ade-
quate for the health and well-being of himself and of 
his family, including food, clothing, housing and 
medical care and necessary social services, and the 
right to security in the event of unemployment, sick-
ness, disability, widowhood, old age or other lack of 
livelihood in circumstances beyond his control.
9. The preamble to the Universal Declaration of Human 
Rights refers also to the “recognition of the inherent dig-
nity and of the equal and inalienable rights of all mem-
bers of the human family”. An earlier formulation of the 
right to health as a fundamental part of human rights was 
first articulated in the 1946 Constitution of the World 
Health Organization (WHO), the preamble to which 
defines health as “a state of complete physical, mental and 
 14 See Official Records of the Economic and Social Council, 2009, 
 Supplement No. 8 (E/2009/28), chap. I, sect. C.
 15 See Ibid., 2014, Supplement No. 8 (E/2014/28), chap. I, sect. C.
 16 Christopher Hallam, “The international drug control regime and 
access to controlled medicines”, Series on Legislative Reform of Drug 
Policies No. 26, Transnational Institute and International Drug Policy 
Consortium (December 2014).
 17 General Assembly resolution 217 A (III).
social well-being and not merely the absence of disease 
or infirmity”. The preamble further states that:
  The enjoyment of the highest attainable standard of 
health is one of the fundamental rights of every 
human being without distinction of race, religion, 
political belief, economic or social condition.
10. Additionally, the right to health was recognized as 
a human right in the 1966 International Covenant on 
Economic, Social and Cultural Rights.18
11. In his report to the Human Rights Council at its 
seventh session, the Special Rapporteur on torture and 
other cruel, inhuman or degrading treatment or punish-
ment stated that:
  The de facto denial of access to pain relief, if it causes 
severe pain and suffering, constitutes cruel, inhuman 
or degrading treatment or punishment.
Further, he added that:
  Given that lack of access to pain treatment and 
 opioid analgesics for patients in need might amount 
to cruel, inhuman and degrading treatment, all 
 measures should be taken to ensure full access and 
to overcome current regulatory, educational and 
 attitudinal obstacles to ensure full access to palliative 
care.19
12. Similarly, in a report published in 2011,20 Human 
Rights Watch argued that under international human 
rights law, “Governments have an obligation to address 
the widespread and unnecessary suffering caused by the 
poor availability of palliative care worldwide.”
13. In addition to the international drug control con-
ventions and the international human rights instruments, 
the international community has developed a series of 
legal instruments in the context of the World Health 
Assembly.
14. Furthermore, WHO has compiled a list of essential 
medicines that are designed to “satisfy the priority health-
care needs of the population” and are selected “with due 
regard to disease prevalence, evidence on efficacy and 
 18 General Assembly resolution 2200 A (XXI), annex.
 19 A/HRC/10/44, paras. 72 and 74 (e).
 20 Human Rights Watch, Global State of Pain Treatment: Access to 
 Palliative Care as a Human Right (2011).
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safety, and comparative cost-effectiveness”.21 Several 
 narcotic drugs and psychotropic substances under 
 international control are part of the list and are therefore 
considered essential to satisfying the priority health-care 
needs of the population.
15. In its resolution WHA55.14 of 2002, on ensuring 
accessibility to essential medicines, the World Health 
Assembly urged Member States:
  to reaffirm their commitment to increasing access to 
medicines, and to translate such commitment into 
specific regulation within countries, especially enact-
ment of national drug policies and establishment of 
lists of essential medicines based on evidence and 
with reference to WHO’s Model List, and into actions 
designed to promote policy for, access to, and qual-
ity and rational use of, medicines within national 
health systems [and] to reaffirm, within the national 
drug policies, WHO’s concept of essential medicines 
as those medicines that satisfy the priority  health-care 
needs of the population, reflecting also availability, 
quality, price and feasibility of delivery, and 
 re-emphasizing the evidence base for overall national 
discussions. 
16. Also in that resolution, the World Health Assembly 
requested the Director-General of WHO “to pursue all 
diplomatic and political opportunities aimed at overcom-
ing barriers to access to essential medicines, collaborat-
ing with Member States in order to make these medicines 
accessible and affordable to the people who need them”.
17. In its resolution WHA58.22 of 2005, on cancer pre-
vention and control, the World Health Assembly urged 
Member States “to ensure the medical availability of opi-
oid analgesics according to international treaties and rec-
ommendations of WHO and the International Narcotics 
Control Board and subject to an efficient monitoring and 
control system”. In addition, it requested the Director-
General of WHO “to examine jointly with the International 
Narcotics Control Board the feasibility of a possible assis-
tance mechanism that would facilitate the adequate treat-
ment of pain using opioid analgesics”.
18.  More recently, on 24 May 2014, the World Health 
Assembly adopted resolution WHA67.19, on strengthen-
ing of palliative care as a component of comprehensive 
 21 World Health Organization, definition of “essential medicines”. 
Available from www.who.int/medicines/services/essmedicines_def 
 (accessed 22/09/2014).
care throughout the life course.22 In that resolution, it 
emphasized that the need for palliative care services 
would continue to grow, partly because of the rising 
preva lence of non-communicable diseases and the ageing 
of populations everywhere.
19. In relation to palliative care services, Human Rights 
Watch, in Global State of Pain Treatment, stated that:
  Under international human rights law, Governments 
must ensure equal access to the right to health and 
take reasonable steps to protect all against inhuman 
and degrading treatment. This should mean that 
health policies address the needs of people who 
require palliative care services; that healthcare work-
ers have at least basic palliative care knowledge and 
skills; that medications like morphine are available 
throughout the country; and that drug regulations 
do not impede the ability of patients facing severe 
pain to get appropriate treatment. Failure to take 
such steps will likely result in a violation of the right 
to health. 
20. Furthermore, the WHO Global Action Plan for the 
Prevention and Control of Non-Communicable Diseases 
2013-2020, endorsed by the World Health Assembly in 
May 2013, includes palliative care among the policy 
options proposed to Member States as a means of reduc-
ing the suffering caused by non-communicable diseases. 
21. The World Cancer Declaration of 2013, elaborated 
by the global cancer community under the leadership of 
the Union for International Cancer Control, which is 
building on the Global Action Plan, is aimed at achiev-
ing major reductions in premature deaths from cancer, as 
well as improvements in quality of life and cancer sur-
vival rates. The Declaration contains nine targets to be 
achieved by 2025. One of them is to make effective pain 
control and distress management services universally 
available. 
22. The Declaration also identifies a series of actions for 
all stakeholders, in particular Governments, to advance 
progress towards the targets. The Declaration urges them 
to:
 22 The World Health Organization defines palliative care as “an 
approach that improves the quality of life of patients and their families 
facing the problem associated with life-threatening illness, through the 
prevention and relief of suffering by means of early identification and 
impeccable assessment and treatment of pain and other problems, 
 physical, psychosocial and spiritual”. Available from www.who.int/ 
cancer/palliative/definition (accessed 22/09/2014).
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 •  Take steps to remove the many barriers to opti-
mal pain control.
 •  Work with all stakeholders, including Governments, 
civil society and relevant private sector players, to 
address the overregulation of pain medicines.
 •  Cooperate with international agencies, including 
WHO, the United Nations Office on Drugs and 
Crime (UNODC) and the International Narcotics 
Control Board, to ensure that global  implementation 
of the international drug control conventions 
strikes an appropriate balance between ensuring 
availability of pain medicines for cancer patients in 
pain and preventing their misuse.
23. A number of regional organizations have also 
emphasized the importance of the availability of inter-
nationally controlled drugs for medical purposes. The 
European Union Drugs Strategy for the 2013-2020 period 
highlighted the need to ensure and improve access to pre-
scribed controlled medications as one challenge that had 
been identified in recent years.23 In 2012, the African 
Union Conference of Ministers of Drug Control adopted 
the African common position on controlled substances 
and access to pain management drugs. That position was 
translated into the African Union Plan of Action on Drug 
Control (2013-2017), which lists among its key objectives 
capacity-building to facilitate the licit movement of nar-
cotic drugs and psychotropic substances for medical and 
scientific purposes. It also describes some outputs related 
to this objective, such as the removal of barriers limiting 
availability of internationally controlled drugs for medi-
cal and scientific purposes.24 The Inter-American Drug 
Abuse Control Commission of the Organization of 
American States, at its forty-seventh session, adopted a 
hemispheric drug strategy that states the following:
  In applying control measures to limit the use of 
 narcotic drugs exclusively to medical and scientific 
purposes, the availability of adequate supplies should 
be ensured. Availability exists when sufficient quan-
tities are on hand and are accessible in accordance 
with international treaties.25
 23 European Union Drugs Strategy (2013-20), Official Journal of the 
European Union, C 402/1, 29 December 2012.
 24 African Union Plan of Action on Drug Control (2013-2017), sub-
mitted for consideration by the African Union Conference of Ministers of 
Drug Control at its fifth session.
 25 Inter-American Drug Abuse Control Commission of the Organi-
zation of American States, Hemispheric Drug Strategy (adopted on 3 May 
2009), para. 37.
C. Action taken by the Board to 
ensure adequate availability
24. The goal of ensuring adequate, not unduly restricted, 
availability of internationally controlled drugs for medi-
cal purposes has been pursued for over 50 years. It is fair 
to say that not all countries, in implementing the provi-
sions of the 1961 and 1971 Conventions at the national 
level, have been able to ensure that this fundamental goal 
has informed the development of policies and adminis-
trative procedures for the distribution of narcotic drugs 
and psychotropic substances. 
25. By becoming parties to the international drug 
 control conventions, Governments have accepted the 
obligation to introduce the provisions of those treaties 
into their national legislation and to implement them. The 
International Narcotics Control Board (INCB) is the body 
established by the 1961 Convention that is responsible for 
monitoring the compliance of Governments with the 
international drug control treaties and for providing 
 support to Governments in that regard.
26. The Board, under article 9 of the 1961 Convention, 
has the responsibility to ensure the availability of narcotic 
drugs for medical and scientific purposes. It is in a unique 
position to monitor the cultivation, production, manufac-
ture, import, export and consumption of narcotic drugs 
and psychotropic substances. 
27. Over the years, the Board has reminded Governments 
of their obligations in this regard. It has repeatedly voiced 
its concern about the disparate and inadequate levels of 
access to controlled substances for medical and scientific 
purposes worldwide. It has raised this problem repeatedly 
in its annual reports and devoted a number of special 
reports to the topic.
28. The Economic and Social Council, in its resolution 
1989/15 of 22 May 1989, requested the International 
Narcotics Control Board to “assess legitimate needs for 
opiates in various regions of the world, hitherto unmet 
because of insufficient health care, difficult economic situ-
ations or other conditions”. Pursuant to that resolution, 
INCB prepared a special report entitled Demand for and 
Supply of Opiates for Medical and Scientific Needs.26
29. In that report, the Board concluded that the  medical 
need for opiates, particularly those related to the  treatment 
of cancer pain, were not being fully satisfied. The report 
further recommended that Governments should:
 26 E/INCB/1989/1/Supp.
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 •  Critically examine their methods for assessing 
domestic medical needs for opiates and collect-
ing and analysing data to ensure that estimates 
reflected actual needs.
 •  Examine the extent to which their health-care 
systems and laws and regulations permitted the 
use of opiates for medical use.
 • Identify impediments to such use.
 •  Develop plans of action to facilitate the supply 
and availability of opiates for all appropriate 
indications.
30. The Economic and Social Council, in its resolutions 
1990/31 and 1991/43, requested the Board to give  priority 
to monitoring the implementation of those recommen-
dations. In 1994, the Board examined the effectiveness 
of the international drug control treaties in a supplement 
to its annual report, entitled Effectiveness of the 
International Drug Control Treaties.27 In its evaluation, 
the Board  concluded that the treaty objective of  ensuring 
an  adequate supply of narcotic drugs, especially opiates 
used for medical purposes, had not been universally 
achieved.
31. In 1995, the Board prepared another special report, 
entitled Availability of Opiates for Medical Needs.28 In that 
report, the Board noted that most Governments had not 
responded to its questionnaire aimed at determining the 
progress made in the implementation of the recommen-
dations, but concluded that the recommendations of 1989 
were far from being implemented, although there had 
been efforts by some Governments. The Board provided 
a new set of recommendations for the consideration of 
Governments; the United Nations Drug Control 
Programme; the Commission on Narcotic Drugs; WHO; 
international and regional drug control, health and 
humanitarian organizations; and educational institutions, 
as well as non-governmental health-care organizations, 
including the International Association for the Study of 
Pain and other health-care representatives.
32. Furthermore, chapter I of the annual report of the 
Board for 1999 was dedicated to the issue of the availa-
bility of narcotic analgesics. As internationally controlled 
drugs were overused in some countries, leading to 
 prescription drug abuse and related problems, chapter I 
of the annual report of the Board for 2000 dealt with 
overconsumption of internationally controlled drugs and 
recommended a balanced approach in their use. 
 27 E/INCB/1994/1/Supp. 1.
 28 E/INCB/1995/Supp. 1.
33. One tool to determine whether countries improve 
availability levels, or at least are aware of the problem and 
show the intention to improve, is an analysis of their 
assessments of annual estimated requirements for narcotic 
drugs, which all countries are required to submit to the 
Board. The Board regularly contacts countries with miss-
ing or particularly low estimates in order to ensure ade-
quate availability of opioids for the treatment of pain. This 
practice was formalized in November 1999, when the 
Board started selecting certain groups of countries with 
low  levels of consumption of opioid analgesics (mainly 
morphine) and with common characteristics. The matter 
was repeatedly brought to the attention of Governments 
in circular letters to all countries and specific letters to 
individual countries. In August 2001, a joint letter from 
the President of the Board and the Chair of the United 
Nations Development Group was sent to all resident coor-
dinators of the United Nations system at the country level, 
urging them, inter alia, to be aware of underconsumption 
and the lack of medicaments available for the treatment 
of severe pain in many developing countries.
34. This request was confirmed in February 2005, in a 
follow-up joint letter from the President of the Board and 
the Chair of the United Nations Development Group. In 
April 2006, in a letter to all countries, the President of the 
Board emphasized the difficulties regarding access to nar-
cotic drugs and psychotropic substances for patients in 
need, and encouraged Governments to take measures to 
ensure the inclusion of the subject of rational use of drugs 
in the curricula of the appropriate university faculties. 
35. In 2010, INCB launched its report entitled Availability 
of Internationally Controlled Drugs: Ensuring Adequate 
Access for Medical and Scientific Purposes, which analysed 
the global situation with regard to the consumption of 
internationally controlled substances, broadening the scope 
of the report to include also psychotropic substances. 
36. The 2010 report identified once more the main 
impediments to adequate availability and provided 
detailed recommendations to various stakeholders. INCB 
noted that, in response to previous recommendations 
concerning the availability of narcotic drugs, a significant 
number of Governments had increased their annual esti-
mated requirements to meet medical demand, issued 
national policies to improve medical use of narcotic 
drugs, supported educational programmes and examined 
their health-care systems, laws and regulations to see if 
they created impediments to availability. 
37. INCB noted improvements in the adequacy of supply 
of certain narcotic drugs and psychotropic substances in 
many countries, but expressed concern about setbacks in 
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others. While the most significant improvements were 
recorded in highly developed countries, the setbacks had 
occurred mostly in the regions with the lowest levels of avail-
ability of internationally controlled substances. The report 
concluded that, in spite of the progress made towards meet-
ing treaty objectives, relatively few countries had an adequate 
drug supply management system and working mechanisms 
that ensured reliable, needs-based assessments, equitable 
availability and cost-effectiveness. 
38. The report pointed to the deficiencies in drug sup-
ply management that remained attributable to a lack of 
financial resources, inadequate infrastructure, the low pri-
ority given to health care, weak government authority, 
inadequate education and professional training, and out-
dated knowledge, which together affected the availability 
of not only controlled drugs but all medicines.
39. In 2012, a publication entitled Guide on Estimating 
Requirements for Substances under International Control29 
was launched with the aim of providing competent 
national authorities with concrete tools to improve the 
assessment of their national needs.
40. At its 108th session, in November 2013, the Board 
decided to prepare a special report to be published in 
2016 as a supplement to the INCB annual report for 2015. 
The Board decided that the report should focus on the 
implementation by Governments of the recommenda-
tions contained in its 2010 report on Availability of 
Internationally Controlled Drugs: Ensuring Adequate 
Access for Medical and Scientific Purposes.
41. Pursuant to that decision, the present report is 
aimed at providing an updated overview of the situation 
with regard to the availability of narcotic drugs and psy-
chotropic substances for medical and scientific purposes 
as compared with the situation presented in 2010. 
D. Methodology
1. Data on consumption
42. The data provided by countries to INCB show one 
aspect of the issue of availability, i.e. the amounts that the 
competent national authorities estimate and report as 
consumed. This information is available for a large num-
ber of countries for several years. However, since the 
 29 International Narcotics Control Board and World Health 
 Organization, Guide on Estimating Requirements for Substances under 
International Control (New York, 2012).
quality of reporting varies from country to country, such 
information is not always reliable, even though INCB has 
the ability to verify reported consumption by using data 
from export and import notifications. The Board evalu-
ates these consumption data in terms of “defined daily 
doses for statistical purposes” to ascertain the degree of 
overprescription or underprescription. 
43. The term “defined daily doses for statistical pur-
poses” (S-DDD) has replaced the term “defined daily 
doses”, which had previously been used by the Board. The 
defined daily doses for statistical purposes is used by 
INCB as a technical unit of measurement for the purpose 
of statistical analysis and is not a recommended prescrip-
tion dose. This definition, which is not free of a certain 
degree of arbitrariness, recognizes that there are no inter-
nationally agreed standard dosages for narcotic drugs and 
psychotropic substances, that they are used in certain 
countries for different treatments or in accordance with 
different medical practices, and that therefore S-DDD 
should be considered an approximate measure to rank 
consumption in different countries. For narcotic drugs, 
levels of consumption, expressed in S-DDD per million 
inhabitants per day, are calculated by using the following 
formula: annual consumption, excluding the manufacture 
of the preparations in Schedule III of the 1961 Convention, 
divided by 365 days. The result obtained is divided suc-
cessively by the population, in  millions, of the country or 
territory during the year in question, and then by the 
defined daily dose of each substance.30
44. Since the 1971 Convention does not foresee report-
ing on consumption of psychotropic substances to the 
Board, the rates of consumption are calculated by the 
Board every year, based on statistics reported by 
Governments on manufacture, industrial use, stocks and 
international trade. The rate of consumption of psycho-
tropic substances is measured in S-DDD per 1,000 inhab-
itants per day. In addition, for the purposes of the  present 
report, three-year averages were used, in order to account 
for the occasional non-submission of annual statistics, 
and in view of the practice by some Governments of 
intermittent manufacture and import of psychotropic 
substances when stocks cover domestic requirements for 
several years.
45. The analysis of the availability of psychotropic sub-
stances contained in the present report is based on the lev-
els of consumption of groups of psychotropic substances. 
 30 For some countries, the S-DDD calculated for the period 2001-
2003 may be higher than the successive periods because of the difficulty 
at that time of distinguishing the quantities of opioids consumed for pain 
relief and the opioids utilized for the manufacture of preparations, listed 
in Schedule III of the 1961 Convention.
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Levels of consumption of psychotropic substances expressed 
in S-DDD are calculated by using the following formula: 
manufacture plus imports plus stocks at the end of the 
 previous year, minus exports minus quantities used for 
industrial purposes, minus stocks at the end of the current 
year, divided by 365 days. The result obtained is divided 
by the population, in thousands, of the country or terri-
tory during the year in question and by the defined daily 
dose. Some cases of high calculated use of psychotropic 
substances could be related to increasing manufacture for 
exports, with a possible lack of reporting of exports and/
or a non-reporting of stocks of manufacturers and/or 
 elevated stocks kept by wholesalers. 
46. The Board has identified levels of consumption that 
it considers to be inadequate (consumption of opioid 
analgesics in quantities between 100 and 200 S-DDD per 
million inhabitants per day) or very inadequate (con-
sumption of opioid analgesics in quantities equal to or 
less than 100 S-DDD). However, the Board has not yet 
defined comparable levels of adequate or inadequate 
 consumption for psychotropic substances.
47. In the analysis of consumption of opioid analgesics 
expressed in S-DDD, the Board did not include metha-
done and buprenorphine because of the impossibility of 
distinguishing their use for pain relief from their use for 
the treatment of drug dependence.
2. Survey of Member States
48. In the summer of 2014, the Board sent  questionnaires 
to competent national authorities asking for information 
on the availability of controlled drugs for medical and 
scientific purposes. One questionnaire was devoted to 
narcotic drugs, and a separate one to psychotropic 
 substances. A total of 107 countries and territories,31 with 
 31 Algeria, Armenia, Australia, Austria, Azerbaijan, Bahrain, Belarus, 
Belgium, Belize, Benin, Bhutan, Bolivia (Plurinational State of), Bosnia 
and Herzegovina, Brazil, Brunei Darussalam, Bulgaria, Burundi, Cabo 
Verde, Canada, Chile, China, Colombia, Costa Rica, Côte d’Ivoire, 
 Croatia, Cyprus, Czech Republic, Denmark, Dominica, Ecuador, Egypt, 
El Salvador, Estonia, Finland, France, Georgia, Germany, Ghana, 
 Guatemala, Guinea-Bissau, Haiti, Honduras, Hungary, India, Indonesia, 
Iran (Islamic Republic of), Iraq, Ireland, Jamaica, Jordan, Kazakhstan, 
Kuwait, Kyrgyzstan, Latvia, Lebanon, Liberia, Lithuania, Malaysia, Malta, 
Mexico, Micronesia (Federated States of), Morocco, Myanmar, Namibia, 
Netherlands, New Zealand, Nicaragua, Oman, Palau, Peru, Philippines, 
Poland, Qatar, Republic of Korea, Republic of Moldova, Russian 
 Federation, Saint Lucia, Senegal, Serbia, Sierra Leone, Slovakia, South 
Africa, Spain, Swaziland, Sweden, Switzerland, Syrian Arab Republic, 
Tajikistan, Togo, Tunisia, Turkey, Turkmenistan, Uganda, Ukraine, 
United Kingdom of Great Britain and Northern Ireland, United States of 
America, Uzbekistan, Vanuatu, Venezuela (Bolivarian Republic of) and 
Zimbabwe, along with Bermuda; Hong Kong, China; Macao, China; 
Montserrat; New Caledonia; and Saint Helena.
75  per cent of the world’s population, responded, 
 providing important information that is discussed in the 
present report.
3. Other sources of information
49. While INCB data are important in measuring 
(through S-DDD) the performance of countries in ensur-
ing the availability of internationally controlled drugs for 
medical use, it is important to also consider other sources 
of information when evaluating the situation. To that end, 
the Board also analysed information on health conditions 
for which internationally controlled drugs are required 
in  order to compare reported consumption against the 
preva lence of the specific health conditions. 
50. The World Health Organization and the Worldwide 
Palliative Care Alliance provided information on health 
conditions requiring palliative care and the level of pal-
liative care development. The International Agency for 
Research on Cancer of WHO provided fundamental 
information on the prevalence of cancer through its 
GLOBOCAN database. Information on the prevalence of 
AIDS was made available by the Joint United Nations 
Programme on HIV/AIDS (UNAIDS). The United 
Nations Office on Drugs and Crime provided informa-
tion on the number of people who inject drugs, which 
was then used to measure the specific availability of inter-
nationally controlled drugs (methadone and buprenor-
phine) used in the treatment of opioid dependence in 
relation to the prevalence of people who would be in need 
of such treatment.
51. In addition, various civil society organizations rep-
resenting patients, families, health professionals and other 
stakeholders have also contributed data and information, 
and offered their views. A number of researchers have 
provided relevant analyses and insights.
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Narcotic drugs
A. Supply of and demand for opiate 
raw materials and opioids
52. Inadequate distribution of consumption of opioid 
analgesics is not the result of a lack of supply of raw mate-
rials and opioids. To the contrary, the Board has been 
concerned by an increase in the production of such sub-
stances without a corresponding increase in consump-
tion, leading to a consequent increase in stocks.
53. Opiates consumed by patients for medical treatment 
are obtained from opiate raw materials (opium, poppy 
straw and concentrate of poppy straw). Adequate availa-
bility of opiate raw materials for the manufacture of opi-
ates is therefore a precondition for ensuring the adequate 
availability of opiates used for medical and scientific 
purposes.
54. Pursuant to the 1961 Convention and the relevant 
resolutions of the Commission on Narcotic Drugs and 
the Economic and Social Council, the Board examines on 
a regular basis developments affecting the supply of and 
demand for opiate raw materials. The Board endeavours, 
in cooperation with Governments, to maintain a lasting 
balance between supply and demand. Global stocks of 
opiate raw materials should cover global demand for 
about one year to ensure the availability of opiates used 
for medical and scientific purposes in the event of an 
unexpected decline in production resulting from, for 
example, adverse weather conditions in producing 
countries.32
55. At the end of 2013, global stocks of opiate raw 
materials rich in morphine were sufficient to cover 
global demand for 14 months. Global stocks of opiate 
raw materials rich in thebaine were sufficient to cover 
global demand for 12 months. In 2014, the global pro-
duction of opiate raw materials rich in morphine was 
greater than the utilization of those materials. The global 
supply (stocks and production) of opiate raw materials 
rich in morphine was fully sufficient to cover global 
demand. 
56. Figure 1 presents data on the manufacture, stocks, 
consumption and utilization33 of morphine during the 
period 1994-2013. Global manufacture of morphine dou-
bled during that 20-year period, increasing from about 
247.1 tons in 1994 to 522.6 tons in 2013, which was a 
further increase from the 475.3 tons recorded in 2012. 
Around 70 per cent of the morphine manufactured glob-
ally is converted into other narcotic drugs or into sub-
stances not covered by the 1961 Convention. The rest is 
used directly for medical purposes.
 32 Report of the International Narcotics Control Board for 2014 
(E/INCB/2014/1), para. 90.
 33 “Consumption” indicates the quantity of the drug to be consumed 
directly for domestic medical and scientific purposes, while “utilization” 
refers to quantity of the drug to be utilized for the manufacture of other 
drugs, preparations included in Schedule III of the 1961 Convention or 
substances not covered by the 1961 Convention.
10  AVAILABILITY OF INTERNATIONALLY CONTROLLED DRUGS
Figure 1. Morphine: global manufacture, 
stocks, consumption and utilization, 1994-2013 
Source: International Narcotics Control Board.
a Stocks as at 31 December of each year.
57. Until the 1990s, thebaine, the other main alkaloid 
obtained from opium poppy, was manufactured mainly 
from opium; since 1999, it has been obtained primarily from 
poppy straw. Thebaine may also be obtained through the 
conversion of oripavine or from semi-synthetic opioids, such 
as hydrocodone. Thebaine itself is not used therapeutically, 
but it is an important starting material for the manufacture 
of a number of opioids, mainly codeine, dihydrocodeine, 
etorphine, hydrocodone, oxycodone and oxymorphone (all 
of which are controlled under the 1961 Convention) and 
buprenorphine (which is controlled under the 1971 
Convention). Global manufacture of thebaine has increased 
sharply since the late 1990s, as a consequence of the grow-
ing demand for oxycodone and other drugs and substances 
that may be derived from it (see figure 2).
Figure 2. Thebaine: global manufacture, 
utilization and stocks, 1994-2013
Source: International Narcotics Control Board.
a Stocks as at 31 December of each year.
58. The information available to the Board indicates 
that global production of opiate raw materials rich in the-
baine exceeded global demand in 2014. Total stocks of 
opiate raw materials rich in thebaine were sufficient to 
cover global demand for about one year. The plans of pro-
ducing countries indicate that global production of opi-
ate raw materials rich in thebaine will be slightly less than 
global demand in 2015. Total stocks of opiate raw mate-
rials rich in thebaine are therefore expected to decrease. 
The global supply (stocks and production) of opiate raw 
materials rich in thebaine will continue to be sufficient 
to fully cover global demand.
59. Codeine is a natural alkaloid of the opium poppy 
plant, but most of the codeine currently being manu-
factured is obtained from morphine through a semi- 
synthetic process. There has been an increase in the 
 cultivation of the opium poppy variety that is rich in 
codeine and in the manufacture of concentrate of poppy 
straw rich in codeine, which is used for the extraction of 
codeine. Global utilization of concentrate of poppy straw 
rich in codeine amounted to 24.6 tons in 2013, which is 
a fraction of the amount of morphine used. Codeine is 
used mainly for the manufacture of preparations in 
Schedule III of the 1961 Convention, while a smaller 
quantity is used for the manufacture of other narcotic 
drugs, such as dihydrocodeine and hydrocodone. The 
trends relating to global manufacture, consumption, 
 utilization and stocks of codeine during the period 1994-
2013 are shown in figure 3.
Figure 3. Codeine: global manufacture, 
stocks, consumption and utilization, 1994-2013
Source: International Narcotics Control Board.
a Stocks as at 31 December of each year.
60. Global demand for opiate raw materials rich in mor-
phine and rich in thebaine is expected to rise in the 
future. It is anticipated that global demand for opiates 
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and opiate raw materials will also continue to rise. 
Figure  4 presents the global level of consumption of 
 opiates and synthetic opioids, including buprenorphine 
and pentazocine, which are opioids controlled under the 
1971 Convention, during the 20-year period from 1994 
to 2013. To allow the aggregation of consumption data 
for substances having different potencies, the levels of 
consumption are expressed in billions of S-DDD.
Figure 4. Global consumption of opioids, 
1994-2013
Source: International Narcotics Control Board.
a Including buprenorphine, an opiate controlled under the 1971 
Convention.
b Including pentazocine, a synthetic opioid controlled under the 
1971 Convention.
c Including opiates and synthetic opioids.
61. Over the past 20 years, global consumption of opi-
oids has more than tripled. The consumption of opiates as 
a percentage of total consumption of opioids fluctuated 
between 62 per cent in 1994 and 52 per cent in 2006, ris-
ing again to 61 per cent in 2013. As a result, the share of 
synthetic opioids, which are used for the same indications 
as opiates, increased from 38 per cent in 1994 to 48 per 
cent in 2008, but declined to 39 per cent in 2013. Between 
2010 and 2013, the ratio of consumption of opiates to syn-
thetic opioids stabilized at about 60 per cent for opiates 
and 40 per cent for synthetic opioids. Throughout the 
period, the supply of opiate raw materials from which 
 opiates were obtained was sufficient to cover increasing 
demand. It is expected that the demand for opiates will 
increase again in the future, while their share of the total 
consumption of opioids may decline, owing to expected 
growth in the consumption of synthetic opioids.
62. Overall, the available data indicate that the amount 
of opiate raw materials available for the manufacture of 
narcotic drugs for pain relief is more than sufficient to 
satisfy the current level of demand as estimated by 
Governments. In addition, both production and stocks 
continue to increase. 
B. Availability of opioid analgesics
63. Opioid analgesics are essential medicines for palli-
ation therapy.34 They are prescribed mainly in relation to 
cancer, but palliation therapy is also needed for other 
health situations that require the management of pain 
(such as surgery and childbirth) and for chronic condi-
tions such as cardiovascular diseases, chronic respiratory 
diseases, HIV/AIDS and diabetes. 
64. Each year, around 5.5 million terminal cancer 
patients, 1 million end-stage HIV/AIDS patients and 
800,000 patients with lethal injuries caused by accidents 
or violence, in addition to patients with chronic illnesses, 
patients recovering from surgery, women in labour and 
paediatric patients, are subjected to untreated or under-
treated moderate to severe pain. All in all, WHO  estimates 
that annually tens of millions of people are suffering 
 without adequate treatment.35
65. It is estimated that, out of the 20 million people in 
need of palliative care at the end of their lives, about 
80  per cent live in low- or middle-income countries.36 
According to the Worldwide Palliative Care Alliance, 
every year at least 100 million people worldwide would 
benefit from palliative care; however, fewer than 8 per 
cent of people in need of palliative care have access to it. 
According to the Harvard Global Equity Initiative-Lancet 
Commission on Global Access to Pain Control and 
Palliative Care, “the absence of palliative care also under-
mines efforts to improve human well-being, and 
 34 World Health Organization, Model List of Essential Medicines, 
19th list (April 2015, amended June 2015). Available from www.who.int/
medicines/publications/essentialmedicines.
 35 World Health Organization, Ensuring Balance in National Policies 
on Controlled Substances: Guidance for Availability and Accessibility of 
Controlled Medicines (Geneva, 2011).
 36 Report by the secretariat of the World Health Organization on the 
strengthening of palliative care as a component of integrated treatment 
throughout the life course.
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impoverishes a host of interventions intended to reduce 
human suffering and strengthen health systems”.37
66. In many countries, especially in less developed 
regions, the possibility of preventing, treating and curing 
cancer early is severely limited by a number of factors, 
including a lack of early detection and prevention  policies, 
and the limits of the health system. In many situations, 
palliation may be the only option available for handling 
an increasing number of cases.
67. Other internationally controlled drugs, such as 
methadone and buprenorphine (an opioid analgesic 
which is controlled under the 1971 Convention and 
whose use in substitution therapy continues to increase), 
can be used in the management of pain but are mostly 
used in the treatment of drug dependence. However, their 
use is also limited in some countries despite a consider-
able prevalence of heroin abuse.
68. In spite of the common prevalence of the above- 
mentioned conditions in all regions, pain relief drugs are not 
available in sufficient quantities, are difficult to obtain because 
of unduly restrictive procedures, and are not prescribed, 
owing to a lack of training and capacity of health profession-
als or because of fear of addiction, which discourages health 
professionals from prescribing such medications. 
69. Consequently, severe pain is often left untreated, 
although medical professionals have the capacity to relieve 
most such pain. Untreated pain diminishes the quality of 
life of patients, their families, their friends and their com-
munities, and may lead to wider losses for society.38
 37 F. Knaul and others, “Closing the divide: the Harvard Global 
Equity Initiative-Lancet Commission on Global Access to Pain Control 
and Palliative Care”, The Lancet (8 March 2015).
 38 N.I. Cherny and others, “The Global Opioid Policy Initiative 
(GOPI) project to evaluate the availability and accessibility of opioids for 
the management of cancer pain in Africa, Asia, Latin America and the 
Carribean, and the Middle East: introduction and methodology”, Annals 
of Oncology, Vol. 24, Suppl. No. 11 (2013), pp. xi7-xi13.
1. Global patterns of consumption of 
opioid analgesics
(a) Inadequate access
70. The data available to INCB indicate an increase in 
the level of reported consumption in S-DDD in the 2011-
2013 period in comparison with the 2001-2003 period 
(see maps 1 and 2). In particular, there was visible pro-
gress with regard to availability in Latin America and in 
the Middle East. In Latin America, consumption of opi-
oid analgesics could possibly be even higher than reported 
because methadone (which is not included in the global 
S-DDD calculation because of its prevalent use in opiate 
substitution treatment) is more frequently used for pain 
relief in this region than in other regions. Very little is 
used for drug dependence treatment, since the prevalence 
of heroin abuse is relatively low and therefore opiate sub-
stitution treatment services are not common.
71. There have been some small improvements in the 
Russian Federation and in some countries in Central 
Asia. However, the situation remains problematic in most 
of Africa and parts of Asia. 
72. The United States, Canada, Australia and some 
countries in Western Europe have increased their levels 
of consumption to above 10,000 S-DDD per million 
inhabitants per day. In some of these countries, there has 
been a considerable increase in prescription drug abuse, 
which Governments have taken action to reduce without 
limiting access for people in need of pain relief 
medicines.
73. Overall, there has been encouraging progress 
towards ensuring availability and increasing access to opi-
oid analgesics, but that goal is still a distant one for a 
considerable number of countries.
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Map 1. Availability of opioids for pain management (2001-2003 average)
Source: International Narcotics Control Board.
Note: Opioids defined as codeine, dextropropoxyphene, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, ketobemidone, 
 morphine, oxycodone, pethidine, tilidine and trimeperidine.
Map 2. Availability of opioids for pain management (2011-2013 average)
Source: International Narcotics Control Board.
Note: Opioids defined as codeine, dextropropoxyphene, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, ketobemidone, 
 morphine, oxycodone, pethidine, tilidine and trimeperidine.
The boundaries and names shown and the designations used on this map do not imply  official  endorsement 
or acceptance by the United Nations. The final boundary between South  Sudan and the Sudan has not 
yet been determined. The dotted line represents  approximately the Line of Control in Jammu and Kashmir 
agreed upon by India and Pakistan. The final status of Jammu and Kashmir has not yet been agreed upon by 
the parties. A  dispute exists between the Governments of Argentina and the United Kingdom of Great Britain 
and Northern Ireland concerning sovereignty over the Falkland Islands (Malvinas).
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The boundaries and names shown and the designations used on this map do not imply official  endorsement 
or acceptance by the United Nations. The final boundary between South  Sudan and the Sudan has not 
yet been determined. The dotted line represents approximately the Line of Control in Jammu and Kashmir 
agreed upon by India and Pakistan. The final status of Jammu and Kashmir has not yet been agreed upon by 
the parties. A dispute exists between the Governments of Argentina and the United Kingdom of Great Britain 
and Northern Ireland concerning sovereignty over the Falkland Islands (Malvinas).
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(b) Evolution of the consumption of 
opioid analgesics over time 
74. In the past two decades, global consumption of opi-
oid analgesics expressed in S-DDD has increased consid-
erably. The long-term trend shows an overall increase of 
618 per cent between the 1991-1993 period and the 2011-
2013 period (see figure 5). That trend was especially pro-
nounced during the initial years: between 1991-1993 and 
2001-2003, there was an increase of 240 per cent, com-
pared with an increase of 84 per cent between 2001-2003 
and 2007-2009. The growth rate declined further to 
14  per cent during the period between 2007-2009 and 
2011-2013. The increase in consumption is mainly the 
result of an increase in the consumption of fentanyl and, 
to a limited extent, the consumption of morphine. Global 
consumption of codeine and pethidine for the treatment 
of pain has decreased.
Figure 5. Global trend in the consumption of 
opioid analgesics, 1991-1993, 2001-2003, 
2007-2009 and 2011-2013 averages
Source: International Narcotics Control Board.
75. The growth in consumption of opioid analgesics 
observed since 1991 has been uneven among regions. It 
has been driven mainly by North America, but also by 
Europe and Oceania, the three major consumer regions 
(see figures 6-17). 
76. In Asia, the situation is mixed. Here, most countries 
saw an increase in their consumption during the past dec-
ade, although with varying trends at the subregional level. 
A moderate increase was observed in East, South-East 
and West Asia, while there was a decrease in South Asia, 
which continued to have the lowest level of consumption 
in the world. This decrease is probably attributable to a 
considerable decrease to the consumption of opioid anal-
gesics in India as a consequence of legislative restrictions 
that had been introduced in the past. Those restrictions 
have recently been lifted, but it will take some time before 
the gap in consumption is closed.
77. In Africa, the situation is problematic and 
 consumption continues to be very low despite progress 
in a few countries. Patterns of consumption fluctuated 
 considerably both in countries with higher levels of 
 consumption and in countries with lower levels of 
 consumption. This is probably due to a lack of capacity 
of competent national authorities to estimate correctly 
their national needs. 
78. In Central America and the Caribbean, the overall 
trend shows increased consumption, but there were con-
siderable variations among countries. Consumption in 
Central American and Caribbean countries was still 
below an adequate level. In South America, most  countries 
had increased their consumption in 2011-2013, even 
though some of them had experienced drops in 
 consumption in earlier periods. The data for these two 
subregions, but particularly for South America, have 
some limitations because, while methadone is used in 
some of the countries of the region as a pain relief 
 medication and not in substitution treatment—heroin 
abuse in the region is not common—it is excluded from 
the S-DDD calculation at the global level. 
79. In Europe, the overall trend showed an increase, 
with some stabilization for some countries. 
80. In Australia and New Zealand, consumption 
increased, which influenced the trend for the whole 
region.
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Figure 6. Trends in consumption, by region, 
2001-2013
Source: International Narcotics Control Board.
Figure 7. Trends in consumption for selected 
subregions, 2001-2013
Source: International Narcotics Control Board.
Figure 8. Average consumption of opioid analgesics, all regions, 2001-2003, 2007-2009 and 2011-2013
Source: International Narcotics Control Board.
Figure 9. Average consumption of opioid analgesics in African countries and territories with 
higher levels of consumption, 2001-2003, 2007-2009 and 2011-2013
Source: International Narcotics Control Board.
Note: Red lines: levels less than 200 S-DDD are considered inadequate; levels less than 100 S-DDD are considered very inadequate. For 
further information on inadequate and very inadequate levels of consumption as identified by the Board, see paragraph 46, above.
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Figure 10. Average consumption of opioid analgesics in African countries with lower levels of 
consumption, 2001-2003, 2007-2009 and 2011-2013
Source: International Narcotics Control Board.
Figure 11. Average consumption of opioid analgesics in Central America and the Caribbean, 
2001-2003, 2007-2009 and 2011-2013
Source: International Narcotics Control Board.
a The Netherlands Antilles was dissolved on 10 October 2010, resulting in two new constituent entities, Curaçao and Sint Maarten.
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Figure 12. Average consumption of opioid analgesics in South America, 2001-2003, 2007-2009 
and 2011-2013
Source: International Narcotics Control Board.
Note: Red lines: levels less than 200 S-DDD are considered inadequate; levels less than 100 S-DDD are considered very inadequate. For 
further information on inadequate and very inadequate levels of consumption as identified by the Board, see paragraph 46, above.
Figure 13. Average consumption of opioid analgesics in Asian countries and territories with 
higher levels of consumption, 2001-2003, 2007-2009 and 2011-2013
Source: International Narcotics Control Board.
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Figure 14. Average consumption of opioid analgesics in Asian countries and territories with lower 
levels of consumption, 2001-2003, 2007-2009 and 2011-2013
Source: International Narcotics Control Board.
Note: Red lines: levels less than 200 S-DDD are considered inadequate; levels less than 100 S-DDD are considered very inadequate. For 
further information on inadequate and very inadequate levels of consumption as identified by the Board, see paragraph 46, above.
Figure 15. Average consumption of opioid analgesics in European countries and territories with 
higher levels of consumption, 2001-2003, 2007-2009 and 2011-2013
Source: International Narcotics Control Board.
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Figure 16. Average consumption of opioid analgesics in European countries with lower levels of 
consumption, 2001-2003, 2007-2009 and 2011-2013
Source: International Narcotics Control Board.
Figure 17. Average consumption of opioid analgesics in Oceania, 2001-2003, 2007-2009 and 
2011-2013
Source: International Narcotics Control Board.
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(c) Overconsumption and prescription 
drug abuse
81. While inadequate access to opioid analgesics in 
some regions is a matter of concern, it is important to 
also consider that in regions with high levels of consump-
tion there are growing public health concerns regarding 
the abuse of prescription drugs, which in some countries 
has outpaced the abuse of illegal drugs. 
82. Many factors are contributing to this development, 
but the main ones are the widespread availability of pre-
scription drugs and the erroneous perception that they 
are less susceptible to abuse than illicit drugs. The non-
prescription use of prescription drugs for self- medication 
has further exacerbated the problem.
83. A comparative analysis by UNODC39 of the con-
sumption of opioid analgesics and the prevalence of their 
 39 World Drug Report 2014, United Nations publication, Sales No. 
E.14.XI.7.
misuse shows a high prevalence of misuse of opioids in 
some countries. This is reported by high-income coun-
tries40 such as Australia, Canada and the United States and 
by lower-middle-income countries such as Nigeria and 
Pakistan, which have the lowest per capita consumption of 
opioids for medical purposes (see figures 18-19).41 
According to UNODC, that suggests that the misuse of 
prescription opioids does not necessarily follow from mak-
ing opioids accessible or available for medical purposes.42 
 40 Based on the World Bank classification of income levels and 
development.
 41 The annual prevalence of misuse of prescription opioids is as 
 follows: Australia, 3.1 per cent; Canada, 1 per cent; Nigeria, 3.6 per cent; 
Pakistan, 1.5 per cent; and United States, 5.2 per cent.
 42 World Drug Report 2014.
Figure 18. Per capita consumption of opioid analgesics, 2011
Source: UNODC.
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Figure 19.  Prevalence of misuse of prescription opioids in the general population, 2013 or latest 
available data
Source: UNODC.
84. To address this problem, countries need to develop 
a comprehensive strategy aimed at tackling the root 
causes of the excessive supply of prescription drugs, 
including overprescribing by medical professionals, “doc-
tor shopping” and inadequate controls on the issuing and 
filling of prescriptions. In addition, public health officials 
identified the presence in households of prescription 
drugs that are no longer needed or used for medical pur-
poses as one of the main sources of prescription drugs 
diverted from licit channels for abuse. Surveys of the 
prevalence of abuse undertaken in several countries have 
revealed that a significant percentage of individuals abus-
ing prescription drugs for the first time had obtained the 
drug from a friend or family member who had acquired 
them legally.
85. Among the measures increasingly being used to 
address this problem are mechanisms to ensure the safe 
return and disposal of medications possessing psycho-
active properties, particularly those containing narcotic 
drugs or psychotropic substances, including through 
 prescription drug take-back days. The setting up of such 
initiatives in many jurisdictions has yielded significant 
results at a relatively low cost.
86. The importance of these measures has been recog-
nized by the international community, including by the 
Commission on Narcotic Drugs. Accordingly, in March 
2013 the Commission adopted resolution 56/8, on pro-
moting initiatives for the safe, secure and appropriate 
return for disposal of prescription drugs, in particular 
those containing narcotic drugs and psychotropic sub-
stances under international control. 
87. In that resolution, the Commission encouraged 
States to consider the adoption of a variety of courses of 
action to address prescription drug abuse, in cooperation 
with various stakeholders such as public health officials, 
pharmacists, pharmaceutical manufacturers and distribu-
tors, physicians, consumer protection associations and 
law enforcement agencies, in order to promote greater 
awareness of the risks associated with the non-medical 
use of prescription drugs, in particular those containing 
narcotic drugs or psychotropic substances. 
(d) Consumption of opioid analgesics and 
the need for palliative care
88. The patterns of consumption of opioid analgesics 
expressed in S-DDD or in milligrams per capita tell only 
part of the story. In order to ascertain if the level of con-
sumption is appropriate, it is important to measure it in 
relation to the prevalence of health conditions requiring 
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palliative care, which include not only cancer but also 
other conditions. Also, while consumption of opioid anal-
gesics is concentrated in a few countries, the prevalence 
of conditions requiring their use is much more 
widespread.
89. Information from the Global Atlas of Palliative Care 
at the End of Life,43 prepared by WHO and the Worldwide 
Palliative Care Alliance, indicates that cancer is respon-
sible for 28 per cent of adult deaths requiring palliative 
care. The majority (66 per cent) of deaths requiring such 
care are related to progressive non-malignant diseases 
(PNMD).44 The remaining 6 per cent are due to AIDS 
(see figure 20).
90. In all but low-income countries, the share of adults 
in need of palliative care for cancer remains more or less 
constant at around 33-38 per cent; that share drops to 
around 23 per cent in low-income countries (see 
 figure  21). Progressive non-malignant diseases continue 
to comprise the majority of cases in all regions. The need 
for AIDS palliative care comprises one third of palliative 
 43 World Health Organization and Worldwide Palliative Care 
 Alliance, Global Atlas of Palliative Care at the End of Life (Worldwide 
 Palliative Care Alliance, 2014).
 44 Progressive non-malignant diseases among adults are considered to 
be Alzheimer’s disease and other dementias, cardiovascular diseases 
(excluding sudden deaths), chronic obstructive pulmonary diseases, 
 cirrhosis of the liver, Diabetes mellitus, multiple sclerosis, kidney diseases, 
Parkinson’s disease, rheumatoid arthritis and tuberculosis (multidrug-
resistant tuberculosis and extensively drug-resistant tuberculosis only).
care cases in low-income countries, but remains below 10 
per cent in countries with higher income levels.
91. The latest data available from the International 
Agency for Research on Cancer, the specialized cancer 
research agency of WHO, show that the global burden of 
cancer has risen to 14.1 million new cases and 8.2 mil-
lion cancer deaths in 2012, compared with 12.7 million 
new cases and 7.6 million deaths in 2008. Prevalence esti-
mates for 2012 show that there were 32.6 million people 
alive and over the age of 15 years who had been  diagnosed 
with cancer in the previous five years (see figure  22). 
According to projections based on estimates presented by 
the GLOBOCAN project for 2012, a substantial increase 
in new cancer cases to 19.3 million per year by 2025 is 
expected, owing to the expected increase and ageing of 
the global population. 
92. More than half of all cancer cases (56.8 per cent) 
and cancer deaths (64.9 per cent) in 2012 occurred in 
less developed regions of the world. Those proportions 
will increase further by 2025. Cancer is often presented 
as a disease of wealthy or developed populations. In real-
ity, over 70 per cent of cancer deaths occur in low- and 
middle-income countries. Without sustained action, the 
incidence of cancer is projected to increase further in 
low- and middle-income countries by 2030. Cancer is 
present throughout the world, but countries that lack the 
health infrastructure to cope with the increasing num-
ber of people suffering from the disease are particularly 
affected. 
Figure 20. Deaths from diseases requiring 
palliative care at the end of life, by type of 
disease, 2011
Source: World Health Organization and Worldwide Palliative Care 
Alliance, Global Atlas of Palliative Care at the End of Life (Worldwide 
Palliative Care Alliance, 2014).
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Figure 21. Distribution of adults in need of 
palliative care at the end of life by income 
group and disease category, 2011
Source: World Health Organization and Worldwide Palliative Care  
Alliance, Global Atlas of Palliative Care at the End of Life (Worldwide 
Palliative Care Alliance, 2014).
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Figure 22. Prevalence of cancer diagnoses 
within the previous five years, per 100,000 
population, 2012
Source: GLOBOCAN database.
93. In low- and middle-income countries, where there 
is limited capacity with regard to prevention and early 
detection of cancer, the disease is mostly discovered when 
it is at an advanced stage. By then, there are not many 
treatment options and palliation is required. Opioid analge-
sics for cancer treatment are therefore are indispensable 
in these countries. 
94. Plotting the level of consumption of opioid analge-
sics against the cancer age-standardized rate45 confirms the 
global imbalance in the consumption of such substances, 
with the United States, Canada, Australia, New Zealand 
and Western and Central European countries registering 
high levels of consumption, with a corresponding high 
cancer age-standardized rate. A global comparison is dif-
ficult owing to the fact that most countries are clustered 
together in the lower levels as a result of the high level of 
consumption in a few countries (see figure 23). If the pat-
terns in each region are examined in detail, it is possible 
to gain a better idea of the global variations.
 45 GLOBOCAN presents cancer data in an age-standardized rate, 
which is a summary measure of the rate that a population would have if it 
had a standard age structure. Standardization is necessary when compar-
ing several populations that differ with respect to age because age has a 
powerful influence on the risk of cancer. The age-standardized rate is a 
weighted mean of the age-specific rates; the weights are taken from the 
population distribution of the standard population. The most frequently 
used standard population is the World Standard Population. The calcu-
lated incidence or mortality rate is then called age-standardized incidence 
or mortality rate (world), and is expressed per 100,000 people. The age-
standardized rate is calculated using 10 age groups (0-14, 15-39, 40-44, 
45-49, 50-54, 55-59, 60-64, 65-69, 70-74 and 75+). The result may be 
slightly different from that computed using the same data categorized 
using the traditional five-year age bands.
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Figure 23. Relationship between cancer incidence, 2012, and consumption of narcotic drugs, 2011-2013
Source: GLOBOCAN database and International Narcotics Control Board.
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95. In the North America region, there is a  considerable 
gap between Mexico on the one hand, and the United 
States and Canada on the other hand (see figure  24).
96. In Central and South America and the Caribbean, 
the distribution of the countries seems to indicate that 
South American countries have increased their consump-
tion of opioid analgesics and that this is the result of an 
increasing rate of cancer (see figure 25). In Central America 
and the Caribbean, there are countries with relatively 
higher rates of cancer, but their consumption of narcotic 
drugs for palliative care is below the adequate level.
97. In Africa, there seems to be a concentration of 
countries with a cancer age-standardized rate of 100, with 
a number of countries exceeding it while the consump-
tion of opioid analgesics remains well below the level of 
200 S-DDD per million inhabitants per day (see 
figure 26).
98. In Asia, the level of consumption in S-DDD per mil-
lion inhabitants per day is higher, but this corresponds 
to higher cancer rates. In Western Europe, consumption 
is high and seems to match the level of cancer prevalence. 
In Eastern and South-Eastern Europe, cancer rates are 
similar to Western Europe but the level of consumption 
of pain relief drugs is considerably lower. Australia and 
New Zealand have very high levels of consumption, while 
other, smaller countries in Oceania have much lower lev-
els (see figures 27-30).
Figure 27. Relationship between cancer 
incidence, 2012, and consumption of narcotic 
drugs, 2011-2013, Asia
Source: GLOBOCAN database and International Narcotics Control 
Board.
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Figure 26. Relationship between cancer 
incidence, 2012, and consumption of narcotic 
drugs, 2011-2013, Africa
Source: GLOBOCAN database and International Narcotics Control 
Board.
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Figure 25. Relationship between the cancer 
age-standardized rate, 2012, and consumption 
of narcotic drugs, 2011-2013, Central and South 
America and  the Caribbean
Source: GLOBOCAN database and International Narcotics Control 
Board.
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Figure 24. Relationship between the cancer 
age-standardized rate, 2012, and consumption 
of narcotic drugs, 2011-2013, North America
Source: GLOBOCAN database and International Narcotics Control 
Board.
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Figure 28. Relationship between cancer 
incidence, 2012, and consumption of narcotic 
drugs, 2011-2013, Western Europe
Source: GLOBOCAN database and International Narcotics Control 
Board.
Figure 29. Relationship between cancer 
incidence, 2012, and consumption of narcotic 
drugs, 2011-2013, Eastern and South-Eastern 
Europe
Source: GLOBOCAN database and International Narcotics Control 
Board.
Figure 30. Relationship between cancer 
incidence, 2012, and consumption of narcotic 
drugs, 2011-2013, Oceania
Source: GLOBOCAN database and International Narcotics Control 
Board.
99. Palliative care is also required for AIDS. A compar-
ison among the various WHO regions in the Global Atlas 
of Palliative Care at the End of Life shows that the per-
centage of adults in need of palliative care in relation to 
AIDS is larger in low-income countries, particularly in 
Africa, than in countries in other income groups. 
Expanded access to antiretroviral therapy and a declining 
incidence of HIV infection have led to a steep fall glob-
ally in the number of adults and children dying from 
HIV-related causes. The drop in HIV-related mortality is 
especially evident in the regions with the greatest burden 
of HIV infection, including the African region, which was 
home to about three in four people who died from HIV-
related causes in 2013. However, HIV and AIDS preva-
lence remains high in low-income countries, and the 
availability of antiretroviral therapy is still limited, despite 
efforts made in that regard by UNAIDS and the broader 
international community. The inadequate availability of 
opioid analgesics to manage AIDS-related pain is a major 
problem for an even larger percentage of the population 
in low-income countries.
100. When comparing the estimated number of AIDS 
deaths in 201346 with the level of consumption of opioid 
analgesics, expressed in S-DDD per million inhabitants 
per day, the countries with highest number of deaths and 
lowest levels of consumption were in sub-Saharan Africa 
and Asia (see table 1). Nigeria, with an estimated 210,000 
AIDS deaths in 2013, reported no consumption of opi-
oid analgesics to INCB. India had an estimated 130,000 
AIDS deaths and just 11 S-DDD per million inhabitants 
per day. Mozambique, with only 5 S-DDD per million 
inhabitants per day, had an estimated number of deaths 
in 2013 of 82,000. The United Republic of Tanzania had 
the same level of S-DDD and 78,000 estimated deaths. 
Zimbabwe had 64,000 estimated deaths and only 35 
S-DDD. Uganda had only 30 S-DDD and 63,000 esti-
mated AIDS-related deaths. South Africa had 338 S-DDD, 
but the estimated number of AIDS-related deaths was 
200,000.
 46 World Health Organization, Global Health Observatory.
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Table 1. Estimated number of AIDS deaths, 
2013, compared with the level of consumption 
of opioid analgesics, 2011-2013
Country
Estimated AIDS 
deaths in 2013
S-DDD per  million 
 inhabitants per 
day, 2011-2013
Nigeria 210 000 0
South Africa 200 000 338
India 130 000 11
Mozambique 82 000 5
United Republic of 
Tanzania
78 000 5
Zimbabwe 64 000 35
Uganda 63 000 30
Kenya 58 000 0
Malawi 48 000 26
Ethiopia 45 000 0
Cameroon 44 000 4
Democratic Republic 
of the Congo
30 000 2
Indonesia 29 000 16
Côte d’Ivoire 28 000 1
Zambia 27 000 32
Source: International Narcotics Control Board and WHO Global 
Health Observatory.
101. Even though the table above confirms that AIDS 
is a major health condition requiring palliation, the dis-
eases classified as progressive non-malignant diseases are 
the major reasons for the demand for palliative care in 
all regions. However, reliable prevalence rates for these 
diseases are not available at the global level, making it 
impossible to compare them with levels of consumption 
of opioid analgesics.
(e) Consumption of opioid analgesics and 
the level of development of palliative care 
102. An important aspect of the availability of opioid 
analgesics is the capacity of health systems to prescribe 
and dispense such substances through appropriate palli-
ative care services. In the Global Atlas of Palliative Care 
at the End of Life, WHO and the Worldwide Palliative 
Care Alliance classified countries in relation to the devel-
opment of the level of palliative care services in six 
categories: 
 • Level 1: no known activity
 • Level 2: capacity-building activity
 • Level 3a: isolated provision
 • Level 3b: generalized provision
 • Level 4a: preliminary health system integration
 • Level 4b: advanced health system integration
103. By looking at the map illustrating the different lev-
els of palliative care services (see map 3) and comparing 
it with the map illustrating the levels of consumption of 
opioid analgesics expressed in S-DDD (see map 4), it is 
possible to see that, even though there is generally a 
 positive direct correlation between high levels of 
 consumption and high levels of development of palliative 
care services, there are some inconsistencies.
104. In East and Southern Africa, for example, there are 
a number of countries at level 4a (Kenya, Malawi, South 
Africa, United Republic of Tanzania, Zambia and 
Zimbabwe) or level 4b (Uganda), but in all of these coun-
tries (except South Africa) the reported consumption of 
opioid analgesics is fairly low.
105. In South America (with the exception of Chile and 
Uruguay, which are considered to be at level 4a, and 
Argentina, which is rated as level 3b), most countries are 
rated at level 3a (Brazil, Colombia, Ecuador, Guyana, 
Paraguay and Peru) or level 2 (Bolivia (Plurinational State 
of) and Suriname). Nevertheless, levels of consumption 
are relatively high in the region. The apparent inconsist-
ency with the level of palliative care services may be an 
indication that consumption is high but concentrated in 
limited or privileged areas.
106. The development of palliative care services is 
important to ensure that, when opioid analgesics are 
made available, they can actually be efficiently and ration-
ally prescribed.
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Map 3. Global levels of palliative care, 2014
Source: World Health Organization and Worldwide Palliative Care Alliance, Global Atlas of Palliative Care at the End of Life (Worldwide 
 Palliative Care Alliance, 2014).
Map 4. Consumption of opioids for pain management, 2011-2013
Source: International Narcotics Control Board.
Note: Opioids defined as codeine, dextropropoxyphene, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, ketobemidone, 
 morphine, oxycodone, pethidine, tilidine and trimeperidine.
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The boundaries and names shown and the designations used on this map do not imply official  endorsement 
or acceptance by the United Nations. The final boundary between South Sudan and the Sudan has not 
yet been determined. The dotted line represents approximately the Line of Control in Jammu and Kashmir 
agreed upon by India and Pakistan. The final status of Jammu and Kashmir has not yet been agreed upon by 
the parties. A dispute exists between the Governments of Argentina and the United Kingdom of Great Britain 
and Northern Ireland concerning sovereignty over the Falkland Islands (Malvinas).
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C. Impediments to the availability 
of narcotic drugs
107. In 2014, INCB carried out a survey asking coun-
tries to provide information on policies and practices at 
the national level to implement the provisions of the 1961 
Convention to ensure the availability of narcotic drugs 
for medical and scientific purposes. The Board received 
responses from 107 countries. The following paragraphs 
are an analysis of those responses, with a particular focus 
on the impediments to availability identified by the com-
petent national authorities.47
108. An analysis of the responses indicates that in recent 
years Member States have taken action to improve availa-
bility. This is likely to have contributed to the increase in 
the consumption of opioid analgesics, as expressed in 
S-DDD per million inhabitants per day, reported earlier. 
The answers to the survey show that a large number of 
countries that are paying attention to the issue of availa-
bility and have taken action to overcome legislative, admin-
istrative and other impediments have increased access to 
narcotic drugs for medical purposes and improved the 
quality of life of people in need of palliative care. 
109. This conclusion emerges from an analysis of the 
consumption patterns examined in previous chapters, but 
it also derives from self-evaluations by countries of their 
performance in relation to the availability of narcotic 
drugs. As shown in figure 31, two thirds of countries con-
sider their situation satisfactory or entirely satisfactory 
(46 and 22 per cent, respectively), while others indicated 
the need for some (22 per cent) or significant improve-
ment (7 per cent). Obviously, these self-evaluations need 
to be checked against the real situation, but they provide 
an insight into how countries perceive their own perfor-
mance and therefore whether they are considering taking 
action or not.
 47 Results shown in the figures are based on replies submitted by 
Member States to the INCB questionnaire on availability. The number of 
responses taken into consideration for the calculation of percentages 
relates to the total number of valid responses for each of the questions, 
and therefore varies. The sum of all percentages may not amount to 100 in 
some figures, as countries are given the option of marking one or more 
options in multiple-choice questions.
Figure 31. Availability of narcotic drugs, as 
evaluated by countries themselves, 2014
Source: International Narcotics Control Board survey 2014.
110. Member States have reported to the Board on the 
main factors that unduly limit the availability of narcotic 
drugs needed for medical or scientific purposes (see 
 figure 32). Out of 96 valid responses to this specific 
 question, 36 per cent of countries indicated as a major 
impediment a lack of training or awareness among 
 members of the medical profession regarding the use of 
narcotic drugs. This was followed by fear of addiction 
(34 per cent) and limited financial resources (32 per cent).
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7%
4%
Entirely satisfactory
Satisfactory
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In need of some improvement
In need of signicant improvement
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Figure 32. Impediments to availability of narcotic drugs
Source: International Narcotics Control Board survey 2014.
111. The Board also reviewed the impediments identi-
fied by researchers and civil society organizations involved 
in health and palliative care. Sometimes the impediments 
and their prioritization identified by these stakeholders 
did not match those identified by the competent national 
authorities. Civil society and academia often consider 
onerous regulations, strict trade control measures and 
problems in sourcing as being among the causes of lim-
ited access to pain relief medications. Countries respond-
ing to the questionnaire, however, highlighted lack of 
training/awareness and fear of addiction as the main 
problems.
112. For some of these factors, it is possible to make a 
comparison with information from the surveys carried 
out by the Board in 1995 and 2010. Fear of addiction, for 
example, was identified as an impediment by 64 per cent 
of countries in 1995, but only by 47 per cent in 2010; in 
the most recent survey, it declined even further, to 34 per 
cent. Similarly, the mention of onerous regulations and 
legislative restrictions decreased considerably, as shown 
in figure 33.
113. The mention of lack of training/awareness among 
medical professionals as an impediment declined between 
1995 and 2010, but it has since increased. It was the most 
mentioned impediment in the 2014 survey, indicated by 
36 per cent of countries. Problems in sourcing or insuf-
ficient supply followed a similar trajectory. From 
31 per cent in 1995, they dropped to 8 per cent in 2010, 
and bounced back to 31 per cent in 2014. 
114. Similar fluctuations can be seen in responses  citing 
the cost of medicines or lack of financial resources: from 
28 per cent in 1995 to 32 per cent in 2014, with a drop 
to 13 per cent in 2010.
Figure 33. Impediments to availability, 
1995-2014
Source: International Narcotics Control Board surveys 1995, 2010 
and 2014.
115. The paragraphs below provide an analysis of 
responses by countries to the 2014 survey. The identified 
impediments are discussed in descending order by num-
ber of mentions. 
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1. Lack of training or awareness 
among health professionals 
116. Lack of training and awareness among health pro-
fessionals was the most often mentioned impediment in 
the responses received from Member States. Several stud-
ies and analyses of the problem confirm this. In several 
countries, health professionals may not have sufficient 
professional knowledge about pain and pain  management. 
There may be excessive concerns about the side effects of 
opioids and the possibility that patients may become 
dependent. Doctors may lack confidence in the patient’s 
report of pain, or assign low priority to pain  management. 
A possible reason for this situation may be the limited 
attention devoted to palliative care in the curricula of 
medical schools. In other cases, doctors may be reluctant 
to prescribe opioid analgesics because they do not trust 
the ability of the patients and their families to safely 
 manage them. 
117. Because of insufficient education and training on 
palliative care treatment, doctors sometimes underesti-
mate the degree of relief that can be attained with proper 
treatment, and the extent to which pain is undermedi-
cated. Physicians may also underestimate the need to use 
potent opioids, such as morphine, for severe pain, and 
instead prescribe less effective drugs. Also, some physi-
cians may not be able to establish, or may not be used to 
establishing, an interpersonal relationship that would help 
to identify the adequate pharmacological therapy and 
allow for personalized prescriptions that take the patient’s 
needs and current health status into account. 
118. In addition, nurses in some countries may not be 
adequately trained to manage pain and support patients, 
and may have misconceptions and prejudices about opi-
oid medications similar to those held by doctors, as 
described above. In some cases, nurses may administer 
lower dosages than required or none at all, or they may 
try to convince the patient to wait and endure the situa-
tion without adequate pain medication.
119. In the 2014 survey, 70 countries reported having 
an educational curriculum for medical practitioners that 
included content on the rational prescription and use of 
narcotic drugs. Of those, 73 per cent (51 countries) had 
registered an increased per capita consumption between 
the 2007-2009 and the 2011-2013 periods. 
120. Out of 61 countries that reported implementing 
awareness-raising measures to foster a deeper under-
standing of responsible prescribing practices for narcotic 
drugs among health professionals, 45 countries (74 per 
cent) had observed an increase in S-DDD per million 
inhabitants per day. Such measures have included work-
shops, seminars, special training and supervision, and 
distribution of informative materials, as well as working 
groups with pharmacists, representatives of the pharma-
ceutical industry and medical associations.
2. Fear of addiction
121. Thirty-three countries (34 per cent) reported fear 
of addiction as an impediment to availability, the second 
most mentioned impediment in the 2014 survey. Out of 
those countries, 18 (55 per cent) remained below the 
minimum levels of consumption.
122. According to Human Rights Watch, the reluctance 
among health professionals to prescribe opioid analgesics 
may be related more to the fear of causing addiction or 
respiratory distress in patients than the fear of  prosecution 
or sanction.48 This emerges also from the 2014 survey, in 
which fear of addiction was identified as an impediment 
by 33 countries and fear of prosecution or sanction by 
21 per cent.
123. It seems that fear of addiction is related to lack of 
awareness and training, as well as cultural attitudes. Both 
patients and medical professionals may be reluctant to pre-
scribe and use narcotic drugs due to lack of knowledge 
about their properties and safe ways to prescribe them, as 
well as prejudices against the use of such substances.
3. Limited financial resources
124. Thirty-one countries (32 per cent) identified finan-
cial issues as an impediment to the availability of narcotic 
drugs. Lack of resources can be particularly prohibitive 
when narcotic drug prices are high. While some formula-
tions, such as oral morphine, can be produced quite 
cheaply, prices of narcotic drugs may be driven up by gov-
ernment regulation, licensing and taxation, as well as poor 
distribution systems (e.g. ones that require expensive and 
lengthy travel to collect medicines), among other things.49 
For example, the Latin-American Association of Palliative 
Care reported that, in one country in Central America, the 
price of a one-month treatment with injectable morphine 
was more than double the national minimum monthly 
wage. In this context, availability is dependent on the abil-
ity of patients to afford narcotic drugs that are prescribed. 
Therefore, it is important to consider whether patients are 
 48 Human Rights Watch, Global State of Pain Treatment: Access to 
 Palliative Care as a Human Right (2011), chap. II.
 49 Ibid.
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expected to cover all or most costs for such drugs, or if 
there is financial support through social security or national 
health insurance schemes. In the responses to the question 
on who pays for narcotic drugs prescribed (see figure 34), 
patients were mentioned the most (83 per cent), followed 
by the government (72 per cent) and health insurance 
schemes (63 per cent). 
125. A cross-sectional study carried out in 2014 sug-
gests that, particularly in countries with limited resources 
for subsidy and reimbursement schemes for opioid anal-
gesics, the additional costs arising from regulatory 
requirements might thus be transferred directly onto 
patients. The study also found that the price of oral solid 
immediate-release morphine was 5.8 times higher in 
lower-middle-income countries than in high-income 
countries. This difference in dispensing prices may be 
related to the artificial lowering of the price of other more 
expensive formulations (fentanyl) owing to heavy subsi-
dies, which in turn creates a condition of economic dis-
advantage for oral solid immediate-release morphine.50
126. Thus, impediments to the affordability of narcotic 
drugs can derive from lack of resources, high prices cre-
ated by restrictive national regulations and international 
trade control measures, and non-supportive policies, 
including lack of public health reimbursement schemes.
Figure 34. Who bears the cost of prescribed 
narcotic drugs, 2014
Source: International Narcotics Control Board survey 2014.
 50 Liliana De Lima and others, “Cross-sectional pilot study to moni-
tor the availability, dispensed prices, and affordability of opioids around 
the globe”, Journal of Pain and Symptom Management, vol. 48, No. 4 
(October 2014).
4. Problems in sourcing from industry 
or imports
127. Many responses indicated problems in sourcing. 
Some formulations of narcotic drugs, such as oral mor-
phine, may not be available in sufficient quantities, as 
manufacturers and importers/exporters, especially in the 
case of smaller populations and/or low market demand, 
may prefer to produce and trade only more expensive for-
mulations. Marketing of such formulations, coupled with 
the subsidies granted for specific products (for example, 
fentanyl), may explain why an analysis of consumption 
data shows a much steeper increase in the consumption 
of fentanyl than of morphine. 
128. In several countries, local pharmaceutical compa-
nies lack interest in manufacturing oral morphine, in part 
because the prescribing of opioids by physicians is too 
limited and the demand from hospitals insufficient to 
 justify production. In some developing countries, mor-
phine is only available through import from international 
pharmaceutical companies, with prices that are unafford-
able both for the government and the population. Finally, 
some local pharmaceutical companies are not interested 
in producing opioid medications because of security costs 
and legal risks associated with this kind of product.
129. In addition to the lack of local production, another 
obstacle to the availability of narcotic drugs is the diffi-
culty in sourcing through imports. Several countries indi-
cated that there were shortages of medications as a result 
of delays in the supply chain due to lengthy and burden-
some regulatory requirements (e.g. import/export licens-
ing). The supply of narcotic drugs has also been found to 
be restricted by inadequate national estimates, time- 
consuming reporting requirements and difficulties in the 
management of narcotic drugs.
5. Cultural and social attitudes 
towards the treatment of pain
130. Impediments related to attitudes and knowledge, 
identified by 31 per cent of countries, included the beliefs 
of doctors, patients and their families, as well as policy-
makers. Patients may sometimes be the ones to refuse 
pain relief due to their reluctance to report pain or to 
accept the idea of taking opioids. Some patients and/or 
their family members may be concerned about the side 
effects of opioids and try to reduce the dosages. They may 
also worry about the stigma associated with the use of 
opiates or pain medication. Some patients may avoid tak-
ing opioids owing to their sedative effects, because they 
want to remain conscious, especially patients in the 
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terminal stages of a disease who may be afraid to lose the 
bond with their families. 
131. Out of 61 countries that had implemented 
 awareness-raising measures among health professionals, 
a large proportion (67 per cent) did not report fear of 
addiction as an impediment to availability (see figure 35). 
This may indicate that investing in fostering a deeper 
understanding of responsible prescribing practices for 
narcotic drugs among health professionals can contribute 
to overcoming the impediments created by the fear of 
addiction and other misconceptions regarding opioid 
analgesics and the management of pain.
Figure 35. Reports of fear of addiction among 
countries and territories that have implemented 
awareness-raising measures, 2014
Source: International Narcotics Control Board survey 2014.
6. Fear of diversion into illicit 
channels
132. Out of 96 responding countries, 29 (30 per cent) 
reported fear of diversion as an impediment to availabil-
ity. Out of these, 20 countries (69 per cent) had levels of 
consumption below 200 S-DDD per million inhabitants 
per day, a level that is not considered to be adequate by 
the Board.
133. Reported fear of diversion can result from the 
experiences of countries with the emergence of unregu-
lated parallel markets for narcotic drugs. Among the 
countries that reported fear of diversion as an impedi-
ment, 41 per cent also reported experiencing problems 
with parallel markets. One country mentioned that lim-
ited availability had been the result of stricter regulatory 
measures enacted in response to the use of the Internet 
to purchase and sell opioid analgesics without 
prescription.
7. Fear of prosecution or sanction
134. Out of 99 responding countries, 81 (82 per cent) 
reported the existence of penalties for inadequate record-
keeping. Reported penalties ranged from monetary fines, 
to licence revocation, to prison sentences. Reports by the 
Access to Opioid Medication in Europe project51 and 
Human Rights Watch52 suggest that fear of sanction may 
arise in the context of unclear, often stigmatizing legisla-
tion, lack of legal knowledge among health professionals 
and harsh penalties, including penalties for unintentional 
violations. In the survey, out of 21 countries reporting 
fear of prosecution/sanction as an impediment, almost all 
indicated the existence of penalties, and three quarters of 
them showed inadequate S-DDD levels, i.e. below 200 per 
million inhabitants per day.
8. International trade control 
measures
135. Policies, rules and regulations to control the pro-
duction, import and export of controlled substances have 
been established and are monitored at the international 
level by INCB. For some countries, the effort to estimate 
the amount of controlled medication needed may be 
beyond their capacities and existing resources, and there-
fore technical and logistical support may be required.
136. Countries have reported difficulties with the 
 issuance of import/export permits, along with other inter-
national drug control measures that require lengthy 
 procedures and thus may lead to delays and shortages. 
9. Onerous regulations 
137. Out of 53 countries that reported having taken leg-
islative or regulatory action in the previous 10 years to 
 51 Access to Opioid Medication in Europe, Final Report and Recom-
mendations to the Ministries of Health, Lukas Radbruch and others, eds. 
(Bonn, Germany, Pallia Med Verlag, November 2014).
 52 Global State of Pain Treatment, chap. II.
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increase the availability of narcotic drugs for medical pur-
poses, 37 countries (70 per cent) had observed an increase 
in S-DDD rates since the 2007-2009 period. Among such 
legislative or regulatory actions, countries reported the 
following: facilitating the prescription and dispensing of 
narcotic drugs, which could include the elimination of 
obligatory prescription pads for doctors and the  extension 
of prescription periods; allowing nurses and midwives to 
prescribe and administer narcotic drugs; facilitating 
accessibility of treatment for patients; simplifying record-
keeping; and issuing informative leaflets on uses, side 
effects, warnings and precautions concerning narcotic 
medicines.
138. At the national level, some countries, out of fear 
of diversion and risk of addiction, have developed regu-
latory systems that go beyond the requirements provided 
in the drug control treaties, with unnecessary impedi-
ments that do not take into full account the WHO and 
INCB recommendations.
139. Regulations that restrict opioid prescription mech-
anisms include the following: requiring special patient 
permits; limiting the authority of physicians to prescribe 
opioids, even for cancer patients with strong pain; impos-
ing dose limits that restrict the ability to adjust the dose 
to individual patient needs; imposing severe limits on the 
duration of prescriptions; restricting the dispensing of 
opioids, making it harder for patients to access such 
medi cation; increasing bureaucratic burdens through the 
use of complex or poorly accessible prescription forms or 
complex reporting requirements; and introducing dispro-
portionate legal sanctions that result in the intimidation 
of health-care providers and pharmacists. 
140. In some countries, regulations prevent doctors 
from prescribing appropriate substances and sufficient 
dosages, so that patients have to visit their physicians very 
frequently, for example, because they are not allowed to 
get a prescription for morphine for more than 7 or 10 
days. Of the countries responding, only 21 per cent stated 
that they allowed refills under certain circumstances 
without requiring a new prescription.
141. Particularly in low-income countries, the ability to 
prescribe morphine and other potent opioids is limited 
to a small number of physicians, who are required to 
undergo a special registration procedure. In some cases, 
not even specialists in diseases requiring palliative care 
have independent prescribing authority.
142. Another example of a regulatory impediment is the 
special triplicate forms doctors have to fill out, which can 
be difficult to obtain and for which in many cases 
doctors have to pay. According to WHO, special multiple- 
copy prescription requirements typically “reduce pre-
scribing of covered drugs by 50 per cent or more”.53
143. Of 102 responding countries, 75 per cent legally 
required prescribers to keep records of narcotic drug pre-
scriptions. This may discourage the stocking of opioid 
analgesics owing to costs and time-consuming proce-
dures, and possibly fear of prosecution and sanctions. It 
is certainly possible to find a way to ensure that records 
are kept while preventing this basic requirement from 
becoming too onerous for those who are doing the 
prescribing.
144. As illustrated in figure 36, nurses are seldom 
allowed to prescribe narcotic drugs. This may also be an 
impediment to availability, especially in countries facing 
challenges in their health-care systems and infrastructure. 
Figure 36. Prescribers of narcotic drugs, 2014
Source: International Narcotics Control Board survey 2014.
145. Some countries that have been able to considera-
bly increase their levels of consumption in S-DDD per 
million inhabitants per day during the past two decades 
have reported that midwives are also allowed to prescribe 
narcotic drugs. The issue of pain during labour is mostly 
overlooked in the discussion, despite its ubiquity, which 
calls for measures to ensure its adequate management, 
including the use of narcotic drugs.
 53 World Health Organization, Cancer Pain Relief, With a Guide to 
Opioid Availability, second edition (1996), part 2.
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146. There was a wide range of prescription validities 
among countries (see figure 37). Forty-three per cent of 
countries reported that prescriptions were valid for up to 
seven days. The second most often reported validity 
(30 per cent of countries) was between two weeks and a 
month. 
147. Centralized systems can furthermore limit ade-
quate distribution, because opioids are often only availa-
ble in major cities and are not delivered to rural areas. 
Sometimes, doctors have to travel to major cities to get 
medications and even prescription forms; patients may 
have to do the same. In some countries, it can take more 
than a month for an opioid medication to be delivered 
from urban centres to provincial and rural areas.
Figure 37. Maximum validity period of 
prescriptions that contain narcotic drugs, 2014
Source: International Narcotics Control Board survey 2014.
148. Member States reported that narcotics were dis-
pensed mostly in licensed hospital pharmacies (75 per 
cent). Slightly more than half of responding countries 
(54 per cent) reported that narcotics could be dispensed 
in regular pharmacies (see figure 38).
Figure 38. Facilities where prescriptions for 
narcotic drugs can be dispensed, 2014
Source: International Narcotics Control Board survey 2014.
149. Restrictions on the number of pharmacies that are 
allowed to dispense controlled substances may also reduce 
availability. The administrative burden for pharmacies is 
an additional factor. In some countries, pharmacists must 
collect a standard set of information: patient name, 
address and date of birth; drug dispensed, as well as the 
date, quantity and dosage, the number of days’ supply and 
the number of refills; and the patient’s health-care 
 provider. Pharmacies are also required to keep such infor-
mation in a central database for several years. This 
 necessitates the use of human resources, time and access 
to specific technology for monitoring and data collection. 
The existence of a legal requirement for dispensing agents 
to keep records was reported by 101 (98 per cent) of 103 
responding countries.
150. In many countries, only one institution, or else a 
few pharmacies, are allowed to stock opioid medication. 
To do so, they have to seek permission from drug regu-
latory authorities through a lengthy process. Even in 
acute-care hospitals, morphine may not be included in 
the drug list for emergencies. In addition, some pharma-
cies located in unsafe areas are afraid to sell opioids 
because of the risk of being robbed.
10. Other impediments
151. Other impediments identified by a smaller num-
ber of countries (seven) point to insufficient supply due 
to a lack of certain opioid formulations, an unexpected 
increase in demand for a specific drug, or business 
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decisions by industry and importers of narcotic drugs. 
Also mentioned were a lack of awareness on the part of 
patients, inadequate estimates and reporting, and the 
existence of illegal markets.
11. Action by the Board
152. In the survey, countries could also indicate that 
actions taken by the Board had been an impediment. 
Only four countries did so. 
153. In addition, countries were asked to suggest meas-
ures the Board could take to improve the availability of 
narcotic drugs for medical and scientific purposes. Most 
countries mentioned the provision of training and infor-
mation to authorities and stakeholders on several issues: 
benefits, rational prescription and use of narcotic drugs; 
management, distribution and control of narcotic 
drugs;  estimates and assessments; and awareness-raising 
 programmes to address fears relating to prescribing or 
dispensing narcotics.
154. Other countries pointed to the need to facilitate 
the procurement of narcotic drugs through quick and 
flexible approval of estimates and supplementary esti-
mates by the Board, as well as the introduction of online 
software for import and export licensing. In addition, 
INCB was requested to play a more active role by urg-
ing manufacturers to deliver the necessary medications 
on time, asking Governments to provide the necessary 
human and financial resources, and facilitating the avail-
ability of limited quantities for the purpose of test and 
reference standards. A few countries mentioned the 
need for more research on availability, the development 
of recommendations to increase access and the estab-
lishment of a laboratory for quality control of narcotic 
drugs.
155. Among responding countries, there was a high 
level of awareness of the procedures for submitting esti-
mates and supplementary estimates (97 per cent), as well 
as knowledge of INCB training materials (82 per cent) 
and joint INCB/WHO guidelines (87 per cent) on the 
preparation of estimates.
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Chapter III.
Psychotropic substances
156. There are currently 125 psychotropic substances54 
under international control pursuant to the 1971 
Convention. Most of them are contained in pharmaceu-
tical preparations of medicines that act on the central 
nervous system, which include stimulants, depressants, 
analgesics and antidepressants. 
157. Psychotropic substances are grouped into four 
schedules according to their therapeutic usefulness, 
potential for dependence, and liability to abuse and pub-
lic health risk. The 1971 Convention provides a different 
control regime for each schedule. The scope of the 
 controls applied to the substances in the four schedules 
varies according to their level of hazard or risk.
158. Five psychotropic substances55 currently under 
international control are included in the latest WHO 
Model List of Essential Medicines.56 The list comprises a 
core and a complementary list.
159. The World Health Organization defines the core 
Model List as a list of minimum medicines needed for a 
basic health-care system. The list includes the most effi-
cacious, safe and cost-effective medicines for priority con-
ditions, which are selected on the basis of current and 
estimated future public health relevance, and potential for 
safe and cost-effective treatment. Diazepam, lorazepam, 
midazolam and phenobarbital are included in the core 
 54 Nine substances were brought under international control (in 
Schedules I and II of the 1971 Convention) during the fifty-eighth session 
of the Commission on Narcotic Drugs, in March 2015.
 55 Buprenorphine, diazepam, lorazepam, midazolam and 
 phenobarbital.
 56 World Health Organization, Model List of Essential Medicines, 
19th list (April 2015, amended June 2015). Available from www.who.int/
medicines/publications/essentialmedicines.
list. Furthermore, the complementary list presents essen-
tial medicines for the treatment of priority diseases for 
which specialized diagnostic or monitoring facilities and/
or specialist training are needed. Buprenorphine is 
included in the complementary list.
160. The framework of control that the 1971 Convention 
requires Governments to establish is directed at protect-
ing public health and welfare. The international commu-
nity, in enacting the Convention, recognized that the 
abuse of psychotropic substances posed a serious health 
hazard to the individual and threatened the social and 
economic fabric of normal life. Only through coordinated 
national and international measures could the dangers of 
drug addiction and illicit trafficking be overcome. 
Disparities in levels of consumption of psychotropic sub-
stances among countries and regions are still observed. 
Inadequate availability and poor access to necessary 
 medical treatments, as well as excessive availability and 
medically unsound use of psychotropic substances, 
 represent the threats related to the control and use of such 
substances.
A. Supply of psychotropic 
substances controlled under the 
1971 Convention
161. The World Health Organization definition of 
rational use of medicines emphasizes that patients need 
to “receive medications appropriate to their clinical needs, 
in doses that meet their own individual requirements, for 
an adequate period of time, and at the lowest cost to them 
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and their community”. According to this definition, irra-
tional use of medicines may refer to lack of access to 
essential medications or to inappropriate use of medica-
tions that are accessible and available. Health-care  delivery 
around the world depends heavily on national health-care 
systems and the availability of adequate resources. 
According to WHO, 14 per cent of the global burden of 
diseases is attributable to mental, neurological and sub-
stance use disorders, with almost three quarters of this 
burden occurring in low- and middle-income countries. 
In those countries, about four out of five people who need 
services do not receive them. Available resources are 
insufficient. 
162. At the same time, the risk of oversupply and exces-
sive availability of psychotropic substances under inter-
national control, combined with weak and/or inadequate 
regulatory control measures, may result in their misuse 
and abuse. Excessive availability of psychotropic sub-
stances resulting from unregulated supply and inappro-
priate or non-medical use of controlled drugs is as much 
of a concern to the Board as inadequate supply.
163. Particularly well-targeted marketing strategies and 
heavy advertising campaigns by specific companies, and 
the pharmaceutical industry as a whole, along with the 
introduction of more competitive products into the 
 market (generics), can contribute to the excessive supply 
and availability of psychotropic substances. This occurs 
mainly in developed countries but can also be observed 
in developing ones. Excess availability often leads to over-
consumption, which leads in turn to dependence and to 
the illicit trafficking of substances.
164. Insufficient resources and expertise required for 
determining medical needs and adjusting drug supply to 
meet those needs jeopardize the balance between availa-
bility and consumption. Moreover, experience shows that 
the actual availability of drugs tends to exceed drug 
requirements in many developed countries. In such 
 countries, societal, cultural and attitudinal factors that 
influence consumption distort the perception and 
 measurement of real medical needs. 
1. Supply of analgesics
165. Buprenorphine, lefetamine and pentazocine are the 
analgesics controlled under the 1971 Convention. Global 
manufacture of buprenorphine, an opioid analgesic listed 
in Schedule III of the 1971 Convention, started to increase 
gradually in the late 1990s, as the substance began to be 
used in higher doses for the treatment of pain and opi-
oid addiction. In 2013, global manufacture reached a new 
record, with almost 9 tons (1.1 billion S-DDD) reported 
by nine countries. The volume of international trade has 
increased as well, with over 60 countries reporting 
imports of the substance in 2013.
166. There was less manufacture of and trade in penta-
zocine. Global manufacture of that substance fluctuated 
between a high of 8 tons and a low of 1 ton per year 
 during the past decade. No steady rate of increase in 
manu facture and trade was discernible. 
167. Lefetamine is both a stimulant and an analgesic, 
with effects similar to codeine. In the 1990s, lefetamine 
was found to be less effective than buprenorphine in the 
detoxification of methadone patients. Consequently, 
 manufacture and consumption of lefetamine ceased in the 
1990s. 
2. Supply of stimulants
168. In contrast to some other psychotropic substances, 
none of the central nervous system stimulants controlled 
under the 1971 Convention are recognized by WHO as 
part of the minimum requirements for a basic health-care 
system; therefore, none of them are included in the WHO 
Model List of Essential Medicines. This would largely 
explain the quasi-absence of these substances in the mar-
kets of low-income and developing countries.
169. Amphetamines and methylphenidate are the only 
stimulants in Schedule II that are manufactured and 
traded in large quantities. In particular, they are manu-
factured in very large quantities in the United States and 
a few European countries. These substances are mostly 
used for the treatment of attention-deficit hyperactivity 
disorder (ADHD) and, in the case of amphetamines, also 
for industrial processes. During the past 20 years, contin-
ual and significant increases in the manufacture of three 
major substances of the group, namely amfetamine, 
 dexamfetamine and methylphenidate, were observed.
170. While the United States has always been the lead-
ing manufacturer of this group of substances, manufac-
ture to meet growing domestic needs also occurs in some 
European countries, including France, Germany, Hungary 
and the United Kingdom. Manufacture of amphetamines 
amounted to 47 tons in 2013, and three countries (United 
States, Canada and Australia) accounted for 88 per cent 
of global imports.
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171. Global manufacture of methylphenidate has pro-
gressively increased in the past 20 years, as shown in fig-
ure 39. In 2013, global output of that substance reached 
a record of nearly 72 tons. The number of countries 
importing methylphenidate during the past decade was 
stable, with about 100 reporting imports in quantities 
ranging from a few grams to a few tons. In 2013, seven 
countries57 in Europe and the Americas accounted for 
more than 70 per cent of global imports.
 57 Switzerland, Germany, Spain, Canada, Brazil, the Netherlands and 
the United Kingdom (in descending order of amounts imported).
Figure 39. Quantities of global manufacture of methylphenidate, 1990-2013
Source: International Narcotics Control Board.
172. Global output of the stimulants listed in Schedule 
IV, which are mainly used in the treatment of obesity as 
anorectics, remained stable during the past 10 years, 
 averaging 90 tons per year. During the same period, total 
imports averaged 21 tons yearly. In 2013, five countries 
in three regions (Americas, Europe and Oceania) 
accounted for more than 80 per cent of global imports. 
3. Supply of benzodiazepines
173. The 35 benzodiazepines currently under inter-
national control are classified as anxiolytics and sedative-
hypnotics and are used in medical practice for the short-
term management of insomnia and for pre-medication 
and the induction of general anaesthesia.
(a) Supply of benzodiazepine-type 
sedative-hypnotics
174. In the past 10 years, manufacture of benzodiazepine- 
type sedative-hypnotics was reported by between 11 and 
16 countries, mainly in Europe (Germany, Italy and 
Switzerland, which jointly accounted for two thirds of 
global stocks in 2013), while countries in Asia (China, 
India and Japan) and in the Americas (Brazil, Canada and 
the United States) jointly supplied one quarter of global 
output. Figure 40 demonstrates that, in the past 10 years, 
the share of this group of substances supplied by Europe 
has increased, while the share supplied by Asia and the 
Americas has decreased. Countries in Africa and Oceania 
did not supply benzodiazepine-type sedative-hypnotics 
during that period (except for 6 kg of nitrazepam man-
ufactured by New Zealand in 2012).
Figure 40. Total reported manufacture of 
benzodiazepine-type sedative-hypnotics, 
by  region, 2004-2006 and 2011-2013
Source: International Narcotics Control Board.
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175. In the past 10 years, global reported manufacture 
of benzodiazepine-type sedative-hypnotics fluctuated 
around an annual average of 7.4 billion S-DDD (see  figure 
41). Out of the 12 substances in this group (brotizolam, 
estazolam, flunitrazepam, flurazepam, haloxazolam, 
loprazolam, lormetazepam, midazolam, nimetazepam, 
nitrazepam, temazepam and triazolam), only midazolam 
is included in the WHO Model List of Essential Medicines. 
Although midazolam accounted for only 4 per cent of 
total supply of this group of substances in 2013 (see 
 figure 42), it was the most widely traded and most widely 
available substance geographically, as 134 countries 
reported imports of this substance. As demonstrated in 
figure 43, Europe and Asia remain the net  suppliers of 
midazolam.
(b) Supply of benzodiazepine-type 
anxiolytics
176. In the past 10 years, between 16 and 20 countries 
reported manufacture of benzodiazepine-type anxiolytics. 
Similar to benzodiazepine-type sedative-hypnotics, the 
supply of this group of substances originated in Europe, 
Asia and the Americas (see figure 44), with Italy remain-
ing the main manufacturer, accounting for 44 per cent of 
global output in 2013.
177. In the past 10 years, global reported manufacture 
of benzodiazepine-type anxiolytics fluctuated between 
18.3 and 29.9 billion S-DDD, around an annual average 
of 22 billion (see figure 45). Twenty-two benzodiazepines 
Figure 41. Total reported manufacture of 
benzodiazepine-type sedative-hypnotics, 
by substance, 2004-2013
Figure 43. Average annual net imports of 
midazolam, by region, 2004-2006 and 
2011-2013
Figure 42. Share of total reported 
manufacture of benzodiazepine-type  
sedative-hypnotics, by substance, 2013
Figure 44. Total reported manufacture of 
benzodiazepine-type anxiolytics, by region, 
2004-2006 and 2011-2013
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are generally classified as anxiolytics; two of them, diaz-
epam and lorazepam, are included in the WHO Model 
List of Essential Medicines. During the 2004-2013 period, 
diazepam and lorazepam accounted for 26 and 18 per 
cent, respectively, of global supply of this group of sub-
stances. The shares of total reported manufacture in 2013 
are presented in figure 46. Diazepam, alprazolam and 
lorazepam are the most widely available substances of this 
group, as 137, 118 and 102 countries, respectively, report 
on imports of these substances. The trends in net imports 
(imports minus exports) of diazepam and lorazepam are 
presented in figures 47 and 48. Countries in Europe and 
Asia remain the main suppliers of these two substances. 
The main changes during the past decade included a 
notable increase in net imports of diazepam by African 
countries, and an increase in net imports of lorazepam 
by countries in the Americas.
4. Supply of anti-epileptics
178. There have been divergent patterns in the manu-
facture and trade of barbiturate-type anti-epileptics 
( phenobarbital and methylphenobarbital) and benzodiaz-
epine-type anti-epileptics (clonazepam) included in 
Schedule  IV  during the past 10 years. Phenobarbital is 
included in the WHO Model List of Essential Medicines.
Figure 45. Total reported manufacture of 
benzodiazepine-type anxiolytics, by substance, 
2004-2013
Figure 47. Average annual net imports 
of diazepam, by region, 2004-2006 and 
2011-2013
Figure 46. Share of total reported 
manufacture of benzodiazepine-type 
anxiolytics, by substance, 2013
Figure 48. Average annual net imports 
of  lorazepam, by region, 2004-2006 and 
2011-2013
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179. Global manufacture of phenobarbital, which had 
fluctuated between 7.1 billion S-DDD and 9.7 billion 
S-DDD during the period 2004-2012, fell to a record low 
of 3.0 billion S-DDD in 2013. That decrease can be attrib-
uted mainly to a substantial decrease in the output of 
China, the world’s leading manufacturer of phenobarbi-
tal. Furthermore, the lack of production and production 
data for 2013 for Hungary and India (two other major 
manufacturing countries) further exerted downward 
pressure on reported global supply. As one of the most 
widely traded psychotropic substances, phenobarbital is 
traded in an average of 140 countries every year. In 2013, 
China, Hungary, India and Switzerland (in descending 
order) together accounted for 89 per cent of total exports, 
and more than 120 countries reported imports. Major 
importers included the Russian Federation, Ukraine and 
the United States.
180. The manufacture of methylphenobarbital, com-
pared with that of phenobarbital, has remained rather 
limited. During the 2004-2012 period, global manufac-
ture of methylphenobarbital fluctuated considerably, 
ranging between 0.2 million S-DDD and 438 million 
S-DDD, mainly because of significant changes in the out-
put reported by India, Switzerland and the United States. 
In 2013, no manufacture of the substance was reported, 
and the total volume of international trade remained sta-
ble (28.2 million S-DDD). 
181. The manufacture and trade of clonazepam, a ben-
zodiazepine that is used mainly as an anti-epileptic, has 
shown a similar upward pattern over the past 10 years. 
Global reported manufacture of clonazepam gradually 
increased from 1.3 billion S-DDD in 2004 to a new record 
of 3.4 billion S-DDD in 2012, but decreased thereafter to 
2.2 billion S-DDD in 2013. That decrease was attributa-
ble mainly to the non-reporting of manufacture data for 
2013 by India, traditionally a major manufacturer of the 
substance. While Switzerland was the world’s leading 
manufacturer of clonazepam during the two decades 
leading up to 2010, Italy took the lead in 2011 and 2012. 
In 2013, Brazil became the largest manufacturer of the 
substance, followed by Italy and Switzerland. About 120 
countries reported imports of clonazepam in 2013.
B. Availability of psychotropic 
substances
182. Conclusions based on the calculated consumption 
of psychotropic substances should be drawn with caution, 
as data on manufacture, industrial use, stocks and trade 
reported by Governments may not be complete or may not 
cover all substances. High levels of consumption may, how-
ever, indicate overprescription and/or diversion into illicit 
channels. The system of control provided for in the 1971 
Convention is based largely on the system devised for the 
control of narcotic drugs under the 1961 Convention. The 
control measures and obligations set out in the 1971 
Convention represent the minimum control requirements 
that Governments must implement and maintain. 
183. The degree of availability of psychotropic sub-
stances is approximated in the present report by using 
measures of calculated consumption of individual sub-
stances and groups of substances. The 1971 Convention 
does not foresee reporting on consumption of  psychotropic 
substances to the Board. Therefore, based on statistics 
reported by Governments on manufacture, industrial use, 
stocks and international trade, the rates of consumption, 
measured in S-DDD per 1,000 inhabitants per day, are 
calculated by the Board every year. For the purposes of 
the present report, three-year averages were used, in order 
to account for the occasional non- submission of annual 
statistics and in view of the  practice by some Governments 
of intermittent manufacture and importing of  psychotropic 
substances when stocks cover domestic requirements for 
several years. 
184. In addition, instances of elevated calculated use of 
psychotropic substances could relate to increasing manu fac-
ture for export, accompanied by a possible lack of reporting 
of exports and/or a non-reporting of stocks of manufac-
turers and/or elevated stocks kept by wholesalers. 
185. Pursuant to Commission on Narcotic Drugs resolu-
tions 53/4 and 54/6, on promoting adequate  availability of 
internationally controlled narcotic drugs and psychotropic 
substances for medical and scientific purposes while pre-
venting their diversion and abuse, Member States are 
strongly encouraged to provide the Board, on a voluntary 
basis, with data on the consumption of psychotropic sub-
stances, in the same manner as for narcotic drugs. Those 
data would be essential in enabling the Board to better 
analyse trends relating to the consumption of psychotropic 
substances and, ultimately, to promote the adequate avail-
ability of such substances for medical and scientific pur-
poses while preventing their diversion and abuse.
186. Since the adoption of the above-mentioned reso-
lutions, a growing number of Governments have started 
to submit data on the consumption of psychotropic 
 substances to the Board. However, the total number of 
Governments supplying the requested information is still 
too low to be used in lieu of the consumption data as 
 calculated by the Board. 
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1. Availability of opioids controlled 
under the 1971 Convention
187. The number of countries and territories using one 
or more of the analgesics controlled under the 1971 
Convention (buprenorphine, lefetamine58 and pentazo-
cine) has remained stable at about 100 since 2004. In con-
trast, the volume of consumption of these opioids 
increased in all regions of the world between 2004 and 
2013 (see figure 49). During the 2004-2006 period, levels 
of consumption were highest in Europe and Oceania (the 
high levels of consumption in Oceania are the result of 
manufacture and calculated consumption in Australia). 
While consumption continued to increase markedly in 
Europe by the 2011-2013 period, it increased more than 
tenfold in the Americas, and almost sixfold in Africa, 
albeit from a low level. 
188. The national per capita level of consumption of 
opioids controlled under the 1971 Convention during the 
2004-2006 and 2011-2013 periods are shown in maps 5 
and 6. As can be seen, the majority of countries and ter-
ritories continue to have a level of consumption below 
0.1 S-DDD per 1,000 inhabitants per day. However, there 
has been a marked increase in the highest level of con-
sumption, of over 1 S-DDD per 1,000 inhabitants per day, 
in the past 10 years. While during the 2004-2006 period, 
only four countries had a per capita level of consumption 
greater than 1 S-DDD per 1,000 inhabitants per day, in 
the 2011-2013 period 16 countries had attained that level.
 58 Lefetamine has not been manufactured and consumed since the 
1990s (see para.  167).
189. The consumption of buprenorphine, which is listed 
in the Model List of Essential Medicines of WHO (com-
plementary list), accounted on average for 97 per cent of 
global consumption of opioid analgesics controlled under 
the 1971 Convention during the 2009-2013 period. 
Consumption of pentazocine, which has properties and 
uses similar to those of morphine, accounted for the 
remainder. 
190. Global calculated consumption of buprenorphine 
has steadily increased since 2000, from less than 1 ton 
(100 million S-DDD) to a new record of almost 10 tons 
(1.2 billion S-DDD) in 2013. During the 1990s, buprenor-
phine was used by no more than 20 countries worldwide, 
whereas in the 2011-2013 period, buprenorphine was 
used in about 90 countries and territories, in every region, 
or about 40 per cent of all countries and territories. That 
increase in the consumption of buprenorphine is mainly 
due to its increasing use in higher-dosage forms for the 
treatment of pain, and for detoxification and substitution 
treatment for opioid dependence. The countries with the 
highest levels of consumption for buprenorphine in the 
period 2011-2013 were Iceland, Belgium, Switzerland, the 
United Kingdom and the United States, in descending 
order (see figure 50 and maps 7 and 8).
191. Global consumption of pentazocine has averaged 
about 5 tons per year during the past decade. The sub-
stance is used in approximately 50 countries. Its use, in 
contrast to that of buprenorphine, is not spreading to 
other countries. The same 50 countries have been using 
pentazocine since 2004, with India, Nigeria, Pakistan and 
the United States accounting for 87 per cent of the global 
total in the period 2011-2013. 
Figure 49. Average consumption of opioid 
analgesics, by region, 2004-2006 and 
2011-2013
0.59
1.53
0
0.5
1
1.5
2
2.5
3
3.5
4
S-
D
D
D
 p
er
 1
,0
00
 in
ha
bi
ta
nt
s 
pe
r d
ay
2004-2006
2011-2013
2004-2006 average
2011-2013 average
0.24
2.56
Americas
1.62
3.52
Oceania
1.02
1.46
Europe
0.03 0.07
Asia
0.01 0.03
Africa
Figure 50. Average consumption of 
buprenorphine, by region, 2004-2006 and 
2011-2013
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Map 5. Average national consumption of opioid analgesics, 2004-2006
Map 6. Average national consumption of opioid analgesics, 2011-2013
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Map 7. Average national consumption of buprenorphine, 2004-2006
Map 8. Average national consumption of buprenorphine, 2011-2013
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2. Availability of central nervous 
system stimulants 
192. As mentioned in paragraph 168 above, none of the 
central nervous system stimulants controlled under the 
1971 Convention are included in the WHO Model List 
of Essential Medicines. This would largely explain the 
quasi-absence of these substances in the markets of low-
income and developing countries.
193. Since the early 1990s, the highest per capita calcu-
lated consumption of amphetamines has traditionally 
been in the Americas. The United States remains the 
major consumer of these substances, mainly for the treat-
ment of ADHD and narcolepsy. These high levels of con-
sumption have increased steadily, and were seven times 
higher in the late 2000s than in the 1990s. 
194. Use of this group of substances was extremely rare 
in Asia59 and nearly non-existent in Africa. Consumption 
 59 Japan is the only country in the Asia-Pacific region that has had a 
noticeable rate of use of the substance.
rates increased in Oceania, from an average of 0.03 
S-DDD per 1,000 inhabitants per day during the 1988-
1990 period to 1.31 S-DDD in the 2011-2013 period, 
mainly due to steadily rising use of dexamfetamine in 
Australia. 
195. In Europe, levels of consumption have been very 
irregular. Main consuming countries during the past dec-
ade included Germany, Hungary and Switzerland. Hungary 
was a significant consumer of these substances until 2002, 
when the level of consumption fell drastically.
196. Countries that were the main users of stimulants 
listed in Schedule II during the 2004-2006 period contin-
ued to have the highest levels of consumption during the 
2011-2013 period. A marked increase was observed for 
some countries (mainly in Europe and the Americas), 
while the vast majority of countries and territories con-
tinued to have a level of consumption below 1 S-DDD 
per 1,000 inhabitants per day (see maps 9 and 10).
Map 9. Average national consumption of stimulants in Schedule II, 2004-2006 
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and Northern Ireland concerning sovereignty over the Falkland Islands (Malvinas).
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Map 10. Average national consumption of stimulants in Schedule II, 2011-2013
197. Methylphenidate is used for the treatment of var-
ious mental and behavioural disorders, in particular of 
ADHD (primarily in children) and narcolepsy, a sleeping 
disorder. Use of methylphenidate started to increase 
noticeably at the beginning of the 1990s (see figure 51). 
In 1994, for example, global use amounted to more than 
five times the level of consumption of the early 1980s. 
This development was mainly due to increasing consump-
tion in the United States, although increasing levels of 
consumption were also observed in several other coun-
tries and parts of the world. 
Figure 51. Global consumption of methylphenidate per 1,000 inhabitants per day, 1990-2013
198. While the United States continues to account for 
more than 80 per cent of the calculated global consump-
tion of methylphenidate, the use of that substance for the 
treatment of ADHD has also sharply risen in many other 
countries, in particular those in Oceania and Europe (see 
figure 52). The prescription levels in most of those 
countries are still low compared with those in the United 
States, however. Growth of global consumption of methyl-
phenidate has continued unabated. In 2013, a new record 
of 2.4 billion S-DDD was attained, with fewer than 20 
countries accounting for almost 85 per cent of the total. 
The countries reporting a significant increase in the 
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consumption of methylphenidate included Iceland, which 
has had the highest per capita consumption of the sub-
stance in the world for the past several years, as well as 
Australia, Canada, Germany, Israel, Norway, Spain, 
Sweden and the United Kingdom. At the same time, the 
Board is also concerned about the underprescription, and 
resulting low use, of methylphenidate in other countries.
Figure 52. Consumption of methylphenidate, 
all regions, 2004-2006 and 2011-2013
199. National per capita levels of consumption for 
methylphenidate during the 2004-2006 and 2011-2013 
periods, approximated by measures of average annual cal-
culated consumption (in S-DDD per 1,000 inhabitants 
per day), are shown in maps 11 and 12. As can be seen, 
the majority of countries and territories continued to have 
a level of consumption below 1 S-DDD per 1,000 inhab-
itants per day, while a handful of countries remained the 
main users of the substance, with a marked increase 
noted in some countries in the Americas, Europe and 
Oceania in the 2011-2013 period. While during the 2004-
2006 period only five countries had a per capita consump-
tion greater than 5 S-DDD per 1,000 inhabitants per day, 
by the 2011-2013 period 17 countries had reached that 
high consumption threshold, including nine countries 
where consumption was greater than 10 S-DDD per 1,000 
inhabitants per day.
200. The Board has regularly voiced its concern about 
the possible overdiagnosis of ADHD and the overpre-
scribing of methylphenidate. In 2009, the Board also 
advised against promotional campaigns for the substance, 
including advertisements directed at potential consumers. 
More recently, in its annual report for 2014, the Board 
considered the use of methylphenidate as a special topic.
Map 11. Average national consumption of methylphenidate, 2004-2006
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Map 12. Average national consumption of methylphenidate, 2011-2013
201. Stimulants included in Schedule IV of the 1971 
Convention are used as anorectics and, to a lesser extent, 
for the treatment of ADHD. Their global use has increased 
steadily since the end of the 1980s. This increase was 
partly due to high consumption in some Latin American 
countries (Argentina, Brazil and Chile), in the United 
States and in some Asian countries and territories 
(Republic of Korea, Singapore and Hong Kong, China). 
202. Since the early 1990s, the highest per capita con-
sumption of stimulants in Schedule IV has always been in 
the Americas. The decline in the use of phentermine after 
a peak observed in 1996 in the United States and the adop-
tion of measures against inappropriate use of certain stim-
ulants in some countries of Latin America, such as Brazil, 
led to some decrease in consumption. However, the levels 
of consumption in that region remained high in compar-
ison to other regions, except for some countries in Asia.
203. Among the stimulants included in Schedule IV of 
the 1971 Convention, phentermine has always been the 
substance comprising the main share of manufacture and 
consumption, fluctuating between one quarter and two 
thirds. In 2013, its share of global consumption reached 
nearly 86 per cent. Reports of misuse of anorectics have 
been received from several countries in all regions of the 
world. In recent years, there has been an observed increase 
in levels of consumption in Africa and Oceania, owing 
to increased calculated consumption in South Africa and 
Australia (see figure 53).
204. Severe restrictions on the use of anorectics and 
stricter policies regarding their medical use were intro-
duced in a number of countries and were successful in 
curbing their inappropriate use, thus preventing irrational 
use and abuse. The changes in consumption of stimulants 
in Schedule IV by country, approximated by measures of 
average annual calculated consumption (in S-DDD per 
1,000 inhabitants per day) between 2004-2006 and 2011-
2013, are presented in maps 13 and 14.
Figure 53. Consumption of stimulants in 
Schedule IV, all regions, 2004-2006 and 2011-2013
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Map 13. Average national consumption of stimulants in Schedule IV, 2004-2006 
Map 14. Average national consumption of stimulants in Schedule IV, 2011-2013
The boundaries and names shown and the designations used on this map do not imply official  endorsement 
or acceptance by the United Nations. The final boundary between South Sudan and the Sudan has not 
yet been determined. The dotted line represents approximately the Line of Control in Jammu and Kashmir 
agreed upon by India and Pakistan. The final status of Jammu and Kashmir has not yet been agreed upon by 
the parties. A dispute exists between the Governments of Argentina and the United Kingdom of Great Britain 
and Northern Ireland concerning sovereignty over the Falkland Islands (Malvinas).
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3. Availability of benzodiazepines
205. For the two groups of benzodiazepines, anxioly tics 
and sedative-hypnotics, the global calculated rate of  average 
annual consumption showed distinct patterns during the 
2004-2013 period. While the average annual rate of per cap-
ita consumption of benzodiazepine-type anxioly tics showed 
an upward trend, the global average annual calculated con-
sumption rate of benzodiazepine-type  sedative-hypnotics 
decreased. During that period,  practically all countries and 
territories that reported to INCB manufactured or traded 
in benzodiazepines, and the reported statistics enabled the 
Board to calculate  consumption rates for over 190 countries 
and territories. In 2013, alprazolam and diazepam remained 
the most used substances among anxiolytics (9.2 and 
4.4  billion S-DDD, respectively), whereas lormetazepam 
and  brotizolam were the most used sedative-hypnotics 
(1.4 and 1.3 billion S-DDD, respectively). 
(a) Benzodiazepine-type anxiolytics
206. Globally, the average annual rate of per capita con-
sumption of benzodiazepine-type anxiolytics increased 
somewhat during the 2004-2013 period, from 20.6 to 23.7 
S-DDD per 1,000 inhabitants per day. As can be seen in 
figure 54, in the beginning of the period the rate of aver-
age annual consumption for this group of substances was 
highest in European countries and the Americas, reflect-
ing the fact that benzodiazepines tend to be prescribed 
frequently for the large cohort of elderly people in those 
regions. Towards the end of that decade, the highest 
increases in the rate of average annual consumption were 
observed in Oceania (123 per cent) and Africa (32 per 
cent). The consumption rates in Africa and Asia remained 
below the global average.
Figure 54. Average annual consumption of 
benzodiazepine-type anxiolytics, 2004-2006 
and 2011-2013
207. During the past decade, the average annual level 
of consumption in Europe decreased from 43.99 to 35.82 
S-DDD per 1,000 inhabitants per day, although an 
increase in consumption was observed in 23 out of 41 
countries in this region that submitted data, in particu-
lar in Finland, where there was a 517 per cent increase. 
The largest decrease in consumption was recorded for 
Denmark (84 per cent, from 77 to 13 S-DDD per 1,000 
inhabitants per day) and Switzerland (73 per cent, from 
266 to 72 S-DDD per 1,000 inhabitants per day). During 
2011-2013, calculated consumption rates exceeded the 
regional average in 15 countries; in six countries, the lev-
els were above the global average of 23.7 S-DDD per 1,000 
inhabitants per day. The European countries with average 
levels of consumption below the global average were 
Iceland, the Czech Republic, the Netherlands, Latvia, 
Norway, Estonia, Germany, Sweden, Denmark, Poland, 
Albania, Greece, Romania, the United Kingdom, Bulgaria, 
the Republic of Moldova, the Russian Federation, Belarus, 
Ukraine and Cyprus, in descending order.
208. Consumption of this group of anxiolytics averaged 
29.2 S-DDD per 1,000 inhabitants per day in the Americas 
during the 2011-2013 period. Only four countries had 
rates of consumption that were higher than the regional 
average: Uruguay (67.9 S-DDD), Argentina (60.1 S-DDD), 
Canada (55.8 S-DDD) and the United States (42.2 
S-DDD). Furthermore, in the Americas significant dis-
parities in levels of consumption of anxiolytics were 
observed among subregions, with North America having 
the highest per capita consumption rate during the 2011-
2013 period, followed by South America and Central 
America and the Caribbean (see maps 15 and 16).
209. The regional average in Oceania (37.9 S-DDD per 
1,000 inhabitants per day), although much higher than 
the global average (23.7 S-DDD per 1,000 inhabitants per 
day), was driven mainly by Australia, which was the only 
country in the region to have calculated consumption 
above the global average during 2011-2013. The rates of 
consumption showed an increase in all countries of the 
region, except for New Zealand, which saw a decrease of 
8 per cent, from 5.1 to 4.6 S-DDD per 1,000 inhabitants 
per day.
210. In Asia, all but 1 of the 48 countries that submit-
ted data had rates of consumption below the global aver-
age. Israel (27.9 S-DDD per 1,000 inhabitants per day), 
Iran (Islamic Republic of) (22.3 S-DDD), Japan (21.1 
S-DDD) and an additional three countries (Jordan, 
Lebanon and Thailand) had calculated rates of consump-
tion above the regional average of 7.3 S-DDD per 1,000 
inhabitants per day during the 2011-2013 period. 
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Map 15. Average national consumption of benzodiazepine anxiolytics, 2004-2006
Map 16. Average national consumption of benzodiazepine anxiolytics, 2011-2013
The boundaries and names shown and the designations used on this map do not imply official  endorsement 
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yet been determined. The dotted line represents approximately the Line of Control in Jammu and Kashmir 
agreed upon by India and Pakistan. The final status of Jammu and Kashmir has not yet been agreed upon by 
the parties. A dispute exists between the Governments of Argentina and the United Kingdom of Great Britain 
and Northern Ireland concerning sovereignty over the Falkland Islands (Malvinas).
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211. In Africa, the average annual rate of consumption 
of benzodiazepine-type anxiolytics increased from 
6.1  S-DDD to 8.6 S-DDD per 1,000 inhabitants per day 
between the 2004-2006 and the 2011-2013 periods. 
The  average calculated consumption rate increased in 
19 African countries or territories, most notably in Saint 
Helena (by a factor of nearly seven, from 1.3 to 9 S-DDD 
per 1,000 inhabitants per day), and Namibia and the 
Democratic Republic of the Congo (both by a factor of 
more than 4.5, from 4.9 to 22.5 S-DDD). Ghana remained 
the country with the highest consumption rate in the 
region (and seventeenth highest in the world), with an 
increase of 146 per cent between the 2004-2006 and 2011-
2013 periods, from 21.3 to 52.3 S-DDD. Next came the 
Democratic Republic of the Congo, with 22.5 S-DDD per 
1,000 inhabitants per day, which remained slightly below 
the global average of 23.7 S-DDD. At the same time, there 
were more than 16 countries that consumed less than 
1 S-DDD per 1,000 inhabitants per day during 2011-2013, 
and more than 10 countries recorded a decrease in the 
rate of consumption. The biggest decrease in the average 
annual rate of calculated consumption was recorded for 
Cabo Verde (from 6.5 to 0.7 S-DDD), Sierra Leone (from 
0.6 to 0.1 S-DDD), Eritrea (from 0.1 to 0.02 S-DDD), the 
United Republic of Tanzania (from 2 to 0.7 S-DDD) and 
Botswana (from 1.4 to 0.7 S-DDD). 
(b) Benzodiazepine-type 
sedative-hypnotics
212. The global average annual calculated consumption 
rate of benzodiazepine-type sedative-hypnotics, when 
measured in S-DDD per 1,000 inhabitants per day, 
decreased by more than 22 per cent between the 2004-
2006 and 2011-2013 periods, from 14.6 S-DDD to 11.3 
S-DDD per 1,000 inhabitants per day. Consumption was 
consistently highest in Europe, while decreases were 
observed in the Americas, Europe and Oceania, and 
increases in Africa and Asia (see figure 55). 
213. In Europe, the average annual rate of calculated 
consumption decreased by 35 per cent between the 2004-
2006 and 2011-2013 periods, from 26.9 S-DDD to 17.5 
S-DDD per 1,000 inhabitants per day. A decrease in con-
sumption rates was observed in 29 countries in this 
region, including Cyprus (from 20.5 S-DDD per 1,000 
inhabitants per day to almost zero), the Republic of 
Moldova (from 0.15 to 0.003 S-DDD), the United 
Kingdom (from 47.3 to 4 S-DDD) and Switzerland (from 
42.6 to 11.4 S-DDD), reflecting a possible change in the 
types of benzodiazepine that were prescribed in medical 
practice. An increase was observed in 12 countries, most 
notably in Andorra (365 per cent), Croatia (300 per cent) 
and Slovakia (244 per cent). During the 2011-2013 period, 
five countries had rates of average annual consumption 
above the regional average of 17.5 S-DDD per 1,000 
inhabitants per day and an additional six countries had 
rates of consumption above the global average of 11.3 
S-DDD.
Figure 55. Average annual consumption of 
benzodiazepine-type sedative-hypnotics,  
2004-2006 and 2011-2013
214. The average annual consumption rate of 
benzodiazepine- type sedative-hypnotics in Oceania, also 
decreased between the 2004-2006 and 2011-2013 periods, 
from 9.9 S-DDD to 9.1 S-DDD per 1,000 inhabitants per 
day. Although their consumption rates decreased by 20 and 
22 per cent, respectively, Australia and New Zealand 
remained the two countries in the region with the highest 
average calculated consumption rates. Micronesia 
(Federated States of), New Caledonia and Wallis and 
Futuna Islands showed increases in average annual con-
sumption rates, albeit from low levels. Except for Australia, 
New Zealand, New Caledonia and French Polynesia, the 
rest of the countries and territories of this region had rates 
of average annual consumption for this group of substances 
below 0.1 S-DDD per 1,000 inhabitants per day.
215. In the Americas, the average annual rate of calcu-
lated consumption decreased by 45 per cent between the 
2004-2006 period and the 2011-2013 period, from 17.7 
S-DDD to 9.8 S-DDD per 1,000 inhabitants per day. 
However, there was a great disparity between subregions. 
As consumption rates increased in countries of North 
America and Central America and the Caribbean, they 
decreased in South America. Only three countries in the 
Americas had consumption rates above the regional 
 average of 9.8 S-DDD per 1,000 inhabitants per day: Cuba 
(30.1 S-DDD), Uruguay (23.3 S-DDD) and Canada 
(14.6 S-DDD). The consumption rates of 33 countries and 
territories were below the global average, including 
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24 countries with rates below 1 S-DDD and 11 countries 
with rates below 0.1 S-DDD per 1,000 inhabitants per 
day. 
216. In Asia, the rate of consumption of benzodiazepine- 
type sedative-hypnotics increased, from an average 
annual rate of 16.8 S-DDD per 1,000 inhabitants per day 
during the 2004-2006 period to 18.3 S-DDD per 1,000 
inhabitants per day during the 2011-2013 period. During 
the latter period, Japan (54.2 S-DDD), Israel (9.5 S-DDD), 
Macao, China (2.6 S-DDD), Hong Kong, China (1.3 
S-DDD) and Bangladesh (1.2 S-DDD) were the only 
countries or territories with average annual rates of 
 calculated consumption above 1 S-DDD per 1,000 inhab-
itants per day. The high rates in Japan and Israel have 
traditionally been attributed to their large cohorts of 
elderly people. During the 2011-2013 period, 37  countries 
in Asia had average annual consumption rates of 
benzodiazepine-type sedative-hypnotics below 1 S-DDD 
per 1,000 inhabitants per day, including 22 countries 
with rates of consumption below 0.1 S-DDD. 
217. In Africa, during the 2011-2013 period, only South 
Africa (2 S-DDD) had an average rate of annual calcu-
lated consumption above the regional average of 1.9 
S-DDD per 1,000 inhabitants per day. That country was 
followed by Nigeria (1.1 S-DDD) and Namibia (0.6 
S-DDD). Twenty-one countries had rates of consumption 
below 0.1 S-DDD, including 14 countries with rates below 
0.01 S-DDD.
218. The changes in consumption of benzodiazepine-
type sedative-hypnotics by country, approximated by 
measures of average annual calculated consumption (in 
S-DDD per 1,000 inhabitants per day) between 2004-2006 
and 2011-2013 are presented in maps 17 and 18.
Map 17. Average national consumption of benzodiazepine sedative-hypnotics, 2004-2006
The boundaries and names shown and the designations used on this map do not imply official  endorsement 
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yet been determined. The dotted line represents approximately the Line of Control in Jammu and Kashmir 
agreed upon by India and Pakistan. The final status of Jammu and Kashmir has not yet been agreed upon by 
the parties. A dispute exists between the Governments of Argentina and the United Kingdom of Great Britain 
and Northern Ireland concerning sovereignty over the Falkland Islands (Malvinas).
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Map 18. Average national consumption of benzodiazepine sedative-hypnotics, 2011-2013 
(c) Essential medicines containing 
benzodiazepines
219. Three benzodiazepine substances are included in 
the WHO Model List of Essential Medicines: diazepam 
and lorazepam (anxiolytics) and midazolam 
(sedative-hypnotic).
Diazepam
220. The global average annual consumption rate of 
diazepam decreased by 20 per cent between the 2004-
2006 and 2011-2013 periods, from 5.2 S-DDD to 4.1 
S-DDD per 1,000 inhabitants per day (see figure 56). The 
biggest decreases in average consumption were observed 
in Asia (70 per cent) and the Americas (44 per cent). By 
contrast, Africa and Oceania were the regions where the 
average annual consumption rate increased (by 70 per 
cent and 11 per cent, respectively). Significant increases 
in Africa were mainly the result of increases in the cal-
culated consumption for the Democratic Republic of the 
Congo and Ghana. Globally, during 2011-2013, out of 164 
countries on record, the consumption rates of 37 coun-
tries were above the global average, with Ghana 
(50.5 S-DDD), the former Yugoslav Republic of Macedonia 
(26.1 S-DDD) and Croatia (25.9 S-DDD) having the high-
est rates. At the bottom end, about 90 countries had con-
sumption rates below 1 S-DDD per 1,000 inhabitants per 
day, with 22 countries consuming at a rate below 0.1 
S-DDD) (see maps 19 and 20).
Figure 56. Average annual consumption of 
diazepam, 2004-2006 and 2011-2013
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Map 19. Average national consumption of diazepam, 2004-2006
Map 20. Average national consumption of diazepam, 2011-2013
The boundaries and names shown and the designations used on this map do not imply official  endorsement 
or acceptance by the United Nations. The final boundary between South Sudan and the Sudan has not 
yet been determined. The dotted line represents approximately the Line of Control in Jammu and Kashmir 
agreed upon by India and Pakistan. The final status of Jammu and Kashmir has not yet been agreed upon by 
the parties. A dispute exists between the Governments of Argentina and the United Kingdom of Great Britain 
and Northern Ireland concerning sovereignty over the Falkland Islands (Malvinas).
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Lorazepam
221. As presented in figure 57, the global average annual 
consumption rate of lorazepam also decreased between 
2004-2006 and 2011-2013, from 3.3 S-DDD to 2.8 S-DDD 
per 1,000 inhabitants per day. However, this relatively 
small (13.4 per cent) decrease was the result of signifi-
cant volatility in different regions. During that period, 
average annual consumption rates increased in the 
Americas by 31 per cent while decreasing in all other 
regions, with the highest declines observed in Africa 
(51.4 per cent), Asia (34.5 per cent), and Europe (25.8 per 
cent). Out of 134 countries that submitted statistics dur-
ing the 2011-2013 period, 31 countries had average 
annual calculated consumption rates above the global 
average. The highest rates were observed in Europe, led 
by Ireland (85.9 S-DDD), Portugal (27.7 S-DDD) and 
Spain (27.2 S-DDD). Eighty-three countries had average 
annual consumption rates below 1 S-DDD per 1,000 
inhabitants per day, including 44 countries with rates 
below 0.1 S-DDD, most notably Bhutan, Chad and Papua 
New Guinea, which had rates below 0.02 S-DDD. Changes 
in the consumption of lorazepam by country are pre-
sented in maps 21 and 22 below.
Figure 57. Average annual consumption of 
lorazepam, 2004-2006 and 2011-2013
Map 21. Average national consumption of lorazepam, 2004-2006
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Map 22. Average national consumption of lorazepam, 2011-2013
Midazolam
222. The global average annual rate of calculated con-
sumption of midazolam decreased by 0.4 per cent between 
the 2004-2006 period and the 2011-2013 period, from 
0.238 S-DDD to 0.237 S-DDD per 1,000 inhabitants per 
day (see figure 58). Europe and the Americas have tradi-
tionally had the highest rates of consumption of mida-
zolam. During the past decade, the most significant 
increases in average consumption rates were observed in 
the Americas (47.2 per cent). At the same time, consump-
tion rates decreased in Africa (by 56 per cent), Europe 
(20 per cent) and Asia (10 per cent). During the 2011-
2013 period, only eight countries and territories had aver-
age annual calculated consumption rates above 1 S-DDD 
per 1,000 inhabitants per day: Switzerland (5 S-DDD), 
Sint Maarten (2.7), Portugal (1.9), Curaçao (1.6), Uruguay 
(1.5), Hungary (1.4), Costa Rica (1.1) and the United 
Kingdom (1), while 37 countries and territories had con-
sumption rates above the global average of 0.237 S-DDD. 
Among the countries and territories having consumption 
rates below the global average, 89 of them had rates below 
0.1 S-DDD, including 51 with rates below 0.01 S-DDD. 
The changes in consumption of midazolam by country 
between 2004-2006 and 2011-2013 are presented in maps 
23 and 24.
Figure 58. Average annual consumption of 
midazolam, 2004-2006 and 2011-2013
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Map 23. Average national consumption of midazolam, 2004-2006
Map 24. Average national consumption of midazolam, 2011-2013
The boundaries and names shown and the designations used on this map do not imply official  endorsement 
or acceptance by the United Nations. The final boundary between South Sudan and the Sudan has not 
yet been determined. The dotted line represents approximately the Line of Control in Jammu and Kashmir 
agreed upon by India and Pakistan. The final status of Jammu and Kashmir has not yet been agreed upon by 
the parties. A dispute exists between the Governments of Argentina and the United Kingdom of Great Britain 
and Northern Ireland concerning sovereignty over the Falkland Islands (Malvinas).
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(d) Availability of anti-epileptics
223. Both barbiturate-type anti-epileptics (phenobarbi-
tal and methylphenobarbital) and benzodiazepine-type 
anti-epileptics (clonazepam) are included in Schedule IV 
of the 1971 Convention. In addition to being used for the 
treatment of epilepsy, these substances are also used to 
induce sleep. As one of the substances on the WHO 
Model List of Essential Medicines, phenobarbital 
accounted for almost all of global consumption of anti-
epileptics during the 2004-2013 period. 
224. During that time, the global consumption of anti-
epileptics decreased in all regions except the Americas. 
In particular, the largest reductions were found in Europe 
(40 per cent), Africa (20 per cent) and Asia (16 per cent). 
At the same time, the rate of consumption of anti- 
epileptics in Oceania remained roughly the same, but that 
in the Americas has increased by 35 per cent (see 
figure 59). The changes in consumption of anti-epileptics 
by country are presented in maps 25 and 26 below.
Figure 59. Consumption of anti-epileptics, 
all  regions, 2004-2006 and 2011-2013
Map 25. Average national consumption of anti-epileptics, 2004-2006
The boundaries and names shown and the designations used on this map do not imply official  endorsement 
or acceptance by the United Nations. The final boundary between South Sudan and the Sudan has not 
yet been determined. The dotted line represents approximately the Line of Control in Jammu and Kashmir 
agreed upon by India and Pakistan. The final status of Jammu and Kashmir has not yet been agreed upon by 
the parties. A dispute exists between the Governments of Argentina and the United Kingdom of Great Britain 
and Northern Ireland concerning sovereignty over the Falkland Islands (Malvinas).
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Map 26. Average national consumption of anti-epileptics, 2011-2013
(e) Benzodiazepine-type anti-epileptics 
(clonazepam)
225. The significant increases in consumption of anti-
epileptics in the Americas were mainly driven by higher 
consumption of benzodiazepine-type anti-epileptics 
(clonazepam) in Brazil, Costa Rica, Nicaragua and 
Panama. Contrary to the overall trend in the consump-
tion of anti-epileptics, consumption of benzodiazepine-
type anti-epileptics (clonazepam) increased in most parts 
of the world during the 2004-2013 period (see figure 60). 
The rise was greatest in the Americas (115 per cent), Asia 
(75 per cent) and Europe (38 per cent). Meanwhile, the 
consumption of clonazepam in Africa and Oceania 
decreased moderately, by 36 per cent and 11 per cent, 
respectively. Regardless of the changes observed in differ-
ent regions, the regional distribution of the consumption 
of clonazepam has stayed the same—with the highest 
 levels of consumption found in the Americas, followed 
by Europe, Oceania, Asia and Africa.
Figure 60. Consumption of clonazepam, 
all  regions, 2004-2006 and 2011-2013
(f) Barbiturate-type anti-epileptics
226. Global consumption of barbiturate-type anti- 
epileptics (phenobarbital and methylphenobarbital) dropped 
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Map 27. Average national consumption of phenobarbital, 2004-2006
substantially during the 2004-2013 period. While the con-
sumption of such substances fell by 95 per cent in Europe, 
it also declined in Asia and Africa, by 33 per cent and 
20 per cent, respectively. The regional pattern of consump-
tion of barbiturate-type anti-epileptics remained the same, 
with Europe and the Americas having the highest levels of 
consumption, followed by Asia, Africa and Oceania. As 
 consumption of phenobarbital accounted for almost all of 
global consumption of barbiturate-type anti-epileptics, the 
consumption trend relating to this type of anti-epileptic has 
been very similar to that of phenobarbital. 
Phenobarbital
227. Between 2004 and 2013, global consumption of phe-
nobarbital, calculated in S-DDD per 1,000 inhabitants per 
day, declined by nearly 30 per cent,60 with rather signifi-
cant regional differences (see figure 61). While both Europe 
and the Americas had higher levels of consumption than 
the rest of the world, the consumption of phenobarbital in 
Europe fell by 51 per cent while that in the Americas only 
edged down by 2 per cent. Among all European countries, 
the largest reductions were in Lithuania, Hungary and 
Greece, in that order. Meanwhile, the consumption of phe-
nobarbital in Asia and Africa also shrank, by 25 per cent 
 60 The calculation is based on a comparison between the three-year 
averages of 2004-2006 and 2011-2013.
and 18 per cent respectively, while that in Oceania went 
up by 6 per cent. Despite these differences in trends, the 
regional distribution of the global consumption of pheno-
barbital remained the same throughout the 2004-2013 
period, with Europe and the Americas being the two 
regions with the highest average levels of consumption, fol-
lowed by Asia, Africa and Oceania. The changes in con-
sumption of phenobarbital by country, approximated by 
measures of average annual calculated consumption (in 
S-DDD per 1,000 inhabitants per day) between 2004-2006 
and 2011-2013, are  presented in maps 27 and 28 below.
Figure 61. Consumption of phenobarbital, 
all  regions, 2004-2006 and 2011-2013
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Map 28. Average national consumption of phenobarbital, 2011-2013
C. Impediments to the availability 
of psychotropic substances
228. The availability of psychotropic substances is 
influenced by various social and economic factors, 
including (a) the structure and capacity of health-care 
systems; (b) the degree of priority given by the author-
ities to the relief of pain and suffering; and (c) social 
attitudes towards health care and medical therapies, as 
well as related laws and regulations. In fact, the availa-
bility of controlled substances does not necessarily imply 
that they are accessible to all patients who need them. 
In reality, further criteria and conditions determine the 
accessibility of the drugs and have an impact on the 
relief of patients.
229. According to the second survey on the availability 
of controlled substances, carried out by the Board in 
2014, to which 107 countries responded, the vast major-
ity of Governments evaluated the situation in their coun-
tries as satisfactory. As shown in figure 62, more than 
three quarters of countries considered their situation to 
be satisfactory or entirely satisfactory (55 and 28 per cent, 
respectively), while others (15 per cent) indicated that the 
availability of those substances in their countries was in 
need of some improvement. Nevertheless, the Board 
wishes to interpret this assessment with a certain amount 
of caution. 
Figure 62. Availability of psychotropic 
substances, as evaluated by countries 
themselves, 2014
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230. Furthermore, the availability of controlled sub-
stances in a country is not always a pertinent factor in 
determining the accessibility of such substances. Many 
aspects must be taken into account and addressed in 
order to achieve a fair and balanced distribution across 
the entire geographical area of a country and among its 
entire population. 
231. The extent of medical use of drugs depends on 
many factors. For instance, prescribers will select treat-
ments according to their established therapeutic effective-
ness, their availability and, importantly, the stability of 
their supply, which would entail a good awareness and 
knowledge of the market situation. The availability and 
accessibility of psychotropic substances have a direct 
impact on the level of consumption of such substances, 
but they do not automatically imply the existence of such 
a level of consumption, given that prescribers may select 
different protocols of treatment that will result in the 
 prescription of other substances (for example, non- 
controlled or cheaper substances). In such cases, access 
by patients to treatment is ensured, but it does not involve 
controlled substances and may result in the artificially low 
availability of such substances.
232. As figure 63 shows, the Board’s 2014 survey on the 
availability of controlled substances revealed the major 
impediments to the availability of such substances under 
international control as perceived by Governments. 
233. With the exception of the fear of diversion, which 
was cited more frequently in relation to narcotic drugs 
than psychotropic substances, the main impediment to 
the availability of psychotropic substances, as was the case 
with regard to narcotic drugs, was inappropriate knowl-
edge and lack of awareness among health-care profession-
als regarding rational use of those substances. Moreover, 
the survey also showed that the impediment least fre-
quently cited by responding countries was action by the 
Board, with regard to the availability of both narcotic 
drugs and psychotropic substances. This is a positive and 
encouraging finding that shows that the Board is not per-
ceived as a contributor to unduly limited availability of 
controlled substances, but rather the opposite. 
Figure 63. Impediments to the availability of psychotropic substances, 2014
Source: International Narcotics Control Board survey 2014.
234. The environment surrounding a patient may hin-
der access to treatment, for example, if the necessary 
health structures (hospitals, clinics or pharmacies) are 
lacking in certain areas of a country or, as is unfortu-
nately common in the rural communities of some 
developing countries, the closest health facilities are too 
far to be reached. The capacity of health systems to 
reach patients affects the accessibility of controlled 
 substances without influencing their availability (if 
 sufficient stocks are available in distant regions). The 
emergence of  parallel markets and counterfeit products, 
with the health hazard they represent, is the result when 
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proper and timely access to safe medicines is not 
possible.
235. In developing countries where the availability of 
medicines is determined by economic factors rather than 
by real medical needs, mental health care might not be 
given the priority it deserves. Furthermore, cultural atti-
tudes vis-à-vis mental disorders and illnesses and the fear 
of addiction were also indicated as impediments to the 
consumption of psychotropic substances. A low level of 
prescription by health-care providers is a deterrent to 
their manufacture and/or import.
236. In some cases, misinformation and misconception 
concerning controlled substances, added to a fear of 
prose cution for storing these substances, often force 
 distributors to refrain from holding large stocks.
237. The most often cited impediment was a lack of 
awareness among health-care professionals about the con-
cept of rational use of psychotropic substances. Such an 
impediment may result from a lack of training and knowl-
edge on the matter and will contribute greatly to low 
 levels of prescription of these substances.
238. In several countries, a lack of knowledge among 
health-care professionals may result in non-justified con-
cerns about the prescription, use and dependence poten-
tial of such substances. As is the case for narcotic drugs, 
insufficient attention to the rational prescription and use 
of psychotropic substances in the curricula of medical 
schools may also be a factor. Consequently, doctors may 
instead prescribe substances with which they are more 
familiar, in particular, substances that are not under inter-
national control. 
239. According to the answers to the Board’s survey, the 
curriculum for medical practitioners in 66 countries 
includes rational prescription and use of psychotropic 
substances. In addition, 58 countries reported 
 implementing awareness-raising measures among health-
care professionals regarding best prescription practices 
for psychotropic substances.
240. Furthermore, among responding countries, 39 per 
cent (29 countries) identified fear of addiction as an 
impediment to the availability of psychotropic substances, 
making it one of the most frequently mentioned imped-
iments in the 2014 survey.
241. As was observed in the case of narcotic drugs, the 
fear of addiction to psychotropic substances seems to be 
related to a lack of awareness and training of health-care 
professionals, as well as cultural attitudes and 
misconceptions. 
242. Clearly, one of the main impediments to access to 
a particular medical treatment is its cost; hence, such a 
treatment might be available but not accessible to those 
who need it most. Furthermore, access to medicines, pro-
vided that they are available, may depend on other fac-
tors, such as the health-care structure itself. Twenty-eight 
countries (37 per cent) identified financial aspects as a 
potential impediment to the availability of psychotropic 
substances. Indeed, limited available financial resources 
can have an impact on the choice of which medicines to 
purchase, and priority might be given to substances that 
are perceived as essential (such as antibiotics). 
243. Furthermore, the availability of psychotropic sub-
stances is also dependent on their affordability for 
patients. In this context, the presence of social security 
or national health insurance schemes plays a crucial role. 
In the responses to the question about who pays for med-
ical treatments containing psychotropic substances pre-
scribed, patients were mentioned the most often (89 per 
cent), followed by the government (73 per cent) and 
health insurance schemes (62 per cent) (see figure 64). 
Figure 64. Who bears the cost of prescribed 
psychotropic substances, 2014
Source: International Narcotics Control Board survey 2014.
244. Cultural and social attitudes regarding the use of 
psychotropic substances were also recognized as playing 
a major role in contributing to restrictions on the use of 
such substances.
245. A better awareness of rational use and prescription 
of psychotropic substances among health-care profession-
als can greatly contribute to overcoming restrictions on 
use that result from fear of addiction. The Board survey 
shows that, out of 58 countries that had implemented 
awareness-raising measures among health-care 
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professionals, a large proportion (75 per cent) did not 
report the fear of addiction as an impediment to the avail-
ability of psychotropic substances (see figure 65). 
246. Countries may refrain from the manufacture and/
or import of controlled substances in order to avoid their 
diversion into illicit traffic and abuse networks. Out of 75 
responding countries, 26 reported fear of diversion of 
 psychotropic substances as an impediment to the availa-
bility of such substances. Furthermore, the emergence of 
unregulated and parallel markets for psychotropic 
 substances can also greatly contribute to the fear of 
 diversion. Patients may sometimes refuse a treatment that 
contains psychotropic substances, as they may be 
 concerned about possible side effects and also worry about 
the stigma associated with the use of such substances.
247. Other major impediments perceived by respond-
ing countries included the burden imposed by some 
internal administrative frameworks for regulating the use 
of controlled substances and the various rules and regu-
lations regarding international trade in those substances, 
as well as the fear of prosecution and/or sanction associ-
ated with dealing with controlled substances. These meas-
ures may concern international trade in psychotropic 
substances and domestic distribution networks (prescrip-
tion and dispensing). The survey found that, out of 37 
countries that reported having taken legislative or regu-
latory action in the previous 10 years to increase the avail-
ability of psychotropic substances for medical purposes, 
35 countries had observed an increase in consumption 
expressed in S-DDD since the 2007-2009 period. However, 
out of 83 responding countries, 75 reported the existence 
of penalties for inadequate record-keeping. 
248. Of 102 responding countries, 66 per cent legally 
required prescribers to keep records of prescriptions for 
psychotropic substances. This may discourage the stock-
ing of such substances, owing to costs and time-consum-
ing procedures, and possibly because of fear of prosecu-
tion and sanctions.
249. As illustrated in figure 66, general practitioners and 
specialized doctors have a nearly identical degree of author-
ity in terms of prescribing psychotropic substances. In a 
large proportion of responding countries, nurses were not 
allowed to prescribe psychotropic substances, which may 
be an impediment to availability, especially in rural areas 
with basic health-care systems and infrastructure. 
250. Lower levels of access to psychotropic substances 
could also result from overly restrictive rules concerning 
distribution networks and dispensing protocols. The 
validity period of a medical prescription that contains 
psychotropic substances, as well as constraints on or 
inflexibility regarding a prescription’s refill, could also 
play a role, especially since treatment that includes psy-
chotropic substances can very often last for years. In this 
context, 26 per cent of countries reported prescriptions 
to be valid for one month or less. The second most 
Figure 66. Prescribers of psychotropic 
substances, 2014
Source: International Narcotics Control Board survey 2014.
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Figure 65. Reports of fear of addiction among 
countries that have implemented awareness-
raising measures, 2014
Source: International Narcotics Control Board survey 2014.
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frequently reported validity period was up to one week 
(22 per cent) (see figure 67). 
251. Member States reported that psychotropic sub-
stances were dispensed mostly in licensed hospital phar-
macies or in regular pharmacies. Less than half of 
responding countries reported that psychotropic sub-
stances could be dispensed in specially licensed pharma-
cies (see figure 68).
252. Restrictions on the number of pharmacies that are 
allowed to dispense psychotropic substances, although 
not as stringent as those observed for the dispensing of 
narcotic drugs, may still reduce the availability of such 
drugs.
253. Finally, in only one country was action by the 
Board identified as an obstacle to the availability of psy-
chotropic substances. While the large majority of coun-
tries are familiar with the procedures for establishing, 
submitting and modifying assessments of their medical 
requirements for psychotropic substances (98 per cent), 
and furthermore more than 80 per cent of responding 
countries were using the INCB training materials, as well 
as the joint INCB/WHO guidelines on the preparation 
of estimates, some responding authorities proposed 
actions that could be taken by the Board that could con-
tribute to the improvement of the availability of psycho-
tropic substances, including the training of and the pro-
vision of information to competent national 
authorities.
Figure 68. Facilities where prescriptions for 
psychotropic substances can be dispensed. 
2014
Source: International Narcotics Control Board survey 2014.
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Figure 67. Maximum validity period of medical 
prescriptions that contain psychotropic 
substances, 2014 
Source: International Narcotics Control Board survey 2014.
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Chapter IV.
Availability of internationally controlled drugs for 
the treatment of opioid dependence
254.  Methadone and buprenorphine are used in the man-
agement of pain, but they are also extensively used in the 
treatment of opioid dependence. In some countries, other 
controlled substances, such as opium, opium tincture,  heroin 
and morphine, are used for the treatment of opioid depend-
ence. The data reported by countries to INCB do not indi-
cate the purpose of use, but estimates for methadone and 
buprenorphine are mainly submitted in relation to pro-
grammes for the treatment of opioid dependence.
Figure 69. Reported manufacture and stocks 
of buprenorphine, 1994-2013
Source: International Narcotics Control Board.
Note: Approximate calculated global consumption, determined on 
the basis of statistical data submitted by Governments.
a Stocks as at 31 December of each year; data are provided on a 
voluntary basis and may therefore be incomplete.
255. An analysis of the trends related to the consump-
tion, manufacture and stocks of both substances shows a 
steady increase over the past 20 years. The global manu-
facture of buprenorphine has increased steadily (with the 
exception of 2010, when there was a sharp decrease), 
reaching a peak of 8.7 tons in 2013. Similarly, the global 
manufacture of methadone also increased steadily during 
the same period, with some fluctuations, and decreased 
slightly in 2013 to 41.4 tons (5.5 tons less than in 2012) 
(see figures 69 and 70). As mentioned in relation to other 
opioid analgesics, it seems that there is no problem with 
the supply of these substances.
Figure 70. Global manufacture, consumption 
and stocks of methadone, 1994-2013
Source: International Narcotics Control Board.
a Stocks as at 31 December of each year.
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256. However, there are large differences in the patterns 
of consumption at the global level, as shown in maps 
29-33. In some cases, the different level of consumption 
(expressed in S-DDD, see figures 71 and 72) is related to 
the presence or absence of people who inject drugs. In 
other cases, despite the existence (more or less prevalent) 
of that phenomenon, it seems that the consumption of 
methadone and buprenorphine, and also the presence of 
opiate substitution treatment services, are limited or not 
present. This is sometimes because of government poli-
cies that do not recognize the effectiveness of these kinds 
of services in the treatment of opioid dependence, polit-
ical and cultural resistance, or simply inaction by the 
responsible authorities or incapacity to recognize the 
problem. In the survey carried out by the Board in 2014, 
67 per cent of countries indicated that they were using 
narcotic drugs for the treatment of drug dependency with 
substitution therapy.
Map 29. Prevalence of people who inject drugs, 2013
The boundaries and names shown and the designations used on this map do not imply official  endorsement 
or acceptance by the United Nations. The final boundary between South Sudan and the Sudan has not 
yet been determined. The dotted line represents approximately the Line of Control in Jammu and Kashmir 
agreed upon by India and Pakistan. The final status of Jammu and Kashmir has not yet been agreed upon by 
the parties. A dispute exists between the Governments of Argentina and the United Kingdom of Great Britain 
and Northern Ireland concerning sovereignty over the Falkland Islands (Malvinas).
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Figure 71. Variations in the consumption of 
methadone between 2004-2006 and 2011-2013
Source: International Narcotics Control Board.
Figure 72. Variations in the consumption of 
buprenorphine between 2004-2006 and 2011-2013
Source: International Narcotics Control Board.
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Map 30. Consumption of methadone, 2004-2006
Map 31. Consumption of methadone, 2011-2013
The boundaries and names shown and the designations used on this map do not imply official  endorsement 
or acceptance by the United Nations. The final boundary between South Sudan and the Sudan has not 
yet been determined. The dotted line represents approximately the Line of Control in Jammu and Kashmir 
agreed upon by India and Pakistan. The final status of Jammu and Kashmir has not yet been agreed upon by 
the parties. A dispute exists between the Governments of Argentina and the United Kingdom of Great Britain 
and Northern Ireland concerning sovereignty over the Falkland Islands (Malvinas).
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Map 32. Consumption of buprenorphine, 2004-2006
Map 33. Consumption of buprenorphine, 2011-2013
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yet been determined. The dotted line represents approximately the Line of Control in Jammu and Kashmir 
agreed upon by India and Pakistan. The final status of Jammu and Kashmir has not yet been agreed upon by 
the parties. A dispute exists between the Governments of Argentina and the United Kingdom of Great Britain 
and Northern Ireland concerning sovereignty over the Falkland Islands (Malvinas).
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257. For methadone, it is important to note the increase 
in consumption in Africa and South-Eastern Europe, 
which corresponds to the expansion of opioid substitu-
tion treatment services in some countries in those regions. 
For buprenorphine, there was a large increase in con-
sumption in Western Europe. The increase in the con-
sumption of buprenorphine registered in some regions 
may be the result of various factors: aggressive market-
ing by producing companies; easier accessibility due to 
the less strict control regime of the 1971 Convention 
compared with the 1961 Convention (under which 
metha done is controlled); and increasing use for pain 
relief. In Central and South America, methadone is used 
for pain management and not for opioid substitution 
treatment, because the prevalence of people who inject 
drugs in the region is relatively low. 
258. A comparison of the level of consumption of 
metha done and the prevalence of people who inject drugs 
in various regions indicates an imbalance in that regard 
in Eastern Europe (see figure 73). As mentioned above, 
the use of methadone is not recognized in some of the 
countries of that region. In Western Europe, there seems 
to be a very high level of methadone consumption despite 
a lower prevalence of people who inject drugs. This may 
be due to the fact that the opioid substitution treatment 
 services provided in the region reach a large number of 
people who inject drugs.
Figure 73. Comparison between consumption of methadone, 2011-2013, and prevalence of 
people who inject drugs, 2013 
Source: International Narcotics Control Board and UNODC.
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Chapter V.
Ensuring the availability of internationally 
controlled drugs in emergency situations
259. Most narcotic drugs and a large number of psy-
chotropic substances controlled under the international 
treaties are indispensable for medical practice. Simplified 
control measures are in place for the provision of inter-
nationally controlled medicines for emergency medical 
care. Emergencies are defined as follows:
  Any acute situation (e.g. earthquakes, floods, hurri-
canes, epidemics, conflicts, displacement of popula-
tions) in which the health conditions of a group of 
individuals are seriously threatened unless immedi-
ate and appropriate action is taken, and which 
demands an extraordinary response and exceptional 
measures.61
260. In 1996, the Board, together with WHO, devised 
simplified control procedures for the export, transport 
and import of controlled medicines for emergency medi-
cal care. The simplified regulations remove the need for 
import authorizations, provided that the import and 
delivery are handled by established international, govern-
mental and/or non-governmental organizations engaged 
in the provision of humanitarian assistance in health mat-
ters recognized by the control authorities of the export-
ing countries. Those simplified procedures are available 
to all States in the Model Guidelines for the International 
Provision of Controlled Medicines for Emergency Medical 
Care.
261. Emergency situations arise following natural or 
man-made catastrophic events in which the need to 
provide treatment to the many victims leads to a 
 61 World Health Organization, Model Guidelines for the Inter-
national Provision of Controlled Medicines for Emergency Medical Care.
sudden need for and an acute shortage of medicines. 
Many of those needed medicines contain narcotic 
drugs, such as morphine, or psychotropic substances, 
such as pentazocine, both of which are under inter-
national control. Under normal circumstances, the 
import and transport of those medications are subject 
to strict regulatory requirements. However, in 
 catastrophic situ ations compliance may delay the 
urgent delivery of medications for emergency 
 humanitarian relief, as national authorities may be 
unable to take the administrative steps required.
262. In responding to humanitarian crises, the Board 
takes active steps to hasten the supply of controlled medi-
cines by reminding all exporting countries that clear 
guidelines are in place for the international provision of 
controlled medicines for emergency medical care and that 
countries can apply those simplified control procedures 
to hasten the supply of urgently needed medicines. The 
Board also informs providers of humanitarian assistance 
about the simplified regulations. 
263. Competent national authorities may allow the 
export of internationally controlled substances to affected 
countries even in the absence of import authorizations or 
estimated requirements. Emergency deliveries need not 
be included in the estimates of the receiving country, and 
exporting Governments may wish to use parts of their 
special stocks of narcotic drugs and psychotropic sub-
stances for that purpose.
264. This solution has been available for a number of 
years. The Board invites Governments and humanitarian 
relief agencies to bring to its attention any problems 
encountered in making deliveries of controlled medicines 
in emergency situations.
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265. In addition, the Board also reminds all States that, 
under international humanitarian law, parties to armed 
conflicts have an obligation not to impede the provision 
of medical care to civilian populations located in territo-
ries under their effective control. This includes access to 
necessary narcotic drugs and psychotropic substances.
77
Chapter VI.
Conclusions and recommendations
266. Ensuring the availability of internationally con-
trolled substances for medical and scientific purposes 
while preventing their illicit trafficking and abuse is the 
role of the control system as established by the inter-
national drug control conventions. An efficient and 
 successful drug regulatory system that maintains this 
 balance requires the involvement of the entire  community, 
as well as the commitment of Governments.
267. The issue of ensuring the availability of narcotic 
drugs and psychotropic substances for medical purposes is 
a complex one. The previous chapters have discussed the 
unequal distribution of these drugs, as well as the barriers 
and impediments that cause this inequality. Apart from the 
data on consumption and prevalence of health conditions 
requiring palliative care, and the information presented by 
Member States, the Board has also reviewed information 
provided by international organizations (WHO, UNODC 
and UNAIDS), academia, research centres and civil society 
organizations. The analysis of this entire set of information 
suggests that there are some key areas that require action 
at the national and international levels.
A. Legislation and regulatory 
systems
268. The regulatory machinery that countries have estab-
lished to implement the provisions of the international 
drug control conventions needs to be reviewed. Most stud-
ies and analyses indicate that some countries, when devel-
oping legislation and regulations, were concerned mostly 
with the need to avoid diversion and abuse rather than the 
need to ensure availability and make  adequate provisions 
to that end. In fact, concerns about the risk of addiction 
are still reported to be a major impediment by countries. 
However, in the three surveys carried out by the Board 
over the past 20 years, the percentage of countries indicat-
ing this as an impediment has dropped from over 70 per 
cent in 1995 to 34 per cent in 2014. This unbalanced or 
asymmetrical view of the  conventions has, in a number of 
countries, generated  regulatory systems that make it diffi-
cult or almost  impossible for people in need to obtain opi-
oid analgesics.
269. The Board has in the past expressed concerns in 
this regard and issued recommendations. It seems that 
some countries have taken action, but there are still coun-
tries that need to address this issue. The Board recom-
mends that they take the following actions:
 •  Review national legislation and regulatory and 
administrative mechanisms, as well as procedures, 
 including domestic distribution channels, with 
the aim of simplifying and streamlining those 
processes, and removing unduly restrictive regu-
lations and impediments to ensure accessibility 
while maintaining adequate control systems.
 •  Allow a larger base of health-care professionals 
(including trained general practitioners, nurses 
and others, as appropriate) to prescribe opioids 
to increase availability, particularly in remote or 
rural areas.
 •  Take measures to prevent the emergence of 
unregulated markets and illicit or counterfeit 
manufacture of narcotic drugs and psychotropic 
substances.
 •  Ensure adequate prescription policies, including, 
where appropriate, by increasing the validity 
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period of prescriptions to enable patients to pro-
cure medications when they need them.
 •  Remove legal sanctions for unintentional mis-
takes in the handling of opioids.
 •  Improve inter-agency and interministerial coop-
eration and coordination at the national level, 
particularly between health and drug control 
agencies.
 •  Provide the medical and pharmaceutical 
 community with updated information on all new 
legislative and administrative measures enacted in 
connection with controlled substances and on 
modalities of distribution and prescription of psy-
chotropic substances to ensure and sustain the 
requisite availability that would satisfy require-
ments with regard to both quantity and quality.
B. Health system
270. The availability of pain relief drugs or psychotropic 
substances alone will not solve the problem of pain 
 management or mental health treatment. There is broad 
consensus that it is important for countries to give appro-
priate attention to the improvement of the health system. 
To that end, the Board recommends that countries: 
 •  Implement the recommendations contained in 
resolution WHA67.19, adopted by the sixty- 
seventh World Health Assembly on 24 May 2014, 
entitled “Strengthening of palliative care as a 
component of comprehensive care throughout 
the life course”.
 •  Develop an appropriate and well-resourced 
health infrastructure that not only ensures the 
availability of opioid analgesics but also provides 
for such availability in the context of the broader 
delivery of palliative care.
 •  Consider, where appropriate, the option of low-
cost, home-based palliative care services.
 •  Improve the distribution of opioid analgesics 
and psychotropic substances to all areas of the 
country, including rural areas.
C. Affordability
271. Another important aspect of improving availabil-
ity is ensuring that opioid analgesics are affordable. In 
this connection, the Board recommends that countries:
 •  Improve access to essential drugs in general and 
to opioid analgesics in particular.
 •  Ensure funding for the purchase of opioid 
analgesics.
 •  Develop and improve health insurance and 
reimbursement schemes that guarantee access to 
medications.
272. With respect to affordability, pharmaceutical com-
panies have an important role to play. The Board will, as 
part of its ongoing efforts to improve the situation, com-
mence consultations with pharmaceutical industry groups 
about the lack of controlled medications in many regions, 
involving relevant international organizations (e.g. WHO), 
and relevant international professional groups and 
 interested Governments in these discussions, which will 
focus on the availability and accessibility in developing 
countries of affordable, effective monotherapies, such as 
morphine for pain, especially cancerous pain. The Board 
recommends that the pharmaceutical industry:
 •  Manufacture high-quality opioid preparations 
that are more affordable.
 •  Manufacture generic pharmaceutical prepara-
tions that are bioequivalent and cost effective.
D. Training of health-care 
professionals
273. Patients have the right to be treated and to receive 
medications that are rationally prescribed. Lack of train-
ing and lack of awareness among health-care providers 
concerning the rational use of narcotic drugs and psy-
chotropic substances, and the resulting reduced levels of 
prescription, will limit the use of such substances. 
Furthermore, certain cultural attitudes towards the man-
agement of mental health disorders and palliation are act-
ing as an impediment to the use of narcotic drugs and 
psychotropic substances. To this end, health-care profes-
sionals need to be properly educated and trained. It is 
recommended that countries:
 •  Include palliative care in the educational curric-
ula of medical schools and in the mandatory 
training of all health professionals.
 •  Provide continued education, training and infor-
mation on palliative care to health-care profes-
sionals, including on rational use and on the 
importance of reducing prescription drug abuse.
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 •  Provide education and training to doctors and 
other health-care professionals on the rational 
use of psychoactive drugs, since this is of para-
mount importance for the prevention of the 
abuse of such drugs. Health actors must exercise 
vigilance to prevent possible misdiagnoses and 
inappropriate prescribing.
 •  Ensure that psychotropic substances are pre-
scribed in conformity with sound medical prac-
tice as set forth in the 1971 Convention (art. 9, 
para. 2), promote the rational use of such sub-
stances and take the necessary measures to limit 
their use to actual medical needs.
E. Education and awareness-raising
274. Opioid analgesics and palliative care in general are 
also limited in some countries by social and cultural 
norms. In some societies and cultures, there is resistance 
to dealing with things related to the end of life or asso-
ciated with the fear of addiction. Also, the use of psycho-
tropic substances faces considerable resistance because of 
the stigma associated with the mental health conditions 
that may require their use. The Board recognizes that it 
is necessary for Governments in cooperation with civil 
society to: 
 •  Develop and implement educational pro-
grammes for the general public and the pharma-
ceutical community involving competent 
national authorities, interest groups (e.g. profes-
sional and consumer interest groups) and the 
media.
 •  Organize workshops to disseminate information 
on palliative care to overcome cultural resistance 
to it.
 •  Ask educational institutions to include education 
on palliative care in their curricula.
 •  Engage civil society organizations representing 
patients, families and other relevant groups to 
advocate for palliative care and for the accepta-
bility of the medical use of opioid analgesics.
 •  Educate the public to reduce stigma and unrea-
sonable fear of addiction.
 •  Reduce excessive marketing by industry and 
improve consumer awareness.
 •  Promote ethical attitudes among medical doc-
tors and pharmaceutical companies, together 
with appropriate information for the general 
public and continued education and training of 
health-care professionals to encourage a better-
justified and more rational use of psychotropic 
substances.
 •  Support campaigns and efforts to prevent the 
non-medical consumption of psychotropic sub-
stances, and encourage the active participation 
of the medical and pharmaceutical community 
in all measures related to the rational use of con-
trolled medicines.
F. Estimates, assessments and 
reporting
275. One of the problems that the Board has noted over 
the past several years is that some countries are not able 
to properly estimate their needs for opioid analgesics and 
to monitor the consumption of those substances. 
Furthermore, many countries still find it difficult to iden-
tify with precision their requirements for psychotropic 
substances. Consequently, they are unable to establish and 
provide the Board with adequate assessments for their 
legitimate use. In addition, in its resolution 53/4 and 
54/6,  the Commission on Narcotic Drugs encouraged 
Governments to provide the Board with data on the 
 consumption of psychotropic substances, in the same 
manner as for narcotic drugs. Finally, the punctuality of 
the submission of reports and their comprehensiveness 
and reliability are important aspects of each Government’s 
cooperation with INCB. The Board recommends that 
countries:
 •  Improve their method of assessing their needs 
by making use of the Guide on Estimating 
Requirements for Substances under International 
Control developed in 2012 by INCB and WHO 
for use by competent national authorities.
 •  Submit appropriate and realistic estimates that 
take into consideration possible variations in 
demand.
 •  Establish proper and feasible monitoring 
 mechanisms at the national level and make use 
of improved technical systems such as the 
 electronic International Import and Export 
Authorization System (I2ES) for narcotic drugs 
and psychotropic substances, which was 
 developed by INCB in close cooperation with 
UNODC.
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 •  Establish a procedure and develop mechanisms 
that will allow their competent national author-
ities to more accurately assess the actual require-
ments for psychotropic substances and submit 
such data to the Board.
 •  Develop adequate systems that will enable the 
collection of reliable data that would be essential 
in enabling the Board to better analyse trends in 
the consumption of psychotropic substances and, 
ultimately, to promote their adequate availability 
for medical and scientific purposes while 
 preventing their diversion and abuse.
G. Benchmarks for consumption 
of substances under international 
control
276. The results of the analysis of the data on availabil-
ity and  consumption reported to INCB, and the answers 
to the questionnaire on availability provided by 
Governments demonstrate the complexity of this analy-
sis. In particular, the levels of consumption of psycho-
tropic substances  calculated by the Board on the basis of 
statistics on  manufacture and trade provided to the Board 
by Governments cannot reflect with precision the levels 
of consumption of these substances. 
277. Furthermore, in the absence of thresholds for per 
capita consumption in S-DDD, the Board is not in a 
 position to evaluate and assess levels of consumption of 
psychotropic substances, and therefore cannot estimate 
whether in some countries or regions the level of 
 consumption of such substances is adequate, too high or 
too low. The Board recommends that WHO work with 
INCB to:
 •  Establish benchmarks for the consumption of 
psychotropic substances.
This would greatly support the work of INCB and of the 
national Governments, as standards would serve as indi-
cators when assessing the availability for legitimate medi-
cal and scientific purposes of psychotropic substances. 
This can be achieved only by using reliable morbidity 
data, and prevalence rates that include geographical dis-
tribution and the medical practice with regard to specific 
psychotropic substances for a related medical condition.
H. International community
278. Some Governments are not in a position to imple-
ment the above recommendations on their own. They 
need advice, training and resources to address the limi-
tations of their systems. For this reason, the international 
community has a role to play. The Board believes that the 
international community should:
 •  Improve cooperation among Governments, 
international organizations (INCB, WHO, 
UNODC, UNAIDS and UNDP, among others), 
the donor community and civil society organi-
zations to ensure the sharing of expertise and 
the coordinated delivery of resources and tech-
nical support to countries in need of 
assistance.
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Annex.
Questionnaire sent in 2014 to competent 
national authorities of Member States on the 
availability of internationally controlled 
substances for medical and scientific purposes
Questionnaire for National Competent Authorities on the availability of 
Internationally Controlled Substances for medical and scientific purposes
Part 1 of 2 — Narcotic drugs
Please return this questionnaire by 31 October 2014 to:
INCB Secretariat
Vienna International Centre
P.O. Box 500
1400 Vienna
Austria
Fax: (+43-1) 26060-5867
Tel.: (+43-1) 26060-4933
E-mail: secretariat@incb.org
Please state the name of the submitting authority:
Country: ....................................................................................................................................................
Authority: ..................................................................................................................................................
Contact person: ........................................................................................................................................
Tel.: ...................................... Fax:  ...........................................  E-mail: .........................................
Please provide the names of authorities and contact persons who might be able to provide additional information 
if required:
Authority/ies: ............................................................................................................................................
Contact person/s:  ....................................................................................................................................
Tel.: ...................................... Fax:  ...........................................  E-mail:  ........................................
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Instructions for filling out this questionnaire.
This questionnaire consists of two parts:
 Part 1 relates to the availability of narcotic drugs subject to international control under 
the 1961 Single Convention on Narcotic Drugs
 Part 2 relates to the availability of psychotropic substances subject to international 
 control under the 1971 Convention on Psychotropic Substances 
According to the national regulatory framework in place in each State, these substances may 
be dealt with by the same competent authority or be controlled by two distinct institutional 
actors. In both cases, each part should be duly filled out by the appropriate stakeholder, and 
the consolidated questionnaire, containing both parts, should be returned to the INCB 
 secretariat using the contact details provided on the cover page by the deadline indicated.
For the purpose of expediency, electronic submission of the completed questionnaire is 
encouraged.
ANNEX  83
Part 1. Narcotic drugs
A. Availability of narcotic drugs
1.  How would you qualify the situation in your country with respect to the availability of opioid 
analgesics for medical and scientific purposes?
 ☐ Entirely satisfactory
 ☐ Satisfactory
 ☐ In need of some improvement
 ☐ In need of significant improvement
2.  What factors are taken into account by your national competent authority in the quantifica-
tion of your country’s consumption needs for narcotic drugs? (Please select one or more answers 
as appropriate.)
 ☐ Consumption patterns in previous year(s)
 ☐  Existence of specialized treatment services (e.g. oncology, palliative care, opioid substitu-
tion or therapy)
 ☐ Information of planned manufacture submitted by industry
 ☐ Epidemiological data, including prevalence rates for common illnesses
 ☐ Other (please specify):
3.  Please describe the methodology employed by your national competent authorities in estab-
lishing consumption estimates for medical and scientific use of narcotic drugs:
4.  Are you aware of the procedure to submit supplementary estimates for narcotic drugs to INCB 
to meet greater than expected need or due to unforeseen circumstances (e.g. natural disasters, 
epidemics)? 
☐ Yes 
☐ No
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5.  Are you aware of the INCB training materials published by the Board in order to assist States 
in preparing their estimates of narcotic drug requirements for submission to the Board, which 
are available from: http://www.incb.org/documents/Narcotic-Drugs/Training-Materials/English/
NAR_2_English_2005.pdf?
☐ Yes 
☐ No
6.  Are you aware of the joint WHO/INCB Guide on Estimating Requirements for Substances under 
International Control, available from: http://www.incb.org/documents/Narcotic-Drugs/
Guidelines/estimating_requirements/NAR_Guide_on_Estimating_EN_Ebook.pdf?
☐ Yes 
☐ No
B. Appropriate use of narcotic drugs 
7.  Is the use of narcotic drugs in your country restricted to specific medical conditions, includ-
ing treatment for palliative care?
 ☐ Yes 
 ☐ No
  If you answered “Yes”, please provide details as to the types of conditions for which the use of 
narcotic drugs is allowed: 
8.  Does your country use narcotic drugs for the treatment of drug dependency (e.g. substitution 
therapy)?
 ☐ Yes 
 ☐ No
 If you answered “Yes”, please provide details:
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C.  Regulatory framework governing prescriptions for narcotic 
drugs
 9.  According to your national legislative and regulatory framework, which of the following 
professional categories is permitted to prescribe narcotic drugs for medical treatment?
 ☐ General practitioners
 ☐ General practitioners licensed to issue prescriptions for narcotic drugs
 ☐ Medical specialists (e.g. psychiatrists, oncologists, surgeons, dentists)
 ☐ Nurses (including nurse practitioners)
 ☐ Veterinarians
 ☐ Others (please specify):
10. Is a second opinion a requirement prior to the issuance of a prescription for narcotic drugs?
 ☐ Yes 
 ☐ No
 If you answered “Yes”, please provide details: 
11. How long is a prescription for narcotic drugs valid for from the date of issuance?
  Is the issuance of prescriptions for narcotic drugs subject to any particular legal/regulatory 
formalities compared to other prescription medications (e.g. requirements for additional 
authorizations, shorter validity period of prescription)?
 ☐ Yes 
 ☐ No
 If you answered “Yes”, please provide details: 
86  AVAILABILITY OF INTERNATIONALLY CONTROLLED DRUGS
12.  Can a single prescription for narcotic drugs cover the entire duration of the treatment, or is 
it limited to a shorter period?
 ☐ Yes 
 ☐ No
 If you answered “No”, please provide details: 
13.  Are there any circumstances that exist where a prescription for narcotic drugs may be deemed 
refillable?a
 ☐ Yes 
 ☐ No
 If you answered “Yes”, please provide details: 
D.  Regulatory framework governing the dispensing of narcotic 
drugs 
14. Are narcotic drugs dispensed in:
 ☐ Licensed hospital pharmacies
 ☐ Specially licensed pharmacies
 ☐ Pharmacies
 ☐ Others (please specify):
 a Please note that the term “refillable” is defined as not requiring subsequent doctor’s approval.
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E. Record-keeping and prescription drug monitoring
15. Are prescribers legally required to keep records of prescriptions issued for narcotic drugs?
 ☐ Yes
 ☐ No
  If you answered “Yes”, please provide details, including the length of time for which records 
should be kept: 
16.  Are dispensing agents (see question 14) legally required to keep records of prescriptions issued 
for narcotic drugs?
 ☐ Yes 
 ☐ No
  If you answered “Yes”, please provide details including the length of time for which records 
should be kept: 
17.  Does the legislative/regulatory framework in place in your country provide for penalties for 
inadequate record-keeping?
 ☐ Yes 
 ☐ No
 If you answered “Yes”, please provide details: 
88  AVAILABILITY OF INTERNATIONALLY CONTROLLED DRUGS
F.  Measures to promote adequate availability and rational use 
of narcotic drugs 
18. Who pays for narcotic drugs prescribed?
 ☐ Government (social security)
 ☐ Patients themselves
 ☐ Health insurance schemes
 ☐ Others
19.  Does the educational curriculum for medical practitioners in your country include any con-
tent with respect to the rational prescription and use of prescription narcotic drugs?
 ☐ Yes 
 ☐ No
 If you answered “Yes”, please provide details: 
20.  Have any awareness-raising measures been implemented by the authorities of your country 
to foster a deeper understanding of responsible prescribing practices for narcotic drugs among 
health-care professionals?
 ☐ Yes 
 ☐ No
 If you answered “Yes”, please provide details: 
21.  In the last 10 years, has your Government taken any legislative or regulatory action to increase 
the availability of narcotic drugs for medical purposes? 
 ☐ Yes 
 ☐ No
 If you answered “Yes”, please provide details: 
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G. Impediments to availability
22.  In the context of your country, have any of the factors below had the effect of unduly limit-
ing the availability of narcotic drugs needed for medical or scientific purposes (please select 
all applicable factors)?
 ☐ Limited financial resources
 ☐ Problems in sourcing from industry/imports
 ☐ Fear of diversion into illicit channels
 ☐ Fear of criminal prosecution/sanction
 ☐  Lack of awareness/training among members of the medical profession regarding the 
rational use of narcotic drugs 
 ☐ Onerous regulatory framework for the prescription of narcotic drugs for medical use
 ☐ Fear of addiction 
 ☐ Cultural attitudes towards the treatment of pain
 ☐  Control measures applicable to international trade, such as requirements for import or 
export authorizations 
 ☐ Action by the Board
 ☐ Other(s):
 Please elaborate as applicable:
23.  What do you consider to be the most significant obstacle to the availability of narcotic drugs 
in your country to meet medical and scientific needs?
24.  Are any particular measures in place in your country to facilitate the availability of narcotic 
drugs for medical purposes in rural or remote regions of your country?
 ☐ Yes 
 ☐ No
 If you answered “Yes”, please provide details: 
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25.  Are there any additional measures that could be taken by INCB to contribute to greater avail-
ability of narcotic drugs for medical and scientific purposes in your country?
H. Overprescription of narcotic drugs
26. Has your country experienced the following with respect to narcotic drugs:
 ☐ Overprescription
 ☐ “Doctor shopping”b
 ☐ Self-medication
 ☐ Parallel unregulated markets
 ☐ Counterfeiting of prescription narcotic drugs
 Please provide details, as applicable: 
Additional information (as required):
 b “Doctor shopping” or “double doctoring” refers to the practice of a patient requesting care from multiple physicians, often 
simultaneously, without making efforts to coordinate care or informing the physicians of the multiple caregivers.
ANNEX  91
Questionnaire for National Competent Authorities on the 
availability of Internationally Controlled Substances for medical 
and scientific purposes
Part 2 of 2 — Psychotropic substances
Please return this questionnaire by 31 October 2014 to:
INCB Secretariat
Vienna International Centre
P.O. Box 500
1400 Vienna
Austria
Fax: (+43-1) 26060-5867
Tel.: (+43-1) 26060-4933
E-mail: secretariat@incb.org
Please state the name of the submitting authority:
Country: ....................................................................................................................................................
Authority: ..................................................................................................................................................
Contact person: ........................................................................................................................................
Tel.: ...................................... Fax:  ...........................................  E-mail: .........................................
Please provide the names of authorities and contact persons who might be able to provide additional information 
if required:
Authority/ies: ............................................................................................................................................
Contact person/s:  ....................................................................................................................................
Tel.: ...................................... Fax:  ...........................................  E-mail:  ........................................
Instructions for filling out this questionnaire.
This questionnaire consists of two parts:
 Part 1 relates to the availability of narcotic drugs subject to international control under 
the 1961 Single Convention on Narcotic Drugs
 Part 2 relates to the availability of psychotropic substances subject to international con-
trol under the 1971 Convention on Psychotropic Substances 
According to the national regulatory framework in place in each State, these substances may 
be dealt with by the same competent authority or be controlled by two distinct institutional 
actors. In both cases, each part should be duly filled out by the appropriate stakeholder, and 
the consolidated questionnaire, containing both parts, should be returned to the INCB 
Secretariat using the contact details provided on the cover page by the deadline indicated.
For the purpose of expediency, electronic submission of the completed questionnaire is 
encouraged.
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Part 2. Psychotropic substances
A. Availability of psychotropic substances
27.  How would you qualify the situation in your country with respect to the availability of psy-
chotropic substances for medical and scientific purposes?
 ☐ Entirely satisfactory
 ☐ Satisfactory
 ☐ In need of some improvement
 ☐ In need of significant improvement
28.  What factors are taken into account by your national competent authority in the quantifica-
tion of your country’s consumption needs for psychotropic substances? (Please select one or 
more answers as appropriate.)
 ☐ Consumption patterns in previous year(s)
 ☐  Existence of specialized treatment services (e.g. specialized mental health services, palli-
ative care, opioid substitution therapy)
 ☐ Information on planned manufacture submitted by industry
 ☐ Epidemiological data including prevalence rates for mental health conditions 
 ☐ Other (please specify):
29.  Please describe the methodology employed by your national authorities in establishing annual 
assessments of requirements for psychotropic substances.
30.  Are you aware of the procedure to submit supplementary assessments for psychotropic sub-
stances to INCB to meet greater than expected need or due to unforeseen circumstances (e.g. 
natural disasters, armed conflicts)? 
 ☐ Yes 
 ☐ No
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31.  Are you aware of the INCB training materials published by the Board in order to assist States 
in preparing their assessments of psychotropic substances requirements for submission to the 
Board, which are available from: http://www.incb.org/documents/Psychotropics/training- 
materials/training-material-eng-2013-86360.pdf?
 ☐ Yes 
 ☐ No
32.  Are you aware of the joint WHO/INCB publication Guide on Estimating Requirements for 
Substances under International Control, available from: http://www.incb.org/documents/
Narcotic-Drugs/Guidelines/estimating_requirements/NAR_Guide_on_Estimating_EN_Ebook.
pdf?
 ☐ Yes 
 ☐ No
B. Appropriate use of psychotropic substances
33.  Is the use of psychotropic substances in your country restricted to specific mental health dis-
orders, including ADHD, insomnia, anxiety, palliative care?
 ☐ Yes 
 ☐ No
 If you answered “Yes”, please provide details: 
34.  Does your country use psychotropic substances for the treatment of drug dependency (e.g. 
substitution therapy)?
 ☐ Yes 
 ☐ No
 If you answered “Yes”, please provide details: 
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C.  Regulatory framework governing prescriptions for 
psychotropic substances 
35.  According to your national legislative and regulatory framework, which of the following pro-
fessional categories is permitted to prescribe psychotropic substances for medical treatment?
 ☐ General practitioners
 ☐ General practitioners licensed to issue prescriptions for psychotropic substances
 ☐ Medical specialists (e.g. psychiatrists, oncologists, surgeons, dentists)
 ☐ Nurses (including nurse practitioners)
 ☐ Veterinarians
 ☐ Others (please specify):
36.  Is a second opinion a requirement prior to the issuance of a prescription for psychotropic 
substances?
 ☐ Yes 
 ☐ No
 If you answered “Yes”, please provide details: 
37. How long is a prescription for psychotropic substances valid for from the date of issuance?
  Is the issuance of prescriptions for psychotropic substances subject to any particular legal/ 
regulatory formalities compared to other prescription medications (e.g. requirements for 
 additional authorizations, shorter validity period of prescription)?
 ☐ Yes 
 ☐ No
 If you answered “Yes”, please provide details: 
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38.  Can a single prescription for psychotropic substances cover the entire duration of the treat-
ment, or is it limited to a shorter period?
 ☐ Yes 
 ☐ No
 If you answered “No”, please provide details: 
39.  Are there any circumstances that exist where a prescription for psychotropic substances may 
be deemed refillable?c
 ☐ Yes 
 ☐ No
 If you answered “Yes”, please provide details: 
D. Regulatory framework governing the dispensing of 
psychotropic substances
40. Are psychotropic substances dispensed in:
 ☐ Licensed hospital pharmacies
 ☐ Specially licensed pharmacies
 ☐ Pharmacies
 ☐ Other (please specify):
 c Please note that the term “refillable” is defined as not requiring subsequent doctor’s approval.
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E. Record-keeping and prescription drug monitoring
41.  Are prescribers legally required to keep records of prescriptions issued for psychotropic 
substances?
 ☐ Yes 
 ☐ No
  If you answered “Yes”, please provide details, including the length of time for which records 
should be kept: 
42.  Are dispensing agents (see question 40) legally required to keep records of prescriptions issued 
for psychotropic substances?
 ☐ Yes 
 ☐ No
  If you answered “Yes”, please provide details, including the length of time for which records 
should be kept: 
43. Does the legislative/regulatory framework in place in your country provide for penalties for 
inadequate record-keeping?
 ☐ Yes 
 ☐ No
 If you answered “Yes”, please provide details: 
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F.  Measures to promote adequate availability and rational use 
of psychotropic substances
44. Who pays for psychotropic substances prescribed?
 ☐ Government (social security)
 ☐ Patients themselves
 ☐ Health insurance schemes
 ☐ Others
45.  Does the educational curriculum for medical practitioners in your country include any con-
tent with respect to the rational prescription and use of psychotropic substances?
 ☐ Yes 
 ☐ No
 If you answered “Yes”, please provide details: 
46.  Have any awareness-raising measures been implemented by the authorities of your country 
to foster a deeper understanding of responsible prescribing practices for psychotropic sub-
stances among health-care professionals?
 ☐ Yes 
 ☐ No
 If you answered “Yes”, please provide details: 
47.  In the last 10 years, has your Government taken any legislative or regulatory action to increase 
the availability of psychotropic substances for medical purposes? 
 ☐ Yes 
 ☐ No
 If you answered “Yes”, please provide details: 
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G. Impediments to availability
48.  In the context of your country, have any of the factors below had the effect of unduly limit-
ing the availability of psychotropic substances needed for medical or scientific purposes? 
(Please select all applicable factors.)
 ☐ Limited financial resources
 ☐ Problems in sourcing from industry/imports
 ☐ Fear of diversion into illicit channels
 ☐ Fear of criminal prosecution/sanction
 ☐  Lack of awareness/training regarding the rational use of psychotropic substances among 
members of the medical profession
 ☐  Onerous regulatory framework for the prescription of psychotropic substances for  medical use
 ☐ Fear of addiction 
 ☐ Cultural attitudes towards the treatment of mental health disorders
 ☐  Control measures applicable to international trade such as requirements for import or 
export authorizations 
 ☐ Action by the Board
 ☐ Other(s):
 Please elaborate as applicable:
49.  What do you consider to be the most significant obstacle to the availability of psychotropic 
substances in your country to meet medical and scientific needs?
50. Are any particular measures in place in your country to facilitate the availability of psycho-
tropic substances for medical purposes in rural or remote regions of your country?
 ☐ Yes 
 ☐ No
 If you answered “Yes”, please provide details: 
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51.  Are there any additional measures that could be taken by INCB to contribute to greater avail-
ability of psychotropic substances for medical and scientific purposes in your country?
G. Overprescription of psychotropic substances
52. Has your country experienced the following with respect to psychotropic substances:
 ☐ Overprescription
 ☐ “Doctor shopping”d
 ☐ Self-medication
 ☐ Parallel unregulated markets
 ☐ Counterfeiting of prescription drugs containing psychotropic substances
 Please provide details, as applicable: 
53. Does your country permit the advertising of psychotropic substances to the general public?
 ☐ Yes 
 ☐ No
 If you answered “Yes”, please provide details: 
Additional information (as required)
 d “Doctor shopping”, or “double doctoring”, refers to the practice of a patient requesting care from multiple physicians, often 
simultaneously, without making efforts to coordinate care or informing the physicians of the multiple caregivers.

 United Nations system and drug control organs and their secretariat
General Assembly
Economic and Social 
Council
INCB Commission onNarcotic Drugs
UNODCa/INCB secretariatb
Key:
Direct connection (administrative or constitutional)
Reporting, cooperating and advising relationship 
a United Nations Office on Drugs and Crime.
b The INCB secretariat reports on substantive matters to INCB only.
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INTERNATIONAL NARCOTICS CONTROL BOARD
The International Narcotics Control Board (INCB) is the independent monitoring body for the 
implementation of United Nations international drug control conventions. It was established in 
1968 in accordance with the Single Convention on Narcotic Drugs, 1961. It had predecessors 
under the former drug control treaties as far back as the time of the League of Nations.
Based on its activities, INCB publishes an annual report that is submitted to the United Nations 
Economic and Social Council through the Commission on Narcotic Drugs. The report provides a 
comprehensive survey of the drug control situation in various parts of the world. As an impartial 
body, INCB tries to identify and predict dangerous trends and suggests necessary measures to 
be taken.
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